#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Cingulate cortex functional connectivity predicts future relapse in alcohol dependent individuals
#Text=Alcohol dependence is a chronic relapsing illness.
1-1	0-9	Cingulate	_	
1-2	10-16	cortex	_	
1-3	17-27	functional	_	
1-4	28-40	connectivity	_	
1-5	41-49	predicts	_	
1-6	50-56	future	_	
1-7	57-64	relapse	_	
1-8	65-67	in	_	
1-9	68-75	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[1]	
1-10	76-85	dependent	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[1]	
1-11	86-97	individuals	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[1]	
1-12	98-105	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[2]	
1-13	106-116	dependence	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[2]	
1-14	117-119	is	_	
1-15	120-121	a	_	
1-16	122-129	chronic	_	
1-17	130-139	relapsing	_	
1-18	140-147	illness	_	
1-19	147-148	.	_	

#Text=Alcohol and stress cues have consistently been shown to increase craving and relapse risk in recovering alcohol dependent (AUD) patients.
2-1	149-156	Alcohol	_	
2-2	157-160	and	_	
2-3	161-167	stress	_	
2-4	168-172	cues	_	
2-5	173-177	have	_	
2-6	178-190	consistently	_	
2-7	191-195	been	_	
2-8	196-201	shown	_	
2-9	202-204	to	_	
2-10	205-213	increase	_	
2-11	214-221	craving	_	
2-12	222-225	and	_	
2-13	226-233	relapse	_	
2-14	234-238	risk	_	
2-15	239-241	in	_	
2-16	242-252	recovering	_	
2-17	253-260	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[3]	
2-18	261-270	dependent	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[3]	
2-19	271-272	(	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[3]	
2-20	272-275	AUD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[3]	
2-21	275-276	)	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[3]	
2-22	277-285	patients	_	
2-23	285-286	.	_	

#Text=However, differences in functional connectivity in response to these cues have not been studied using data-driven approaches.
3-1	287-294	However	_	
3-2	294-295	,	_	
3-3	296-307	differences	_	
3-4	308-310	in	_	
3-5	311-321	functional	_	
3-6	322-334	connectivity	_	
3-7	335-337	in	_	
3-8	338-346	response	_	
3-9	347-349	to	_	
3-10	350-355	these	_	
3-11	356-360	cues	_	
3-12	361-365	have	_	
3-13	366-369	not	_	
3-14	370-374	been	_	
3-15	375-382	studied	_	
3-16	383-388	using	_	
3-17	389-400	data-driven	_	
3-18	401-411	approaches	_	
3-19	411-412	.	_	

#Text=Here, voxel-wise connectivity is used in a whole-brain investigation of functional connectivity differences associated with alcohol and stress cues and to examine whether these differences are related to subsequent relapse.
4-1	413-417	Here	_	
4-2	417-418	,	_	
4-3	419-429	voxel-wise	_	
4-4	430-442	connectivity	_	
4-5	443-445	is	_	
4-6	446-450	used	_	
4-7	451-453	in	_	
4-8	454-455	a	_	
4-9	456-467	whole-brain	_	
4-10	468-481	investigation	_	
4-11	482-484	of	_	
4-12	485-495	functional	_	
4-13	496-508	connectivity	_	
4-14	509-520	differences	_	
4-15	521-531	associated	_	
4-16	532-536	with	_	
4-17	537-544	alcohol	_	
4-18	545-548	and	_	
4-19	549-555	stress	_	
4-20	556-560	cues	_	
4-21	561-564	and	_	
4-22	565-567	to	_	
4-23	568-575	examine	_	
4-24	576-583	whether	_	
4-25	584-589	these	_	
4-26	590-601	differences	_	
4-27	602-605	are	_	
4-28	606-613	related	_	
4-29	614-616	to	_	
4-30	617-627	subsequent	_	
4-31	628-635	relapse	_	
4-32	635-636	.	_	

#Text=In Study 1, 45, 4- to 8-week abstinent, recovering AUD patients underwent functional magnetic resonance imaging during individualized imagery of alcohol, stress, and neutral cues.
5-1	637-639	In	_	
5-2	640-645	Study	_	
5-3	646-647	1	_	
5-4	647-648	,	_	
5-5	649-651	45	_	
5-6	651-652	,	_	
5-7	653-654	4	_	
5-8	654-655	-	_	
5-9	656-658	to	_	
5-10	659-660	8	_	
5-11	660-661	-	_	
5-12	661-665	week	_	
5-13	666-675	abstinent	_	
5-14	675-676	,	_	
5-15	677-687	recovering	_	
5-16	688-691	AUD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	
5-17	692-700	patients	_	
5-18	701-710	underwent	_	
5-19	711-721	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[4]	
5-20	722-730	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[4]	
5-21	731-740	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[4]	
5-22	741-748	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[4]	
5-23	749-755	during	_	
5-24	756-770	individualized	_	
5-25	771-778	imagery	_	
5-26	779-781	of	_	
5-27	782-789	alcohol	_	
5-28	789-790	,	_	
5-29	791-797	stress	_	
5-30	797-798	,	_	
5-31	799-802	and	_	
5-32	803-810	neutral	_	
5-33	811-815	cues	_	
5-34	815-816	.	_	

#Text=Relapse measures were collected prospectively for 90 days post-discharge from inpatient treatment.
6-1	817-824	Relapse	_	
6-2	825-833	measures	_	
6-3	834-838	were	_	
6-4	839-848	collected	_	
6-5	849-862	prospectively	_	
6-6	863-866	for	_	
6-7	867-869	90	_	
6-8	869-870	 	_	
6-9	870-874	days	_	
6-10	875-889	post-discharge	_	
6-11	890-894	from	_	
6-12	895-904	inpatient	_	
6-13	905-914	treatment	_	
6-14	914-915	.	_	

#Text=AUD patients showed blunted anterior (ACC), mid (MCC) and posterior cingulate cortex (PCC), voxel-wise connectivity responses to stress compared to neutral cues and blunted PCC response to alcohol compared to neutral cues.
7-1	916-919	AUD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	
7-2	920-928	patients	_	
7-3	929-935	showed	_	
7-4	936-943	blunted	_	
7-5	944-952	anterior	_	
7-6	953-954	(	_	
7-7	954-957	ACC	_	
7-8	957-958	)	_	
7-9	958-959	,	_	
7-10	960-963	mid	_	
7-11	964-965	(	_	
7-12	965-968	MCC	_	
7-13	968-969	)	_	
7-14	970-973	and	_	
7-15	974-983	posterior	_	
7-16	984-993	cingulate	_	
7-17	994-1000	cortex	_	
7-18	1001-1002	(	_	
7-19	1002-1005	PCC	_	
7-20	1005-1006	)	_	
7-21	1006-1007	,	_	
7-22	1008-1018	voxel-wise	_	
7-23	1019-1031	connectivity	_	
7-24	1032-1041	responses	_	
7-25	1042-1044	to	_	
7-26	1045-1051	stress	_	
7-27	1052-1060	compared	_	
7-28	1061-1063	to	_	
7-29	1064-1071	neutral	_	
7-30	1072-1076	cues	_	
7-31	1077-1080	and	_	
7-32	1081-1088	blunted	_	
7-33	1089-1092	PCC	_	
7-34	1093-1101	response	_	
7-35	1102-1104	to	_	
7-36	1105-1112	alcohol	_	
7-37	1113-1121	compared	_	
7-38	1122-1124	to	_	
7-39	1125-1132	neutral	_	
7-40	1133-1137	cues	_	
7-41	1137-1138	.	_	

#Text=Using Cox proportional hazard regression, weaker connectivity in ACC and MCC during neutral exposure was associated with longer time to relapse (better recovery outcome).
8-1	1139-1144	Using	_	
8-2	1145-1148	Cox	_	
8-3	1149-1161	proportional	_	
8-4	1162-1168	hazard	_	
8-5	1169-1179	regression	_	
8-6	1179-1180	,	_	
8-7	1181-1187	weaker	_	
8-8	1188-1200	connectivity	_	
8-9	1201-1203	in	_	
8-10	1204-1207	ACC	_	
8-11	1208-1211	and	_	
8-12	1212-1215	MCC	_	
8-13	1216-1222	during	_	
8-14	1223-1230	neutral	_	
8-15	1231-1239	exposure	_	
8-16	1240-1243	was	_	
8-17	1244-1254	associated	_	
8-18	1255-1259	with	_	
8-19	1260-1266	longer	_	
8-20	1267-1271	time	_	
8-21	1272-1274	to	_	
8-22	1275-1282	relapse	_	
8-23	1283-1284	(	_	
8-24	1284-1290	better	_	
8-25	1291-1299	recovery	_	
8-26	1300-1307	outcome	_	
8-27	1307-1308	)	_	
8-28	1308-1309	.	_	

#Text=Similarly, greater connectivity in PCC during alcohol-cue compared to stress cue was associated with longer time to relapse.
9-1	1310-1319	Similarly	_	
9-2	1319-1320	,	_	
9-3	1321-1328	greater	_	
9-4	1329-1341	connectivity	_	
9-5	1342-1344	in	_	
9-6	1345-1348	PCC	_	
9-7	1349-1355	during	_	
9-8	1356-1367	alcohol-cue	_	
9-9	1368-1376	compared	_	
9-10	1377-1379	to	_	
9-11	1380-1386	stress	_	
9-12	1387-1390	cue	_	
9-13	1391-1394	was	_	
9-14	1395-1405	associated	_	
9-15	1406-1410	with	_	
9-16	1411-1417	longer	_	
9-17	1418-1422	time	_	
9-18	1423-1425	to	_	
9-19	1426-1433	relapse	_	
9-20	1433-1434	.	_	

#Text=In Study 2, a sub-group of 30 AUD patients were demographically-matched to 30 healthy control (HC) participants for group comparisons.
10-1	1435-1437	In	_	
10-2	1438-1443	Study	_	
10-3	1444-1445	2	_	
10-4	1445-1446	,	_	
10-5	1447-1448	a	_	
10-6	1449-1458	sub-group	_	
10-7	1459-1461	of	_	
10-8	1462-1464	30	_	
10-9	1465-1468	AUD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	
10-10	1469-1477	patients	_	
10-11	1478-1482	were	_	
10-12	1483-1506	demographically-matched	_	
10-13	1507-1509	to	_	
10-14	1510-1512	30	_	
10-15	1513-1520	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[5]	
10-16	1521-1528	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[5]	
10-17	1529-1530	(	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[5]	
10-18	1530-1532	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[5]	
10-19	1532-1533	)	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[5]	
10-20	1534-1546	participants	_	
10-21	1547-1550	for	_	
10-22	1551-1556	group	_	
10-23	1557-1568	comparisons	_	
10-24	1568-1569	.	_	

#Text=AUD compared to HC participants showed reduced cingulate connectivity during alcohol and stress cues.
11-1	1570-1573	AUD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	
11-2	1574-1582	compared	_	
11-3	1583-1585	to	_	
11-4	1586-1588	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
11-5	1589-1601	participants	_	
11-6	1602-1608	showed	_	
11-7	1609-1616	reduced	_	
11-8	1617-1626	cingulate	_	
11-9	1627-1639	connectivity	_	
11-10	1640-1646	during	_	
11-11	1647-1654	alcohol	_	
11-12	1655-1658	and	_	
11-13	1659-1665	stress	_	
11-14	1666-1670	cues	_	
11-15	1670-1671	.	_	

#Text=Using novel data-driven approaches, the cingulate cortex emerged as a key region in the disruption of functional connectivity during alcohol and stress-cue processing in AUD patients and as a marker of subsequent alcohol relapse.
12-1	1672-1677	Using	_	
12-2	1678-1683	novel	_	
12-3	1684-1695	data-driven	_	
12-4	1696-1706	approaches	_	
12-5	1706-1707	,	_	
12-6	1708-1711	the	_	
12-7	1712-1721	cingulate	_	
12-8	1722-1728	cortex	_	
12-9	1729-1736	emerged	_	
12-10	1737-1739	as	_	
12-11	1740-1741	a	_	
12-12	1742-1745	key	_	
12-13	1746-1752	region	_	
12-14	1753-1755	in	_	
12-15	1756-1759	the	_	
12-16	1760-1770	disruption	_	
12-17	1771-1773	of	_	
12-18	1774-1784	functional	_	
12-19	1785-1797	connectivity	_	
12-20	1798-1804	during	_	
12-21	1805-1812	alcohol	_	
12-22	1813-1816	and	_	
12-23	1817-1827	stress-cue	_	
12-24	1828-1838	processing	_	
12-25	1839-1841	in	_	
12-26	1842-1845	AUD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	
12-27	1846-1854	patients	_	
12-28	1855-1858	and	_	
12-29	1859-1861	as	_	
12-30	1862-1863	a	_	
12-31	1864-1870	marker	_	
12-32	1871-1873	of	_	
12-33	1874-1884	subsequent	_	
12-34	1885-1892	alcohol	_	
12-35	1893-1900	relapse	_	
12-36	1900-1901	.	_	

#Text=Highlights
#Text=AUD patients showed blunted cingulate connectivity to alcohol and stress cues.
13-1	1902-1912	Highlights	_	
13-2	1913-1916	AUD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	
13-3	1917-1925	patients	_	
13-4	1926-1932	showed	_	
13-5	1933-1940	blunted	_	
13-6	1941-1950	cingulate	_	
13-7	1951-1963	connectivity	_	
13-8	1964-1966	to	_	
13-9	1967-1974	alcohol	_	
13-10	1975-1978	and	_	
13-11	1979-1985	stress	_	
13-12	1986-1990	cues	_	
13-13	1990-1991	.	_	

#Text=Cingulate connectivity predicted time to relapse in AUD patients.
14-1	1992-2001	Cingulate	_	
14-2	2002-2014	connectivity	_	
14-3	2015-2024	predicted	_	
14-4	2025-2029	time	_	
14-5	2030-2032	to	_	
14-6	2033-2040	relapse	_	
14-7	2041-2043	in	_	
14-8	2044-2047	AUD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	
14-9	2048-2056	patients	_	
14-10	2056-2057	.	_	

#Text=Greater PCC connectivity during alcohol cues predicted longer time to relapse.
15-1	2058-2065	Greater	_	
15-2	2066-2069	PCC	_	
15-3	2070-2082	connectivity	_	
15-4	2083-2089	during	_	
15-5	2090-2097	alcohol	_	
15-6	2098-2102	cues	_	
15-7	2103-2112	predicted	_	
15-8	2113-2119	longer	_	
15-9	2120-2124	time	_	
15-10	2125-2127	to	_	
15-11	2128-2135	relapse	_	
15-12	2135-2136	.	_	

#Text=AUD vs.
16-1	2137-2140	AUD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	
16-2	2141-2143	vs	_	
16-3	2143-2144	.	_	

#Text=HC subjects showed less cingulate connectivity to alcohol and stress cues.
17-1	2145-2147	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
17-2	2148-2156	subjects	_	
17-3	2157-2163	showed	_	
17-4	2164-2168	less	_	
17-5	2169-2178	cingulate	_	
17-6	2179-2191	connectivity	_	
17-7	2192-2194	to	_	
17-8	2195-2202	alcohol	_	
17-9	2203-2206	and	_	
17-10	2207-2213	stress	_	
17-11	2214-2218	cues	_	
17-12	2218-2219	.	_	

#Text=The cingulate cortex emerged as a marker of subsequent alcohol relapse.
18-1	2220-2223	The	_	
18-2	2224-2233	cingulate	_	
18-3	2234-2240	cortex	_	
18-4	2241-2248	emerged	_	
18-5	2249-2251	as	_	
18-6	2252-2253	a	_	
18-7	2254-2260	marker	_	
18-8	2261-2263	of	_	
18-9	2264-2274	subsequent	_	
18-10	2275-2282	alcohol	_	
18-11	2283-2290	relapse	_	
18-12	2290-2291	.	_	

#Text=Introduction
#Text=Alcohol dependence is a chronic relapsing disease that poses a substantial global health problem.
19-1	2292-2304	Introduction	_	
19-2	2305-2312	Alcohol	_	
19-3	2313-2323	dependence	_	
19-4	2324-2326	is	_	
19-5	2327-2328	a	_	
19-6	2329-2336	chronic	_	
19-7	2337-2346	relapsing	_	
19-8	2347-2354	disease	_	
19-9	2355-2359	that	_	
19-10	2360-2365	poses	_	
19-11	2366-2367	a	_	
19-12	2368-2379	substantial	_	
19-13	2380-2386	global	_	
19-14	2387-2393	health	_	
19-15	2394-2401	problem	_	
19-16	2401-2402	.	_	

#Text=Alcohol and stress-related cues have consistently been shown to increase craving, and relapse rates in recovering alcohol dependent (AUD) patients.
20-1	2403-2410	Alcohol	_	
20-2	2411-2414	and	_	
20-3	2415-2429	stress-related	_	
20-4	2430-2434	cues	_	
20-5	2435-2439	have	_	
20-6	2440-2452	consistently	_	
20-7	2453-2457	been	_	
20-8	2458-2463	shown	_	
20-9	2464-2466	to	_	
20-10	2467-2475	increase	_	
20-11	2476-2483	craving	_	
20-12	2483-2484	,	_	
20-13	2485-2488	and	_	
20-14	2489-2496	relapse	_	
20-15	2497-2502	rates	_	
20-16	2503-2505	in	_	
20-17	2506-2516	recovering	_	
20-18	2517-2524	alcohol	_	
20-19	2525-2534	dependent	_	
20-20	2535-2536	(	_	
20-21	2536-2539	AUD	_	
20-22	2539-2540	)	_	
20-23	2541-2549	patients	_	
20-24	2549-2550	.	_	

#Text=A better understanding of the neural correlates of alcohol and stress cues that contribute to relapse may lead to better treatment strategies for AUD patients.
21-1	2551-2552	A	_	
21-2	2553-2559	better	_	
21-3	2560-2573	understanding	_	
21-4	2574-2576	of	_	
21-5	2577-2580	the	_	
21-6	2581-2587	neural	_	
21-7	2588-2598	correlates	_	
21-8	2599-2601	of	_	
21-9	2602-2609	alcohol	_	
21-10	2610-2613	and	_	
21-11	2614-2620	stress	_	
21-12	2621-2625	cues	_	
21-13	2626-2630	that	_	
21-14	2631-2641	contribute	_	
21-15	2642-2644	to	_	
21-16	2645-2652	relapse	_	
21-17	2653-2656	may	_	
21-18	2657-2661	lead	_	
21-19	2662-2664	to	_	
21-20	2665-2671	better	_	
21-21	2672-2681	treatment	_	
21-22	2682-2692	strategies	_	
21-23	2693-2696	for	_	
21-24	2697-2700	AUD	_	
21-25	2701-2709	patients	_	
21-26	2709-2710	.	_	

#Text=Functional magnetic resonance imaging (fMRI) studies have largely converged on the dysregulation of cortico-limbic pathways in response to alcohol and stress cues for alcohol dependence.
22-1	2711-2721	Functional	_	
22-2	2722-2730	magnetic	_	
22-3	2731-2740	resonance	_	
22-4	2741-2748	imaging	_	
22-5	2749-2750	(	_	
22-6	2750-2754	fMRI	_	
22-7	2754-2755	)	_	
22-8	2756-2763	studies	_	
22-9	2764-2768	have	_	
22-10	2769-2776	largely	_	
22-11	2777-2786	converged	_	
22-12	2787-2789	on	_	
22-13	2790-2793	the	_	
22-14	2794-2807	dysregulation	_	
22-15	2808-2810	of	_	
22-16	2811-2825	cortico-limbic	_	
22-17	2826-2834	pathways	_	
22-18	2835-2837	in	_	
22-19	2838-2846	response	_	
22-20	2847-2849	to	_	
22-21	2850-2857	alcohol	_	
22-22	2858-2861	and	_	
22-23	2862-2868	stress	_	
22-24	2869-2873	cues	_	
22-25	2874-2877	for	_	
22-26	2878-2885	alcohol	_	
22-27	2886-2896	dependence	_	
22-28	2896-2897	.	_	

#Text=Some authors have hypothesized that these alterations in cortico-limbic regions may trigger attention allocation to and reinforcement of drug-related cues in addicted populations, known as the incentive salience theory.
23-1	2898-2902	Some	_	
23-2	2903-2910	authors	_	
23-3	2911-2915	have	_	
23-4	2916-2928	hypothesized	_	
23-5	2929-2933	that	_	
23-6	2934-2939	these	_	
23-7	2940-2951	alterations	_	
23-8	2952-2954	in	_	
23-9	2955-2969	cortico-limbic	_	
23-10	2970-2977	regions	_	
23-11	2978-2981	may	_	
23-12	2982-2989	trigger	_	
23-13	2990-2999	attention	_	
23-14	3000-3010	allocation	_	
23-15	3011-3013	to	_	
23-16	3014-3017	and	_	
23-17	3018-3031	reinforcement	_	
23-18	3032-3034	of	_	
23-19	3035-3047	drug-related	_	
23-20	3048-3052	cues	_	
23-21	3053-3055	in	_	
23-22	3056-3064	addicted	_	
23-23	3065-3076	populations	_	
23-24	3076-3077	,	_	
23-25	3078-3083	known	_	
23-26	3084-3086	as	_	
23-27	3087-3090	the	_	
23-28	3091-3100	incentive	_	
23-29	3101-3109	salience	_	
23-30	3110-3116	theory	_	
23-31	3116-3117	.	_	

#Text=Cortico-limbic regions that are commonly implicated in reward circuitry include the prefrontal cortex (PFC), the anterior cingulate cortex (ACC), the amygdala, and the striatum.
24-1	3118-3132	Cortico-limbic	_	
24-2	3133-3140	regions	_	
24-3	3141-3145	that	_	
24-4	3146-3149	are	_	
24-5	3150-3158	commonly	_	
24-6	3159-3169	implicated	_	
24-7	3170-3172	in	_	
24-8	3173-3179	reward	_	
24-9	3180-3189	circuitry	_	
24-10	3190-3197	include	_	
24-11	3198-3201	the	_	
24-12	3202-3212	prefrontal	_	
24-13	3213-3219	cortex	_	
24-14	3220-3221	(	_	
24-15	3221-3224	PFC	_	
24-16	3224-3225	)	_	
24-17	3225-3226	,	_	
24-18	3227-3230	the	_	
24-19	3231-3239	anterior	_	
24-20	3240-3249	cingulate	_	
24-21	3250-3256	cortex	_	
24-22	3257-3258	(	_	
24-23	3258-3261	ACC	_	
24-24	3261-3262	)	_	
24-25	3262-3263	,	_	
24-26	3264-3267	the	_	
24-27	3268-3276	amygdala	_	
24-28	3276-3277	,	_	
24-29	3278-3281	and	_	
24-30	3282-3285	the	_	
24-31	3286-3294	striatum	_	
24-32	3294-3295	.	_	

#Text=However, activation-based fMRI studies are limited as they only measure the magnitude of activation in a single region, and, thus, provide an incomplete picture of neural dynamics between regions.
25-1	3296-3303	However	_	
25-2	3303-3304	,	_	
25-3	3305-3321	activation-based	_	
25-4	3322-3326	fMRI	_	
25-5	3327-3334	studies	_	
25-6	3335-3338	are	_	
25-7	3339-3346	limited	_	
25-8	3347-3349	as	_	
25-9	3350-3354	they	_	
25-10	3355-3359	only	_	
25-11	3360-3367	measure	_	
25-12	3368-3371	the	_	
25-13	3372-3381	magnitude	_	
25-14	3382-3384	of	_	
25-15	3385-3395	activation	_	
25-16	3396-3398	in	_	
25-17	3399-3400	a	_	
25-18	3401-3407	single	_	
25-19	3408-3414	region	_	
25-20	3414-3415	,	_	
25-21	3416-3419	and	_	
25-22	3419-3420	,	_	
25-23	3421-3425	thus	_	
25-24	3425-3426	,	_	
25-25	3427-3434	provide	_	
25-26	3435-3437	an	_	
25-27	3438-3448	incomplete	_	
25-28	3449-3456	picture	_	
25-29	3457-3459	of	_	
25-30	3460-3466	neural	_	
25-31	3467-3475	dynamics	_	
25-32	3476-3483	between	_	
25-33	3484-3491	regions	_	
25-34	3491-3492	.	_	

#Text=Functional connectivity methods overcome these limitations by detecting synchrony of activations over time, exposing patterns of correlated brain activity, and shed light on the functional architecture of both the healthy and diseased brain.
26-1	3493-3503	Functional	_	
26-2	3504-3516	connectivity	_	
26-3	3517-3524	methods	_	
26-4	3525-3533	overcome	_	
26-5	3534-3539	these	_	
26-6	3540-3551	limitations	_	
26-7	3552-3554	by	_	
26-8	3555-3564	detecting	_	
26-9	3565-3574	synchrony	_	
26-10	3575-3577	of	_	
26-11	3578-3589	activations	_	
26-12	3590-3594	over	_	
26-13	3595-3599	time	_	
26-14	3599-3600	,	_	
26-15	3601-3609	exposing	_	
26-16	3610-3618	patterns	_	
26-17	3619-3621	of	_	
26-18	3622-3632	correlated	_	
26-19	3633-3638	brain	_	
26-20	3639-3647	activity	_	
26-21	3647-3648	,	_	
26-22	3649-3652	and	_	
26-23	3653-3657	shed	_	
26-24	3658-3663	light	_	
26-25	3664-3666	on	_	
26-26	3667-3670	the	_	
26-27	3671-3681	functional	_	
26-28	3682-3694	architecture	_	
26-29	3695-3697	of	_	
26-30	3698-3702	both	_	
26-31	3703-3706	the	_	
26-32	3707-3714	healthy	_	
26-33	3715-3718	and	_	
26-34	3719-3727	diseased	_	
26-35	3728-3733	brain	_	
26-36	3733-3734	.	_	

#Text=Recent studies of resting state and task-based connectivity in AUD patients point toward the involvement of large-scale brain networks in addiction.
27-1	3735-3741	Recent	_	
27-2	3742-3749	studies	_	
27-3	3750-3752	of	_	
27-4	3753-3760	resting	_	
27-5	3761-3766	state	_	
27-6	3767-3770	and	_	
27-7	3771-3781	task-based	_	
27-8	3782-3794	connectivity	_	
27-9	3795-3797	in	_	
27-10	3798-3801	AUD	_	
27-11	3802-3810	patients	_	
27-12	3811-3816	point	_	
27-13	3817-3823	toward	_	
27-14	3824-3827	the	_	
27-15	3828-3839	involvement	_	
27-16	3840-3842	of	_	
27-17	3843-3854	large-scale	_	
27-18	3855-3860	brain	_	
27-19	3861-3869	networks	_	
27-20	3870-3872	in	_	
27-21	3873-3882	addiction	_	
27-22	3882-3883	.	_	

#Text=These networks overlap with previously identified brain regions as well as offer potentially new brain regions of interest in addiction research.
28-1	3884-3889	These	_	
28-2	3890-3898	networks	_	
28-3	3899-3906	overlap	_	
28-4	3907-3911	with	_	
28-5	3912-3922	previously	_	
28-6	3923-3933	identified	_	
28-7	3934-3939	brain	_	
28-8	3940-3947	regions	_	
28-9	3948-3950	as	_	
28-10	3951-3955	well	_	
28-11	3956-3958	as	_	
28-12	3959-3964	offer	_	
28-13	3965-3976	potentially	_	
28-14	3977-3980	new	_	
28-15	3981-3986	brain	_	
28-16	3987-3994	regions	_	
28-17	3995-3997	of	_	
28-18	3998-4006	interest	_	
28-19	4007-4009	in	_	
28-20	4010-4019	addiction	_	
28-21	4020-4028	research	_	
28-22	4028-4029	.	_	

#Text=For example, the salience network (SN) is composed of two historically studied regions in addiction literature, the insular cortex and the ACC.
29-1	4030-4033	For	_	
29-2	4034-4041	example	_	
29-3	4041-4042	,	_	
29-4	4043-4046	the	_	
29-5	4047-4055	salience	_	
29-6	4056-4063	network	_	
29-7	4064-4065	(	_	
29-8	4065-4067	SN	_	
29-9	4067-4068	)	_	
29-10	4069-4071	is	_	
29-11	4072-4080	composed	_	
29-12	4081-4083	of	_	
29-13	4084-4087	two	_	
29-14	4088-4100	historically	_	
29-15	4101-4108	studied	_	
29-16	4109-4116	regions	_	
29-17	4117-4119	in	_	
29-18	4120-4129	addiction	_	
29-19	4130-4140	literature	_	
29-20	4140-4141	,	_	
29-21	4142-4145	the	_	
29-22	4146-4153	insular	_	
29-23	4154-4160	cortex	_	
29-24	4161-4164	and	_	
29-25	4165-4168	the	_	
29-26	4169-4172	ACC	_	
29-27	4172-4173	.	_	

#Text=In contrast, the default mode network (DMN) characteristically includes the medial PFC (mPFC), a previously identified brain region, as well as the posterior cingulate (PCC), a newly emphasized brain region in alcoholism literature.
30-1	4174-4176	In	_	
30-2	4177-4185	contrast	_	
30-3	4185-4186	,	_	
30-4	4187-4190	the	_	
30-5	4191-4198	default	_	
30-6	4199-4203	mode	_	
30-7	4204-4211	network	_	
30-8	4212-4213	(	_	
30-9	4213-4216	DMN	_	
30-10	4216-4217	)	_	
30-11	4218-4236	characteristically	_	
30-12	4237-4245	includes	_	
30-13	4246-4249	the	_	
30-14	4250-4256	medial	_	
30-15	4257-4260	PFC	_	
30-16	4261-4262	(	_	
30-17	4262-4266	mPFC	_	
30-18	4266-4267	)	_	
30-19	4267-4268	,	_	
30-20	4269-4270	a	_	
30-21	4271-4281	previously	_	
30-22	4282-4292	identified	_	
30-23	4293-4298	brain	_	
30-24	4299-4305	region	_	
30-25	4305-4306	,	_	
30-26	4307-4309	as	_	
30-27	4310-4314	well	_	
30-28	4315-4317	as	_	
30-29	4318-4321	the	_	
30-30	4322-4331	posterior	_	
30-31	4332-4341	cingulate	_	
30-32	4342-4343	(	_	
30-33	4343-4346	PCC	_	
30-34	4346-4347	)	_	
30-35	4347-4348	,	_	
30-36	4349-4350	a	_	
30-37	4351-4356	newly	_	
30-38	4357-4367	emphasized	_	
30-39	4368-4373	brain	_	
30-40	4374-4380	region	_	
30-41	4381-4383	in	_	
30-42	4384-4394	alcoholism	_	
30-43	4395-4405	literature	_	
30-44	4405-4406	.	_	

#Text=Increasingly, the interplay between these networks is being recognized as an important factor in clinical disorders, suggesting a need to utilize whole brain data-driven approaches in studies of addiction.
31-1	4407-4419	Increasingly	_	
31-2	4419-4420	,	_	
31-3	4421-4424	the	_	
31-4	4425-4434	interplay	_	
31-5	4435-4442	between	_	
31-6	4443-4448	these	_	
31-7	4449-4457	networks	_	
31-8	4458-4460	is	_	
31-9	4461-4466	being	_	
31-10	4467-4477	recognized	_	
31-11	4478-4480	as	_	
31-12	4481-4483	an	_	
31-13	4484-4493	important	_	
31-14	4494-4500	factor	_	
31-15	4501-4503	in	_	
31-16	4504-4512	clinical	_	
31-17	4513-4522	disorders	_	
31-18	4522-4523	,	_	
31-19	4524-4534	suggesting	_	
31-20	4535-4536	a	_	
31-21	4537-4541	need	_	
31-22	4542-4544	to	_	
31-23	4545-4552	utilize	_	
31-24	4553-4558	whole	_	
31-25	4559-4564	brain	_	
31-26	4565-4576	data-driven	_	
31-27	4577-4587	approaches	_	
31-28	4588-4590	in	_	
31-29	4591-4598	studies	_	
31-30	4599-4601	of	_	
31-31	4602-4611	addiction	_	
31-32	4611-4612	.	_	

#Text=However, these studies have examined connections between specific regions of interest (ROI) or canonical, large-scale networks requiring a priori knowledge of ROI or network boundaries.
32-1	4613-4620	However	_	
32-2	4620-4621	,	_	
32-3	4622-4627	these	_	
32-4	4628-4635	studies	_	
32-5	4636-4640	have	_	
32-6	4641-4649	examined	_	
32-7	4650-4661	connections	_	
32-8	4662-4669	between	_	
32-9	4670-4678	specific	_	
32-10	4679-4686	regions	_	
32-11	4687-4689	of	_	
32-12	4690-4698	interest	_	
32-13	4699-4700	(	_	
32-14	4700-4703	ROI	_	
32-15	4703-4704	)	_	
32-16	4705-4707	or	_	
32-17	4708-4717	canonical	_	
32-18	4717-4718	,	_	
32-19	4719-4730	large-scale	_	
32-20	4731-4739	networks	_	
32-21	4740-4749	requiring	_	
32-22	4750-4751	a	_	
32-23	4752-4758	priori	_	
32-24	4759-4768	knowledge	_	
32-25	4769-4771	of	_	
32-26	4772-4775	ROI	_	
32-27	4776-4778	or	_	
32-28	4779-4786	network	_	
32-29	4787-4797	boundaries	_	
32-30	4797-4798	.	_	

#Text=An innovative alternative, voxel-wise method, called the intrinsic connectivity distribution (ICD), eschews pre-defined regions or networks and examines every voxel's connectivity to every other voxel in the brain.
33-1	4799-4801	An	_	
33-2	4802-4812	innovative	_	
33-3	4813-4824	alternative	_	
33-4	4824-4825	,	_	
33-5	4826-4836	voxel-wise	_	
33-6	4837-4843	method	_	
33-7	4843-4844	,	_	
33-8	4845-4851	called	_	
33-9	4852-4855	the	_	
33-10	4856-4865	intrinsic	_	
33-11	4866-4878	connectivity	_	
33-12	4879-4891	distribution	_	
33-13	4892-4893	(	_	
33-14	4893-4896	ICD	_	
33-15	4896-4897	)	_	
33-16	4897-4898	,	_	
33-17	4899-4906	eschews	_	
33-18	4907-4918	pre-defined	_	
33-19	4919-4926	regions	_	
33-20	4927-4929	or	_	
33-21	4930-4938	networks	_	
33-22	4939-4942	and	_	
33-23	4943-4951	examines	_	
33-24	4952-4957	every	_	
33-25	4958-4965	voxel's	_	
33-26	4966-4978	connectivity	_	
33-27	4979-4981	to	_	
33-28	4982-4987	every	_	
33-29	4988-4993	other	_	
33-30	4994-4999	voxel	_	
33-31	5000-5002	in	_	
33-32	5003-5006	the	_	
33-33	5007-5012	brain	_	
33-34	5012-5013	.	_	

#Text=As voxels are not constrained to a particular ROI or network, ICD enables characterization of the full range of connectivity for that voxel and may lead to a more complete picture of the neural correlates of alcohol and stress cues for recovering AUD patients.
34-1	5014-5016	As	_	
34-2	5017-5023	voxels	_	
34-3	5024-5027	are	_	
34-4	5028-5031	not	_	
34-5	5032-5043	constrained	_	
34-6	5044-5046	to	_	
34-7	5047-5048	a	_	
34-8	5049-5059	particular	_	
34-9	5060-5063	ROI	_	
34-10	5064-5066	or	_	
34-11	5067-5074	network	_	
34-12	5074-5075	,	_	
34-13	5076-5079	ICD	_	
34-14	5080-5087	enables	_	
34-15	5088-5104	characterization	_	
34-16	5105-5107	of	_	
34-17	5108-5111	the	_	
34-18	5112-5116	full	_	
34-19	5117-5122	range	_	
34-20	5123-5125	of	_	
34-21	5126-5138	connectivity	_	
34-22	5139-5142	for	_	
34-23	5143-5147	that	_	
34-24	5148-5153	voxel	_	
34-25	5154-5157	and	_	
34-26	5158-5161	may	_	
34-27	5162-5166	lead	_	
34-28	5167-5169	to	_	
34-29	5170-5171	a	_	
34-30	5172-5176	more	_	
34-31	5177-5185	complete	_	
34-32	5186-5193	picture	_	
34-33	5194-5196	of	_	
34-34	5197-5200	the	_	
34-35	5201-5207	neural	_	
34-36	5208-5218	correlates	_	
34-37	5219-5221	of	_	
34-38	5222-5229	alcohol	_	
34-39	5230-5233	and	_	
34-40	5234-5240	stress	_	
34-41	5241-5245	cues	_	
34-42	5246-5249	for	_	
34-43	5250-5260	recovering	_	
34-44	5261-5264	AUD	_	
34-45	5265-5273	patients	_	
34-46	5273-5274	.	_	

#Text=Previous studies have also required the definition of an arbitrary tissue connectivity threshold whereas ICD characterizes connections across the entire degree curve.
35-1	5275-5283	Previous	_	
35-2	5284-5291	studies	_	
35-3	5292-5296	have	_	
35-4	5297-5301	also	_	
35-5	5302-5310	required	_	
35-6	5311-5314	the	_	
35-7	5315-5325	definition	_	
35-8	5326-5328	of	_	
35-9	5329-5331	an	_	
35-10	5332-5341	arbitrary	_	
35-11	5342-5348	tissue	_	
35-12	5349-5361	connectivity	_	
35-13	5362-5371	threshold	_	
35-14	5372-5379	whereas	_	
35-15	5380-5383	ICD	_	
35-16	5384-5397	characterizes	_	
35-17	5398-5409	connections	_	
35-18	5410-5416	across	_	
35-19	5417-5420	the	_	
35-20	5421-5427	entire	_	
35-21	5428-5434	degree	_	
35-22	5435-5440	curve	_	
35-23	5440-5441	.	_	

#Text=Functional connectivity and ICD overcome these limitations by investigating spatial and temporal patterns between all voxels in the brain, rather than only focusing on changes in activation.
36-1	5442-5452	Functional	_	
36-2	5453-5465	connectivity	_	
36-3	5466-5469	and	_	
36-4	5470-5473	ICD	_	
36-5	5474-5482	overcome	_	
36-6	5483-5488	these	_	
36-7	5489-5500	limitations	_	
36-8	5501-5503	by	_	
36-9	5504-5517	investigating	_	
36-10	5518-5525	spatial	_	
36-11	5526-5529	and	_	
36-12	5530-5538	temporal	_	
36-13	5539-5547	patterns	_	
36-14	5548-5555	between	_	
36-15	5556-5559	all	_	
36-16	5560-5566	voxels	_	
36-17	5567-5569	in	_	
36-18	5570-5573	the	_	
36-19	5574-5579	brain	_	
36-20	5579-5580	,	_	
36-21	5581-5587	rather	_	
36-22	5588-5592	than	_	
36-23	5593-5597	only	_	
36-24	5598-5606	focusing	_	
36-25	5607-5609	on	_	
36-26	5610-5617	changes	_	
36-27	5618-5620	in	_	
36-28	5621-5631	activation	_	
36-29	5631-5632	.	_	

#Text=Thus, this measure provides a strong index of the connectivity of any particular brain structure allowing connectivity maps of patients to be compared with healthy controls or to behavioral outcomes such as subsequent time to relapse.
37-1	5633-5637	Thus	_	
37-2	5637-5638	,	_	
37-3	5639-5643	this	_	
37-4	5644-5651	measure	_	
37-5	5652-5660	provides	_	
37-6	5661-5662	a	_	
37-7	5663-5669	strong	_	
37-8	5670-5675	index	_	
37-9	5676-5678	of	_	
37-10	5679-5682	the	_	
37-11	5683-5695	connectivity	_	
37-12	5696-5698	of	_	
37-13	5699-5702	any	_	
37-14	5703-5713	particular	_	
37-15	5714-5719	brain	_	
37-16	5720-5729	structure	_	
37-17	5730-5738	allowing	_	
37-18	5739-5751	connectivity	_	
37-19	5752-5756	maps	_	
37-20	5757-5759	of	_	
37-21	5760-5768	patients	_	
37-22	5769-5771	to	_	
37-23	5772-5774	be	_	
37-24	5775-5783	compared	_	
37-25	5784-5788	with	_	
37-26	5789-5796	healthy	_	
37-27	5797-5805	controls	_	
37-28	5806-5808	or	_	
37-29	5809-5811	to	_	
37-30	5812-5822	behavioral	_	
37-31	5823-5831	outcomes	_	
37-32	5832-5836	such	_	
37-33	5837-5839	as	_	
37-34	5840-5850	subsequent	_	
37-35	5851-5855	time	_	
37-36	5856-5858	to	_	
37-37	5859-5866	relapse	_	
37-38	5866-5867	.	_	

#Text=Using a well-validated, individualized imagery paradigm, we investigated differences in ICD associated with alcohol, stress and neutral/relaxing cue scripts in 45 recovering AUD patients and associated these differences with relapse.
38-1	5868-5873	Using	_	
38-2	5874-5875	a	_	
38-3	5876-5890	well-validated	_	
38-4	5890-5891	,	_	
38-5	5892-5906	individualized	_	
38-6	5907-5914	imagery	_	
38-7	5915-5923	paradigm	_	
38-8	5923-5924	,	_	
38-9	5925-5927	we	_	
38-10	5928-5940	investigated	_	
38-11	5941-5952	differences	_	
38-12	5953-5955	in	_	
38-13	5956-5959	ICD	_	
38-14	5960-5970	associated	_	
38-15	5971-5975	with	_	
38-16	5976-5983	alcohol	_	
38-17	5983-5984	,	_	
38-18	5985-5991	stress	_	
38-19	5992-5995	and	_	
38-20	5996-6003	neutral	_	
38-21	6003-6004	/	_	
38-22	6004-6012	relaxing	_	
38-23	6013-6016	cue	_	
38-24	6017-6024	scripts	_	
38-25	6025-6027	in	_	
38-26	6028-6030	45	_	
38-27	6031-6041	recovering	_	
38-28	6042-6045	AUD	_	
38-29	6046-6054	patients	_	
38-30	6055-6058	and	_	
38-31	6059-6069	associated	_	
38-32	6070-6075	these	_	
38-33	6076-6087	differences	_	
38-34	6088-6092	with	_	
38-35	6093-6100	relapse	_	
38-36	6100-6101	.	_	

#Text=Imagery scripts were developed from recent experiences described by participants with alcohol-related, stressful, or neutral/relaxing content.
39-1	6102-6109	Imagery	_	
39-2	6110-6117	scripts	_	
39-3	6118-6122	were	_	
39-4	6123-6132	developed	_	
39-5	6133-6137	from	_	
39-6	6138-6144	recent	_	
39-7	6145-6156	experiences	_	
39-8	6157-6166	described	_	
39-9	6167-6169	by	_	
39-10	6170-6182	participants	_	
39-11	6183-6187	with	_	
39-12	6188-6203	alcohol-related	_	
39-13	6203-6204	,	_	
39-14	6205-6214	stressful	_	
39-15	6214-6215	,	_	
39-16	6216-6218	or	_	
39-17	6219-6226	neutral	_	
39-18	6226-6227	/	_	
39-19	6227-6235	relaxing	_	
39-20	6236-6243	content	_	
39-21	6243-6244	.	_	

#Text=In a second study, for group comparison purposes, a subgroup of 30 AUD patients was matched for age, sex, and intelligence to 30 healthy control (HC) participants that underwent an identical imagery paradigm.
40-1	6245-6247	In	_	
40-2	6248-6249	a	_	
40-3	6250-6256	second	_	
40-4	6257-6262	study	_	
40-5	6262-6263	,	_	
40-6	6264-6267	for	_	
40-7	6268-6273	group	_	
40-8	6274-6284	comparison	_	
40-9	6285-6293	purposes	_	
40-10	6293-6294	,	_	
40-11	6295-6296	a	_	
40-12	6297-6305	subgroup	_	
40-13	6306-6308	of	_	
40-14	6309-6311	30	_	
40-15	6312-6315	AUD	_	
40-16	6316-6324	patients	_	
40-17	6325-6328	was	_	
40-18	6329-6336	matched	_	
40-19	6337-6340	for	_	
40-20	6341-6344	age	_	
40-21	6344-6345	,	_	
40-22	6346-6349	sex	_	
40-23	6349-6350	,	_	
40-24	6351-6354	and	_	
40-25	6355-6367	intelligence	_	
40-26	6368-6370	to	_	
40-27	6371-6373	30	_	
40-28	6374-6381	healthy	_	
40-29	6382-6389	control	_	
40-30	6390-6391	(	_	
40-31	6391-6393	HC	_	
40-32	6393-6394	)	_	
40-33	6395-6407	participants	_	
40-34	6408-6412	that	_	
40-35	6413-6422	underwent	_	
40-36	6423-6425	an	_	
40-37	6426-6435	identical	_	
40-38	6436-6443	imagery	_	
40-39	6444-6452	paradigm	_	
40-40	6452-6453	.	_	

#Text=We hypothesized that our innovative, data-driven analysis would reveal altered patterns of connectivity consistent with classic addiction regions described above, and identify new, less well-characterized networks.
41-1	6454-6456	We	_	
41-2	6457-6469	hypothesized	_	
41-3	6470-6474	that	_	
41-4	6475-6478	our	_	
41-5	6479-6489	innovative	_	
41-6	6489-6490	,	_	
41-7	6491-6502	data-driven	_	
41-8	6503-6511	analysis	_	
41-9	6512-6517	would	_	
41-10	6518-6524	reveal	_	
41-11	6525-6532	altered	_	
41-12	6533-6541	patterns	_	
41-13	6542-6544	of	_	
41-14	6545-6557	connectivity	_	
41-15	6558-6568	consistent	_	
41-16	6569-6573	with	_	
41-17	6574-6581	classic	_	
41-18	6582-6591	addiction	_	
41-19	6592-6599	regions	_	
41-20	6600-6609	described	_	
41-21	6610-6615	above	_	
41-22	6615-6616	,	_	
41-23	6617-6620	and	_	
41-24	6621-6629	identify	_	
41-25	6630-6633	new	_	
41-26	6633-6634	,	_	
41-27	6635-6639	less	_	
41-28	6640-6658	well-characterized	_	
41-29	6659-6667	networks	_	
41-30	6667-6668	.	_	

#Text=Specifically, we hypothesized that the AUD group would show altered corticolimbic connectivity during alcohol and stress relative to neutral cue conditions and, ICD connectivity in these regions would be associated with relapse.
42-1	6669-6681	Specifically	_	
42-2	6681-6682	,	_	
42-3	6683-6685	we	_	
42-4	6686-6698	hypothesized	_	
42-5	6699-6703	that	_	
42-6	6704-6707	the	_	
42-7	6708-6711	AUD	_	
42-8	6712-6717	group	_	
42-9	6718-6723	would	_	
42-10	6724-6728	show	_	
42-11	6729-6736	altered	_	
42-12	6737-6750	corticolimbic	_	
42-13	6751-6763	connectivity	_	
42-14	6764-6770	during	_	
42-15	6771-6778	alcohol	_	
42-16	6779-6782	and	_	
42-17	6783-6789	stress	_	
42-18	6790-6798	relative	_	
42-19	6799-6801	to	_	
42-20	6802-6809	neutral	_	
42-21	6810-6813	cue	_	
42-22	6814-6824	conditions	_	
42-23	6825-6828	and	_	
42-24	6828-6829	,	_	
42-25	6830-6833	ICD	_	
42-26	6834-6846	connectivity	_	
42-27	6847-6849	in	_	
42-28	6850-6855	these	_	
42-29	6856-6863	regions	_	
42-30	6864-6869	would	_	
42-31	6870-6872	be	_	
42-32	6873-6883	associated	_	
42-33	6884-6888	with	_	
42-34	6889-6896	relapse	_	
42-35	6896-6897	.	_	

#Text=In the second study, we expected to observe differential connectivity in corticolimbic regions during all script conditions in AUD patients relative to healthy controls.
43-1	6898-6900	In	_	
43-2	6901-6904	the	_	
43-3	6905-6911	second	_	
43-4	6912-6917	study	_	
43-5	6917-6918	,	_	
43-6	6919-6921	we	_	
43-7	6922-6930	expected	_	
43-8	6931-6933	to	_	
43-9	6934-6941	observe	_	
43-10	6942-6954	differential	_	
43-11	6955-6967	connectivity	_	
43-12	6968-6970	in	_	
43-13	6971-6984	corticolimbic	_	
43-14	6985-6992	regions	_	
43-15	6993-6999	during	_	
43-16	7000-7003	all	_	
43-17	7004-7010	script	_	
43-18	7011-7021	conditions	_	
43-19	7022-7024	in	_	
43-20	7025-7028	AUD	_	
43-21	7029-7037	patients	_	
43-22	7038-7046	relative	_	
43-23	7047-7049	to	_	
43-24	7050-7057	healthy	_	
43-25	7058-7066	controls	_	
43-26	7066-7067	.	_	

#Text=Materials and methods
#Text=All study procedures were approved by the Human Investigation Committee of the Yale University School of Medicine.
44-1	7068-7077	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[6]	
44-2	7078-7081	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[6]	
44-3	7082-7089	methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[6]	
44-4	7090-7093	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
44-5	7094-7099	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
44-6	7100-7110	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
44-7	7111-7115	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
44-8	7116-7124	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
44-9	7125-7127	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
44-10	7128-7131	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
44-11	7132-7137	Human	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
44-12	7138-7151	Investigation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
44-13	7152-7161	Committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
44-14	7162-7164	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
44-15	7165-7168	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
44-16	7169-7173	Yale	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
44-17	7174-7184	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
44-18	7185-7191	School	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
44-19	7192-7194	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
44-20	7195-7203	Medicine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
44-21	7203-7204	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	

#Text=All participants signed a written informed consent form.
45-1	7205-7208	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-2	7209-7221	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-3	7222-7228	signed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-4	7229-7230	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-5	7231-7238	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-6	7239-7247	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-7	7248-7255	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-8	7256-7260	form	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
45-9	7260-7261	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	

#Text=Participants
#Text=Study 1: Forty-five recovering AUD patients (10 female, aged 18–50, M = 37.7) and 30 healthy control individuals (9 female, aged 18–50, M = 34.5) participated in this study.
46-1	7262-7274	Participants	_	
46-2	7275-7280	Study	_	
46-3	7281-7282	1	_	
46-4	7282-7283	:	_	
46-5	7284-7294	Forty-five	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-6	7295-7305	recovering	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-7	7306-7309	AUD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[9]	
46-8	7310-7318	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-9	7319-7320	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-10	7320-7322	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-11	7323-7329	female	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-12	7329-7330	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-13	7331-7335	aged	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-14	7336-7338	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-15	7338-7339	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-16	7339-7341	50	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-17	7341-7342	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-18	7343-7344	M	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-19	7344-7345	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-20	7345-7346	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-21	7346-7347	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-22	7347-7351	37.7	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-23	7351-7352	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-24	7353-7356	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-25	7357-7359	30	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-26	7360-7367	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[10]	
46-27	7368-7375	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[10]	
46-28	7376-7387	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-29	7388-7389	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-30	7389-7390	9	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-31	7391-7397	female	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-32	7397-7398	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-33	7399-7403	aged	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-34	7404-7406	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-35	7406-7407	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-36	7407-7409	50	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-37	7409-7410	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-38	7411-7412	M	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-39	7412-7413	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-40	7413-7414	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-41	7414-7415	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-42	7415-7419	34.5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-43	7419-7420	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-44	7421-7433	participated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-45	7434-7436	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-46	7437-7441	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-47	7442-7447	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
46-48	7447-7448	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	

#Text=Task-based fMRI results on this sample and full details on the participants, imagery method and validation, and relapse measures were previously published in.
47-1	7449-7459	Task-based	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[11]	
47-2	7460-7464	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]|http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[11]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[12]	
47-3	7465-7472	results	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-4	7473-7475	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-5	7476-7480	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-6	7481-7487	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-7	7488-7491	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-8	7492-7496	full	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-9	7497-7504	details	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-10	7505-7507	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-11	7508-7511	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-12	7512-7524	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-13	7524-7525	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-14	7526-7533	imagery	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-15	7534-7540	method	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-16	7541-7544	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-17	7545-7555	validation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-18	7555-7556	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-19	7557-7560	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-20	7561-7568	relapse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-21	7569-7577	measures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-22	7578-7582	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-23	7583-7593	previously	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-24	7594-7603	published	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-25	7604-7606	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
47-26	7606-7607	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	

#Text=All AUD patients had a current diagnosis of alcohol dependence as determined by a Structured Clinical Interview for DSM-IV, and abstained from alcohol for 4 to 6 weeks (mean = 34 days, SE = 1.14) while actively engaged in inpatient non-pharmacological substance abuse treatment.
48-1	7608-7611	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-2	7612-7615	AUD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[14]	
48-3	7616-7624	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-4	7625-7628	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-5	7629-7630	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-6	7631-7638	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-7	7639-7648	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-8	7649-7651	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-9	7652-7659	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[15]	
48-10	7660-7670	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[15]	
48-11	7671-7673	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-12	7674-7684	determined	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-13	7685-7687	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-14	7688-7689	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-15	7690-7700	Structured	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[16]	
48-16	7701-7709	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[16]	
48-17	7710-7719	Interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[16]	
48-18	7720-7723	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[16]	
48-19	7724-7730	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[16]	
48-20	7730-7731	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-21	7732-7735	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-22	7736-7745	abstained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-23	7746-7750	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-24	7751-7758	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-25	7759-7762	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-26	7763-7764	4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-27	7765-7767	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-28	7768-7769	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-29	7769-7770	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-30	7770-7775	weeks	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-31	7776-7777	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-32	7777-7781	mean	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-33	7781-7782	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-34	7782-7783	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-35	7783-7784	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-36	7784-7786	34	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-37	7786-7787	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-38	7787-7791	days	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-39	7791-7792	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-40	7793-7795	SE	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-41	7795-7796	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-42	7796-7797	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-43	7797-7798	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-44	7798-7802	1.14	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-45	7802-7803	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-46	7804-7809	while	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-47	7810-7818	actively	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-48	7819-7826	engaged	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-49	7827-7829	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-50	7830-7839	inpatient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-51	7840-7859	non-pharmacological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-52	7860-7869	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-53	7870-7875	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-54	7876-7885	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
48-55	7885-7886	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	

#Text=Demographic details are presented in Table S1.
49-1	7887-7898	Demographic	_	
49-2	7899-7906	details	_	
49-3	7907-7910	are	_	
49-4	7911-7920	presented	_	
49-5	7921-7923	in	_	
49-6	7924-7929	Table	_	
49-7	7930-7932	S1	_	
49-8	7932-7933	.	_	

#Text=Tobacco-using AUD patients were allowed to smoke prior to initiating the fMRI scan and thus, were not nicotine deprived at the time of scan.
50-1	7934-7947	Tobacco-using	_	
50-2	7948-7951	AUD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	
50-3	7952-7960	patients	_	
50-4	7961-7965	were	_	
50-5	7966-7973	allowed	_	
50-6	7974-7976	to	_	
50-7	7977-7982	smoke	_	
50-8	7983-7988	prior	_	
50-9	7989-7991	to	_	
50-10	7992-8002	initiating	_	
50-11	8003-8006	the	_	
50-12	8007-8011	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
50-13	8012-8016	scan	_	
50-14	8017-8020	and	_	
50-15	8021-8025	thus	_	
50-16	8025-8026	,	_	
50-17	8027-8031	were	_	
50-18	8032-8035	not	_	
50-19	8036-8044	nicotine	_	
50-20	8045-8053	deprived	_	
50-21	8054-8056	at	_	
50-22	8057-8060	the	_	
50-23	8061-8065	time	_	
50-24	8066-8068	of	_	
50-25	8069-8073	scan	_	
50-26	8073-8074	.	_	

#Text=Patients were scanned in week 5 of treatment and were discharged shortly after and referred to outpatient treatment for aftercare.
51-1	8075-8083	Patients	_	
51-2	8084-8088	were	_	
51-3	8089-8096	scanned	_	
51-4	8097-8099	in	_	
51-5	8100-8104	week	_	
51-6	8105-8106	5	_	
51-7	8107-8109	of	_	
51-8	8110-8119	treatment	_	
51-9	8120-8123	and	_	
51-10	8124-8128	were	_	
51-11	8129-8139	discharged	_	
51-12	8140-8147	shortly	_	
51-13	8148-8153	after	_	
51-14	8154-8157	and	_	
51-15	8158-8166	referred	_	
51-16	8167-8169	to	_	
51-17	8170-8180	outpatient	_	
51-18	8181-8190	treatment	_	
51-19	8191-8194	for	_	
51-20	8195-8204	aftercare	_	
51-21	8204-8205	.	_	

#Text=All patients were followed-up with in-person interviews conducted at 14, 30, and 90 days post-discharge to evaluate relapse outcomes using urine and breathalyzer samples and the Form 90 Substance Use Calendar based on the timeline follow-back method.
52-1	8206-8209	All	_	
52-2	8210-8218	patients	_	
52-3	8219-8223	were	_	
52-4	8224-8235	followed-up	_	
52-5	8236-8240	with	_	
52-6	8241-8250	in-person	_	
52-7	8251-8261	interviews	_	
52-8	8262-8271	conducted	_	
52-9	8272-8274	at	_	
52-10	8275-8277	14	_	
52-11	8277-8278	,	_	
52-12	8279-8281	30	_	
52-13	8281-8282	,	_	
52-14	8283-8286	and	_	
52-15	8287-8289	90	_	
52-16	8289-8290	 	_	
52-17	8290-8294	days	_	
52-18	8295-8309	post-discharge	_	
52-19	8310-8312	to	_	
52-20	8313-8321	evaluate	_	
52-21	8322-8329	relapse	_	
52-22	8330-8338	outcomes	_	
52-23	8339-8344	using	_	
52-24	8345-8350	urine	_	
52-25	8351-8354	and	_	
52-26	8355-8367	breathalyzer	_	
52-27	8368-8375	samples	_	
52-28	8376-8379	and	_	
52-29	8380-8383	the	_	
52-30	8384-8388	Form	_	
52-31	8389-8391	90	_	
52-32	8392-8401	Substance	_	
52-33	8402-8405	Use	_	
52-34	8406-8414	Calendar	_	
52-35	8415-8420	based	_	
52-36	8421-8423	on	_	
52-37	8424-8427	the	_	
52-38	8428-8436	timeline	_	
52-39	8437-8448	follow-back	_	
52-40	8449-8455	method	_	
52-41	8455-8456	.	_	

#Text=Study 2: For group comparisons, 30 HC participants were demographically-matched to 30 (8 female, aged 18–50, M = 36.0) of the 45 AUD patients on age, sex, IQ, and lifetime prevalence of psychiatric disorders except for alcohol dependence and smoking status.
53-1	8457-8462	Study	_	
53-2	8463-8464	2	_	
53-3	8464-8465	:	_	
53-4	8466-8469	For	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-5	8470-8475	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-6	8476-8487	comparisons	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-7	8487-8488	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-8	8489-8491	30	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-9	8492-8494	HC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[18]	
53-10	8495-8507	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-11	8508-8512	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-12	8513-8536	demographically-matched	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-13	8537-8539	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-14	8540-8542	30	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-15	8543-8544	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-16	8544-8545	8	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-17	8546-8552	female	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-18	8552-8553	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-19	8554-8558	aged	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-20	8559-8561	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-21	8561-8562	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-22	8562-8564	50	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-23	8564-8565	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-24	8566-8567	M	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-25	8567-8568	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-26	8568-8569	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-27	8569-8570	 	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-28	8570-8574	36.0	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-29	8574-8575	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-30	8576-8578	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-31	8579-8582	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-32	8583-8585	45	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-33	8586-8589	AUD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[19]	
53-34	8590-8598	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-35	8599-8601	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-36	8602-8605	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-37	8605-8606	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-38	8607-8610	sex	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-39	8610-8611	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-40	8612-8614	IQ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-41	8614-8615	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-42	8616-8619	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-43	8620-8628	lifetime	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-44	8629-8639	prevalence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-45	8640-8642	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-46	8643-8654	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-47	8655-8664	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-48	8665-8671	except	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-49	8672-8675	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-50	8676-8683	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-51	8684-8694	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-52	8695-8698	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-53	8699-8706	smoking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-54	8707-8713	status	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
53-55	8713-8714	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	

#Text=Smoking status was included as a covariate in the group analyses.
54-1	8715-8722	Smoking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
54-2	8723-8729	status	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
54-3	8730-8733	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
54-4	8734-8742	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
54-5	8743-8745	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
54-6	8746-8747	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
54-7	8748-8757	covariate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
54-8	8758-8760	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
54-9	8761-8764	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
54-10	8765-8770	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
54-11	8771-8779	analyses	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
54-12	8779-8780	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	

#Text=We chose to demographically match as many AUD patients as possible to the HC participants instead of comparing all 45 AUD patients to HC as IQ and years of education were significantly lower in the full AUD group.
55-1	8781-8783	We	_	
55-2	8784-8789	chose	_	
55-3	8790-8792	to	_	
55-4	8793-8808	demographically	_	
55-5	8809-8814	match	_	
55-6	8815-8817	as	_	
55-7	8818-8822	many	_	
55-8	8823-8826	AUD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	
55-9	8827-8835	patients	_	
55-10	8836-8838	as	_	
55-11	8839-8847	possible	_	
55-12	8848-8850	to	_	
55-13	8851-8854	the	_	
55-14	8855-8857	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
55-15	8858-8870	participants	_	
55-16	8871-8878	instead	_	
55-17	8879-8881	of	_	
55-18	8882-8891	comparing	_	
55-19	8892-8895	all	_	
55-20	8896-8898	45	_	
55-21	8899-8902	AUD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	
55-22	8903-8911	patients	_	
55-23	8912-8914	to	_	
55-24	8915-8917	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
55-25	8918-8920	as	_	
55-26	8921-8923	IQ	_	
55-27	8924-8927	and	_	
55-28	8928-8933	years	_	
55-29	8934-8936	of	_	
55-30	8937-8946	education	_	
55-31	8947-8951	were	_	
55-32	8952-8965	significantly	_	
55-33	8966-8971	lower	_	
55-34	8972-8974	in	_	
55-35	8975-8978	the	_	
55-36	8979-8983	full	_	
55-37	8984-8987	AUD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	
55-38	8988-8993	group	_	
55-39	8993-8994	.	_	

#Text=Matching allowed us to minimize this potential confound, as the AUD subgroup was not significantly different from HC participants in several demographics including age, sex and IQ, but was significantly different in number of smokers in the AUD versus the HC group (See Table S1).
56-1	8995-9003	Matching	_	
56-2	9004-9011	allowed	_	
56-3	9012-9014	us	_	
56-4	9015-9017	to	_	
56-5	9018-9026	minimize	_	
56-6	9027-9031	this	_	
56-7	9032-9041	potential	_	
56-8	9042-9050	confound	_	
56-9	9050-9051	,	_	
56-10	9052-9054	as	_	
56-11	9055-9058	the	_	
56-12	9059-9062	AUD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	
56-13	9063-9071	subgroup	_	
56-14	9072-9075	was	_	
56-15	9076-9079	not	_	
56-16	9080-9093	significantly	_	
56-17	9094-9103	different	_	
56-18	9104-9108	from	_	
56-19	9109-9111	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
56-20	9112-9124	participants	_	
56-21	9125-9127	in	_	
56-22	9128-9135	several	_	
56-23	9136-9148	demographics	_	
56-24	9149-9158	including	_	
56-25	9159-9162	age	_	
56-26	9162-9163	,	_	
56-27	9164-9167	sex	_	
56-28	9168-9171	and	_	
56-29	9172-9174	IQ	_	
56-30	9174-9175	,	_	
56-31	9176-9179	but	_	
56-32	9180-9183	was	_	
56-33	9184-9197	significantly	_	
56-34	9198-9207	different	_	
56-35	9208-9210	in	_	
56-36	9211-9217	number	_	
56-37	9218-9220	of	_	
56-38	9221-9228	smokers	_	
56-39	9229-9231	in	_	
56-40	9232-9235	the	_	
56-41	9236-9239	AUD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	
56-42	9240-9246	versus	_	
56-43	9247-9250	the	_	
56-44	9251-9253	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
56-45	9254-9259	group	_	
56-46	9260-9261	(	_	
56-47	9261-9264	See	_	
56-48	9265-9270	Table	_	
56-49	9271-9273	S1	_	
56-50	9273-9274	)	_	
56-51	9274-9275	.	_	

#Text=Imagery paradigm
#Text=All participants engaged in an imagery paradigm composed of individualized 2-min imagery scripts designed to provoke either alcohol, stressful, or neutral/relaxing states.
57-1	9276-9283	Imagery	_	
57-2	9284-9292	paradigm	_	
57-3	9293-9296	All	_	
57-4	9297-9309	participants	_	
57-5	9310-9317	engaged	_	
57-6	9318-9320	in	_	
57-7	9321-9323	an	_	
57-8	9324-9331	imagery	_	
57-9	9332-9340	paradigm	_	
57-10	9341-9349	composed	_	
57-11	9350-9352	of	_	
57-12	9353-9367	individualized	_	
57-13	9368-9369	2	_	
57-14	9369-9370	-	_	
57-15	9370-9373	min	_	
57-16	9374-9381	imagery	_	
57-17	9382-9389	scripts	_	
57-18	9390-9398	designed	_	
57-19	9399-9401	to	_	
57-20	9402-9409	provoke	_	
57-21	9410-9416	either	_	
57-22	9417-9424	alcohol	_	
57-23	9424-9425	,	_	
57-24	9426-9435	stressful	_	
57-25	9435-9436	,	_	
57-26	9437-9439	or	_	
57-27	9440-9447	neutral	_	
57-28	9447-9448	/	_	
57-29	9448-9456	relaxing	_	
57-30	9457-9463	states	_	
57-31	9463-9464	.	_	

#Text=Alcohol and stress scripts relative to neutral have previously been shown to increase craving, anxiety, heart rate and cortisol levels.
58-1	9465-9472	Alcohol	_	
58-2	9473-9476	and	_	
58-3	9477-9483	stress	_	
58-4	9484-9491	scripts	_	
58-5	9492-9500	relative	_	
58-6	9501-9503	to	_	
58-7	9504-9511	neutral	_	
58-8	9512-9516	have	_	
58-9	9517-9527	previously	_	
58-10	9528-9532	been	_	
58-11	9533-9538	shown	_	
58-12	9539-9541	to	_	
58-13	9542-9550	increase	_	
58-14	9551-9558	craving	_	
58-15	9558-9559	,	_	
58-16	9560-9567	anxiety	_	
58-17	9567-9568	,	_	
58-18	9569-9574	heart	_	
58-19	9575-9579	rate	_	
58-20	9580-9583	and	_	
58-21	9584-9592	cortisol	_	
58-22	9593-9599	levels	_	
58-23	9599-9600	.	_	

#Text=Each 2-min script was based on a personal experience described by the participant and audiotaped for presentation during scanning session (see Supplemental material for further information).
59-1	9601-9605	Each	_	
59-2	9606-9607	2	_	
59-3	9607-9608	-	_	
59-4	9608-9611	min	_	
59-5	9612-9618	script	_	
59-6	9619-9622	was	_	
59-7	9623-9628	based	_	
59-8	9629-9631	on	_	
59-9	9632-9633	a	_	
59-10	9634-9642	personal	_	
59-11	9643-9653	experience	_	
59-12	9654-9663	described	_	
59-13	9664-9666	by	_	
59-14	9667-9670	the	_	
59-15	9671-9682	participant	_	
59-16	9683-9686	and	_	
59-17	9687-9697	audiotaped	_	
59-18	9698-9701	for	_	
59-19	9702-9714	presentation	_	
59-20	9715-9721	during	_	
59-21	9722-9730	scanning	_	
59-22	9731-9738	session	_	
59-23	9739-9740	(	_	
59-24	9740-9743	see	_	
59-25	9744-9756	Supplemental	_	
59-26	9757-9765	material	_	
59-27	9766-9769	for	_	
59-28	9770-9777	further	_	
59-29	9778-9789	information	_	
59-30	9789-9790	)	_	
59-31	9790-9791	.	_	

#Text=Six fMRI trials (2 per condition) were acquired using a block design.
60-1	9792-9795	Six	_	
60-2	9796-9800	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
60-3	9801-9807	trials	_	
60-4	9808-9809	(	_	
60-5	9809-9810	2	_	
60-6	9811-9814	per	_	
60-7	9815-9824	condition	_	
60-8	9824-9825	)	_	
60-9	9826-9830	were	_	
60-10	9831-9839	acquired	_	
60-11	9840-9845	using	_	
60-12	9846-9847	a	_	
60-13	9848-9853	block	_	
60-14	9854-9860	design	_	
60-15	9860-9861	.	_	

#Text=The order of the 3 script conditions were randomized and counterbalanced across participants.
61-1	9862-9865	The	_	
61-2	9866-9871	order	_	
61-3	9872-9874	of	_	
61-4	9875-9878	the	_	
61-5	9879-9880	3	_	
61-6	9881-9887	script	_	
61-7	9888-9898	conditions	_	
61-8	9899-9903	were	_	
61-9	9904-9914	randomized	_	
61-10	9915-9918	and	_	
61-11	9919-9934	counterbalanced	_	
61-12	9935-9941	across	_	
61-13	9942-9954	participants	_	
61-14	9954-9955	.	_	

#Text=Each script was presented only once for each participant, and scripts of the same condition were not presented consecutively.
62-1	9956-9960	Each	_	
62-2	9961-9967	script	_	
62-3	9968-9971	was	_	
62-4	9972-9981	presented	_	
62-5	9982-9986	only	_	
62-6	9987-9991	once	_	
62-7	9992-9995	for	_	
62-8	9996-10000	each	_	
62-9	10001-10012	participant	_	
62-10	10012-10013	,	_	
62-11	10014-10017	and	_	
62-12	10018-10025	scripts	_	
62-13	10026-10028	of	_	
62-14	10029-10032	the	_	
62-15	10033-10037	same	_	
62-16	10038-10047	condition	_	
62-17	10048-10052	were	_	
62-18	10053-10056	not	_	
62-19	10057-10066	presented	_	
62-20	10067-10080	consecutively	_	
62-21	10080-10081	.	_	

#Text=Each trial lasted 5 min, including a 1.5-min quiet baseline period followed by a continuous 2.5-min imagery period (2-min read imagery, 0.5-min quiet imagery) and a 1-min quiet recovery.
63-1	10082-10086	Each	_	
63-2	10087-10092	trial	_	
63-3	10093-10099	lasted	_	
63-4	10100-10101	5	_	
63-5	10101-10102	 	_	
63-6	10102-10105	min	_	
63-7	10105-10106	,	_	
63-8	10107-10116	including	_	
63-9	10117-10118	a	_	
63-10	10119-10122	1.5	_	
63-11	10122-10123	-	_	
63-12	10123-10126	min	_	
63-13	10127-10132	quiet	_	
63-14	10133-10141	baseline	_	
63-15	10142-10148	period	_	
63-16	10149-10157	followed	_	
63-17	10158-10160	by	_	
63-18	10161-10162	a	_	
63-19	10163-10173	continuous	_	
63-20	10174-10177	2.5	_	
63-21	10177-10178	-	_	
63-22	10178-10181	min	_	
63-23	10182-10189	imagery	_	
63-24	10190-10196	period	_	
63-25	10197-10198	(	_	
63-26	10198-10199	2	_	
63-27	10199-10200	-	_	
63-28	10200-10203	min	_	
63-29	10204-10208	read	_	
63-30	10209-10216	imagery	_	
63-31	10216-10217	,	_	
63-32	10218-10221	0.5	_	
63-33	10221-10222	-	_	
63-34	10222-10225	min	_	
63-35	10226-10231	quiet	_	
63-36	10232-10239	imagery	_	
63-37	10239-10240	)	_	
63-38	10241-10244	and	_	
63-39	10245-10246	a	_	
63-40	10247-10248	1	_	
63-41	10248-10249	-	_	
63-42	10249-10252	min	_	
63-43	10253-10258	quiet	_	
63-44	10259-10267	recovery	_	
63-45	10267-10268	.	_	

#Text=During baseline, participants were instructed to stay still in the scanner without engaging in any mental activity.
64-1	10269-10275	During	_	
64-2	10276-10284	baseline	_	
64-3	10284-10285	,	_	
64-4	10286-10298	participants	_	
64-5	10299-10303	were	_	
64-6	10304-10314	instructed	_	
64-7	10315-10317	to	_	
64-8	10318-10322	stay	_	
64-9	10323-10328	still	_	
64-10	10329-10331	in	_	
64-11	10332-10335	the	_	
64-12	10336-10343	scanner	_	
64-13	10344-10351	without	_	
64-14	10352-10360	engaging	_	
64-15	10361-10363	in	_	
64-16	10364-10367	any	_	
64-17	10368-10374	mental	_	
64-18	10375-10383	activity	_	
64-19	10383-10384	.	_	

#Text=To minimize residual craving/anxiety between trials, all subjects were asked to practice 2-min progressive relaxation.
65-1	10385-10387	To	_	
65-2	10388-10396	minimize	_	
65-3	10397-10405	residual	_	
65-4	10406-10413	craving	_	
65-5	10413-10414	/	_	
65-6	10414-10421	anxiety	_	
65-7	10422-10429	between	_	
65-8	10430-10436	trials	_	
65-9	10436-10437	,	_	
65-10	10438-10441	all	_	
65-11	10442-10450	subjects	_	
65-12	10451-10455	were	_	
65-13	10456-10461	asked	_	
65-14	10462-10464	to	_	
65-15	10465-10473	practice	_	
65-16	10474-10475	2	_	
65-17	10475-10476	-	_	
65-18	10476-10479	min	_	
65-19	10480-10491	progressive	_	
65-20	10492-10502	relaxation	_	
65-21	10502-10503	.	_	

#Text=After relaxation, all participants returned to baseline levels of subjective craving and anxiety ratings, before starting the next cue trial, verified by no statistical difference in baseline ratings across trials.
66-1	10504-10509	After	_	
66-2	10510-10520	relaxation	_	
66-3	10520-10521	,	_	
66-4	10522-10525	all	_	
66-5	10526-10538	participants	_	
66-6	10539-10547	returned	_	
66-7	10548-10550	to	_	
66-8	10551-10559	baseline	_	
66-9	10560-10566	levels	_	
66-10	10567-10569	of	_	
66-11	10570-10580	subjective	_	
66-12	10581-10588	craving	_	
66-13	10589-10592	and	_	
66-14	10593-10600	anxiety	_	
66-15	10601-10608	ratings	_	
66-16	10608-10609	,	_	
66-17	10610-10616	before	_	
66-18	10617-10625	starting	_	
66-19	10626-10629	the	_	
66-20	10630-10634	next	_	
66-21	10635-10638	cue	_	
66-22	10639-10644	trial	_	
66-23	10644-10645	,	_	
66-24	10646-10654	verified	_	
66-25	10655-10657	by	_	
66-26	10658-10660	no	_	
66-27	10661-10672	statistical	_	
66-28	10673-10683	difference	_	
66-29	10684-10686	in	_	
66-30	10687-10695	baseline	_	
66-31	10696-10703	ratings	_	
66-32	10704-10710	across	_	
66-33	10711-10717	trials	_	
66-34	10717-10718	.	_	

#Text=Connectivity preprocessing
#Text=Images were slice-time and motion corrected using SPM5 (http://www.fil.ion.ucl.ac.uk).
67-1	10719-10731	Connectivity	_	
67-2	10732-10745	preprocessing	_	
67-3	10746-10752	Images	_	
67-4	10753-10757	were	_	
67-5	10758-10768	slice-time	_	
67-6	10769-10772	and	_	
67-7	10773-10779	motion	_	
67-8	10780-10789	corrected	_	
67-9	10790-10795	using	_	
67-10	10796-10800	SPM5	_	
67-11	10801-10802	(	_	
67-12	10802-10806	http	_	
67-13	10806-10807	:	_	
67-14	10807-10808	/	_	
67-15	10808-10809	/	_	
67-16	10809-10830	www.fil.ion.ucl.ac.uk	_	
67-17	10830-10831	)	_	
67-18	10831-10832	.	_	

#Text=Images were iteratively smoothed until the smoothness for any image had a full width half maximum of approximately 6 mm.
68-1	10833-10839	Images	_	
68-2	10840-10844	were	_	
68-3	10845-10856	iteratively	_	
68-4	10857-10865	smoothed	_	
68-5	10866-10871	until	_	
68-6	10872-10875	the	_	
68-7	10876-10886	smoothness	_	
68-8	10887-10890	for	_	
68-9	10891-10894	any	_	
68-10	10895-10900	image	_	
68-11	10901-10904	had	_	
68-12	10905-10906	a	_	
68-13	10907-10911	full	_	
68-14	10912-10917	width	_	
68-15	10918-10922	half	_	
68-16	10923-10930	maximum	_	
68-17	10931-10933	of	_	
68-18	10934-10947	approximately	_	
68-19	10948-10949	6	_	
68-20	10949-10950	 	_	
68-21	10950-10952	mm	_	
68-22	10952-10953	.	_	

#Text=This iterative smoothing has been shown to minimize motion confounds associated with resting-state fMRI.
69-1	10954-10958	This	_	
69-2	10959-10968	iterative	_	
69-3	10969-10978	smoothing	_	
69-4	10979-10982	has	_	
69-5	10983-10987	been	_	
69-6	10988-10993	shown	_	
69-7	10994-10996	to	_	
69-8	10997-11005	minimize	_	
69-9	11006-11012	motion	_	
69-10	11013-11022	confounds	_	
69-11	11023-11033	associated	_	
69-12	11034-11038	with	_	
69-13	11039-11052	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[20]	
69-14	11053-11057	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[20]	
69-15	11057-11058	.	_	

#Text=All further analysis was performed using BioImage Suite unless otherwise specified.
70-1	11059-11062	All	_	
70-2	11063-11070	further	_	
70-3	11071-11079	analysis	_	
70-4	11080-11083	was	_	
70-5	11084-11093	performed	_	
70-6	11094-11099	using	_	
70-7	11100-11108	BioImage	_	
70-8	11109-11114	Suite	_	
70-9	11115-11121	unless	_	
70-10	11122-11131	otherwise	_	
70-11	11132-11141	specified	_	
70-12	11141-11142	.	_	

#Text=Runs were further preprocessed individually for connectivity analysis.
71-1	11143-11147	Runs	_	
71-2	11148-11152	were	_	
71-3	11153-11160	further	_	
71-4	11161-11173	preprocessed	_	
71-5	11174-11186	individually	_	
71-6	11187-11190	for	_	
71-7	11191-11203	connectivity	_	
71-8	11204-11212	analysis	_	
71-9	11212-11213	.	_	

#Text=Several covariates of no interest were regressed from the data including linear and quadratic drift, six rigid-body motion parameters, mean cerebral-spinal fluid (CSF) signal, mean white matter signal, and mean global signal.
72-1	11214-11221	Several	_	
72-2	11222-11232	covariates	_	
72-3	11233-11235	of	_	
72-4	11236-11238	no	_	
72-5	11239-11247	interest	_	
72-6	11248-11252	were	_	
72-7	11253-11262	regressed	_	
72-8	11263-11267	from	_	
72-9	11268-11271	the	_	
72-10	11272-11276	data	_	
72-11	11277-11286	including	_	
72-12	11287-11293	linear	_	
72-13	11294-11297	and	_	
72-14	11298-11307	quadratic	_	
72-15	11308-11313	drift	_	
72-16	11313-11314	,	_	
72-17	11315-11318	six	_	
72-18	11319-11329	rigid-body	_	
72-19	11330-11336	motion	_	
72-20	11337-11347	parameters	_	
72-21	11347-11348	,	_	
72-22	11349-11353	mean	_	
72-23	11354-11369	cerebral-spinal	_	
72-24	11370-11375	fluid	_	
72-25	11376-11377	(	_	
72-26	11377-11380	CSF	_	
72-27	11380-11381	)	_	
72-28	11382-11388	signal	_	
72-29	11388-11389	,	_	
72-30	11390-11394	mean	_	
72-31	11395-11400	white	_	
72-32	11401-11407	matter	_	
72-33	11408-11414	signal	_	
72-34	11414-11415	,	_	
72-35	11416-11419	and	_	
72-36	11420-11424	mean	_	
72-37	11425-11431	global	_	
72-38	11432-11438	signal	_	
72-39	11438-11439	.	_	

#Text=Finally, the data were temporally smoothed with a zero mean unit variance Gaussian filter (cutoff frequency = 0.12 Hz).
73-1	11440-11447	Finally	_	
73-2	11447-11448	,	_	
73-3	11449-11452	the	_	
73-4	11453-11457	data	_	
73-5	11458-11462	were	_	
73-6	11463-11473	temporally	_	
73-7	11474-11482	smoothed	_	
73-8	11483-11487	with	_	
73-9	11488-11489	a	_	
73-10	11490-11494	zero	_	
73-11	11495-11499	mean	_	
73-12	11500-11504	unit	_	
73-13	11505-11513	variance	_	
73-14	11514-11522	Gaussian	_	
73-15	11523-11529	filter	_	
73-16	11530-11531	(	_	
73-17	11531-11537	cutoff	_	
73-18	11538-11547	frequency	_	
73-19	11547-11548	 	_	
73-20	11548-11549	=	_	
73-21	11549-11550	 	_	
73-22	11550-11554	0.12	_	
73-23	11554-11555	 	_	
73-24	11555-11557	Hz	_	
73-25	11557-11558	)	_	
73-26	11558-11559	.	_	

#Text=A gray matter mask was applied to the data so that only voxels in the gray matter were used in the calculation.
74-1	11560-11561	A	_	
74-2	11562-11566	gray	_	
74-3	11567-11573	matter	_	
74-4	11574-11578	mask	_	
74-5	11579-11582	was	_	
74-6	11583-11590	applied	_	
74-7	11591-11593	to	_	
74-8	11594-11597	the	_	
74-9	11598-11602	data	_	
74-10	11603-11605	so	_	
74-11	11606-11610	that	_	
74-12	11611-11615	only	_	
74-13	11616-11622	voxels	_	
74-14	11623-11625	in	_	
74-15	11626-11629	the	_	
74-16	11630-11634	gray	_	
74-17	11635-11641	matter	_	
74-18	11642-11646	were	_	
74-19	11647-11651	used	_	
74-20	11652-11654	in	_	
74-21	11655-11658	the	_	
74-22	11659-11670	calculation	_	
74-23	11670-11671	.	_	

#Text=Finally, for each voxel, time courses were normalized by removing that time course's mean and dividing by that time course's standard deviation.
75-1	11672-11679	Finally	_	
75-2	11679-11680	,	_	
75-3	11681-11684	for	_	
75-4	11685-11689	each	_	
75-5	11690-11695	voxel	_	
75-6	11695-11696	,	_	
75-7	11697-11701	time	_	
75-8	11702-11709	courses	_	
75-9	11710-11714	were	_	
75-10	11715-11725	normalized	_	
75-11	11726-11728	by	_	
75-12	11729-11737	removing	_	
75-13	11738-11742	that	_	
75-14	11743-11747	time	_	
75-15	11748-11756	course's	_	
75-16	11757-11761	mean	_	
75-17	11762-11765	and	_	
75-18	11766-11774	dividing	_	
75-19	11775-11777	by	_	
75-20	11778-11782	that	_	
75-21	11783-11787	time	_	
75-22	11788-11796	course's	_	
75-23	11797-11805	standard	_	
75-24	11806-11815	deviation	_	
75-25	11815-11816	.	_	

#Text=As previously described, connectivity analysis was only performed on the continuous 2.5-min imagery period.
76-1	11817-11819	As	_	
76-2	11820-11830	previously	_	
76-3	11831-11840	described	_	
76-4	11840-11841	,	_	
76-5	11842-11854	connectivity	_	
76-6	11855-11863	analysis	_	
76-7	11864-11867	was	_	
76-8	11868-11872	only	_	
76-9	11873-11882	performed	_	
76-10	11883-11885	on	_	
76-11	11886-11889	the	_	
76-12	11890-11900	continuous	_	
76-13	11901-11904	2.5	_	
76-14	11904-11905	-	_	
76-15	11905-11908	min	_	
76-16	11909-11916	imagery	_	
76-17	11917-11923	period	_	
76-18	11923-11924	.	_	

#Text=The 2-min active imagery period and 0.5-min passive imagery period were extracted from the full dataset and imagery periods of the same cue trial were concatenated for further analysis, resulting in approximately 5 min of data for each cue condition.
77-1	11925-11928	The	_	
77-2	11929-11930	2	_	
77-3	11930-11931	-	_	
77-4	11931-11934	min	_	
77-5	11935-11941	active	_	
77-6	11942-11949	imagery	_	
77-7	11950-11956	period	_	
77-8	11957-11960	and	_	
77-9	11961-11964	0.5	_	
77-10	11964-11965	-	_	
77-11	11965-11968	min	_	
77-12	11969-11976	passive	_	
77-13	11977-11984	imagery	_	
77-14	11985-11991	period	_	
77-15	11992-11996	were	_	
77-16	11997-12006	extracted	_	
77-17	12007-12011	from	_	
77-18	12012-12015	the	_	
77-19	12016-12020	full	_	
77-20	12021-12028	dataset	_	
77-21	12029-12032	and	_	
77-22	12033-12040	imagery	_	
77-23	12041-12048	periods	_	
77-24	12049-12051	of	_	
77-25	12052-12055	the	_	
77-26	12056-12060	same	_	
77-27	12061-12064	cue	_	
77-28	12065-12070	trial	_	
77-29	12071-12075	were	_	
77-30	12076-12088	concatenated	_	
77-31	12089-12092	for	_	
77-32	12093-12100	further	_	
77-33	12101-12109	analysis	_	
77-34	12109-12110	,	_	
77-35	12111-12120	resulting	_	
77-36	12121-12123	in	_	
77-37	12124-12137	approximately	_	
77-38	12138-12139	5	_	
77-39	12139-12140	 	_	
77-40	12140-12143	min	_	
77-41	12144-12146	of	_	
77-42	12147-12151	data	_	
77-43	12152-12155	for	_	
77-44	12156-12160	each	_	
77-45	12161-12164	cue	_	
77-46	12165-12174	condition	_	
77-47	12174-12175	.	_	

#Text=The large amount of continuous task data allows us to use novel data-driven connectivity methods usually reserved for resting-state fMRI.
78-1	12176-12179	The	_	
78-2	12180-12185	large	_	
78-3	12186-12192	amount	_	
78-4	12193-12195	of	_	
78-5	12196-12206	continuous	_	
78-6	12207-12211	task	_	
78-7	12212-12216	data	_	
78-8	12217-12223	allows	_	
78-9	12224-12226	us	_	
78-10	12227-12229	to	_	
78-11	12230-12233	use	_	
78-12	12234-12239	novel	_	
78-13	12240-12251	data-driven	_	
78-14	12252-12264	connectivity	_	
78-15	12265-12272	methods	_	
78-16	12273-12280	usually	_	
78-17	12281-12289	reserved	_	
78-18	12290-12293	for	_	
78-19	12294-12307	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[21]	
78-20	12308-12312	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[21]	
78-21	12312-12313	.	_	

#Text=Standard block design tasks with ~ 30 s blocks or event-related design tasks would not provide a sufficient amount of continuous data for such methods.
79-1	12314-12322	Standard	_	
79-2	12323-12328	block	_	
79-3	12329-12335	design	_	
79-4	12336-12341	tasks	_	
79-5	12342-12346	with	_	
79-6	12347-12348	~	_	
79-7	12348-12349	 	_	
79-8	12349-12351	30	_	
79-9	12351-12352	 	_	
79-10	12352-12353	s	_	
79-11	12354-12360	blocks	_	
79-12	12361-12363	or	_	
79-13	12364-12377	event-related	_	
79-14	12378-12384	design	_	
79-15	12385-12390	tasks	_	
79-16	12391-12396	would	_	
79-17	12397-12400	not	_	
79-18	12401-12408	provide	_	
79-19	12409-12410	a	_	
79-20	12411-12421	sufficient	_	
79-21	12422-12428	amount	_	
79-22	12429-12431	of	_	
79-23	12432-12442	continuous	_	
79-24	12443-12447	data	_	
79-25	12448-12451	for	_	
79-26	12452-12456	such	_	
79-27	12457-12464	methods	_	
79-28	12464-12465	.	_	

#Text=As each run was individually processed and normalized, concatenating runs as the same cue trials and performing correlation analysis is the equivalent of performing correlation analysis for each individually and averaging the resulting correlation.
80-1	12466-12468	As	_	
80-2	12469-12473	each	_	
80-3	12474-12477	run	_	
80-4	12478-12481	was	_	
80-5	12482-12494	individually	_	
80-6	12495-12504	processed	_	
80-7	12505-12508	and	_	
80-8	12509-12519	normalized	_	
80-9	12519-12520	,	_	
80-10	12521-12534	concatenating	_	
80-11	12535-12539	runs	_	
80-12	12540-12542	as	_	
80-13	12543-12546	the	_	
80-14	12547-12551	same	_	
80-15	12552-12555	cue	_	
80-16	12556-12562	trials	_	
80-17	12563-12566	and	_	
80-18	12567-12577	performing	_	
80-19	12578-12589	correlation	_	
80-20	12590-12598	analysis	_	
80-21	12599-12601	is	_	
80-22	12602-12605	the	_	
80-23	12606-12616	equivalent	_	
80-24	12617-12619	of	_	
80-25	12620-12630	performing	_	
80-26	12631-12642	correlation	_	
80-27	12643-12651	analysis	_	
80-28	12652-12655	for	_	
80-29	12656-12660	each	_	
80-30	12661-12673	individually	_	
80-31	12674-12677	and	_	
80-32	12678-12687	averaging	_	
80-33	12688-12691	the	_	
80-34	12692-12701	resulting	_	
80-35	12702-12713	correlation	_	
80-36	12713-12714	.	_	

#Text=ICD connectivity
#Text=To investigate cue related differences in connectivity between AUD patients, connectivity of each voxel as measured by the intrinsic connectivity distribution (ICD) was calculated for each individual participant as described previously.
81-1	12715-12718	ICD	_	
81-2	12719-12731	connectivity	_	
81-3	12732-12734	To	_	
81-4	12735-12746	investigate	_	
81-5	12747-12750	cue	_	
81-6	12751-12758	related	_	
81-7	12759-12770	differences	_	
81-8	12771-12773	in	_	
81-9	12774-12786	connectivity	_	
81-10	12787-12794	between	_	
81-11	12795-12798	AUD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	
81-12	12799-12807	patients	_	
81-13	12807-12808	,	_	
81-14	12809-12821	connectivity	_	
81-15	12822-12824	of	_	
81-16	12825-12829	each	_	
81-17	12830-12835	voxel	_	
81-18	12836-12838	as	_	
81-19	12839-12847	measured	_	
81-20	12848-12850	by	_	
81-21	12851-12854	the	_	
81-22	12855-12864	intrinsic	_	
81-23	12865-12877	connectivity	_	
81-24	12878-12890	distribution	_	
81-25	12891-12892	(	_	
81-26	12892-12895	ICD	_	
81-27	12895-12896	)	_	
81-28	12897-12900	was	_	
81-29	12901-12911	calculated	_	
81-30	12912-12915	for	_	
81-31	12916-12920	each	_	
81-32	12921-12931	individual	_	
81-33	12932-12943	participant	_	
81-34	12944-12946	as	_	
81-35	12947-12956	described	_	
81-36	12957-12967	previously	_	
81-37	12967-12968	.	_	

#Text=ICD represents a generalization of the network theory measure of degree.
82-1	12969-12972	ICD	_	
82-2	12973-12983	represents	_	
82-3	12984-12985	a	_	
82-4	12986-13000	generalization	_	
82-5	13001-13003	of	_	
82-6	13004-13007	the	_	
82-7	13008-13015	network	_	
82-8	13016-13022	theory	_	
82-9	13023-13030	measure	_	
82-10	13031-13033	of	_	
82-11	13034-13040	degree	_	
82-12	13040-13041	.	_	

#Text=In the context of neuroimaging, degree involves correlating the time course for any voxel with every other voxel time course in the brain and is defined as the number of connections to that voxel with correlations greater than an arbitrary threshold.
83-1	13042-13044	In	_	
83-2	13045-13048	the	_	
83-3	13049-13056	context	_	
83-4	13057-13059	of	_	
83-5	13060-13072	neuroimaging	_	
83-6	13072-13073	,	_	
83-7	13074-13080	degree	_	
83-8	13081-13089	involves	_	
83-9	13090-13101	correlating	_	
83-10	13102-13105	the	_	
83-11	13106-13110	time	_	
83-12	13111-13117	course	_	
83-13	13118-13121	for	_	
83-14	13122-13125	any	_	
83-15	13126-13131	voxel	_	
83-16	13132-13136	with	_	
83-17	13137-13142	every	_	
83-18	13143-13148	other	_	
83-19	13149-13154	voxel	_	
83-20	13155-13159	time	_	
83-21	13160-13166	course	_	
83-22	13167-13169	in	_	
83-23	13170-13173	the	_	
83-24	13174-13179	brain	_	
83-25	13180-13183	and	_	
83-26	13184-13186	is	_	
83-27	13187-13194	defined	_	
83-28	13195-13197	as	_	
83-29	13198-13201	the	_	
83-30	13202-13208	number	_	
83-31	13209-13211	of	_	
83-32	13212-13223	connections	_	
83-33	13224-13226	to	_	
83-34	13227-13231	that	_	
83-35	13232-13237	voxel	_	
83-36	13238-13242	with	_	
83-37	13243-13255	correlations	_	
83-38	13256-13263	greater	_	
83-39	13264-13268	than	_	
83-40	13269-13271	an	_	
83-41	13272-13281	arbitrary	_	
83-42	13282-13291	threshold	_	
83-43	13291-13292	.	_	

#Text=ICD calculates degree over all possible arbitrary thresholds and then models the change in degree as the threshold is increased.
84-1	13293-13296	ICD	_	
84-2	13297-13307	calculates	_	
84-3	13308-13314	degree	_	
84-4	13315-13319	over	_	
84-5	13320-13323	all	_	
84-6	13324-13332	possible	_	
84-7	13333-13342	arbitrary	_	
84-8	13343-13353	thresholds	_	
84-9	13354-13357	and	_	
84-10	13358-13362	then	_	
84-11	13363-13369	models	_	
84-12	13370-13373	the	_	
84-13	13374-13380	change	_	
84-14	13381-13383	in	_	
84-15	13384-13390	degree	_	
84-16	13391-13393	as	_	
84-17	13394-13397	the	_	
84-18	13398-13407	threshold	_	
84-19	13408-13410	is	_	
84-20	13411-13420	increased	_	
84-21	13420-13421	.	_	

#Text=By examining all possible arbitrary thresholds, ICD is not dependent on a single threshold and eliminates the need to specify an arbitrary threshold.
85-1	13422-13424	By	_	
85-2	13425-13434	examining	_	
85-3	13435-13438	all	_	
85-4	13439-13447	possible	_	
85-5	13448-13457	arbitrary	_	
85-6	13458-13468	thresholds	_	
85-7	13468-13469	,	_	
85-8	13470-13473	ICD	_	
85-9	13474-13476	is	_	
85-10	13477-13480	not	_	
85-11	13481-13490	dependent	_	
85-12	13491-13493	on	_	
85-13	13494-13495	a	_	
85-14	13496-13502	single	_	
85-15	13503-13512	threshold	_	
85-16	13513-13516	and	_	
85-17	13517-13527	eliminates	_	
85-18	13528-13531	the	_	
85-19	13532-13536	need	_	
85-20	13537-13539	to	_	
85-21	13540-13547	specify	_	
85-22	13548-13550	an	_	
85-23	13551-13560	arbitrary	_	
85-24	13561-13570	threshold	_	
85-25	13570-13571	.	_	

#Text=Specifically, for the current voxel, a histogram of all the time series correlations to that voxel was constructed to estimate the distribution of functional connectivity to that voxel.
86-1	13572-13584	Specifically	_	
86-2	13584-13585	,	_	
86-3	13586-13589	for	_	
86-4	13590-13593	the	_	
86-5	13594-13601	current	_	
86-6	13602-13607	voxel	_	
86-7	13607-13608	,	_	
86-8	13609-13610	a	_	
86-9	13611-13620	histogram	_	
86-10	13621-13623	of	_	
86-11	13624-13627	all	_	
86-12	13628-13631	the	_	
86-13	13632-13636	time	_	
86-14	13637-13643	series	_	
86-15	13644-13656	correlations	_	
86-16	13657-13659	to	_	
86-17	13660-13664	that	_	
86-18	13665-13670	voxel	_	
86-19	13671-13674	was	_	
86-20	13675-13686	constructed	_	
86-21	13687-13689	to	_	
86-22	13690-13698	estimate	_	
86-23	13699-13702	the	_	
86-24	13703-13715	distribution	_	
86-25	13716-13718	of	_	
86-26	13719-13729	functional	_	
86-27	13730-13742	connectivity	_	
86-28	13743-13745	to	_	
86-29	13746-13750	that	_	
86-30	13751-13756	voxel	_	
86-31	13756-13757	.	_	

#Text=This distribution of connectivity was converted to a survival function and the survival function was fitted with a stretched exponential with unknown variance, α.
87-1	13758-13762	This	_	
87-2	13763-13775	distribution	_	
87-3	13776-13778	of	_	
87-4	13779-13791	connectivity	_	
87-5	13792-13795	was	_	
87-6	13796-13805	converted	_	
87-7	13806-13808	to	_	
87-8	13809-13810	a	_	
87-9	13811-13819	survival	_	
87-10	13820-13828	function	_	
87-11	13829-13832	and	_	
87-12	13833-13836	the	_	
87-13	13837-13845	survival	_	
87-14	13846-13854	function	_	
87-15	13855-13858	was	_	
87-16	13859-13865	fitted	_	
87-17	13866-13870	with	_	
87-18	13871-13872	a	_	
87-19	13873-13882	stretched	_	
87-20	13883-13894	exponential	_	
87-21	13895-13899	with	_	
87-22	13900-13907	unknown	_	
87-23	13908-13916	variance	_	
87-24	13916-13917	,	_	
87-25	13918-13919	α	_	
87-26	13919-13920	.	_	

#Text=As alpha controls the spread of the distribution of connections, a larger alpha indicates a greater number of high correlation connections.
88-1	13921-13923	As	_	
88-2	13924-13929	alpha	_	
88-3	13930-13938	controls	_	
88-4	13939-13942	the	_	
88-5	13943-13949	spread	_	
88-6	13950-13952	of	_	
88-7	13953-13956	the	_	
88-8	13957-13969	distribution	_	
88-9	13970-13972	of	_	
88-10	13973-13984	connections	_	
88-11	13984-13985	,	_	
88-12	13986-13987	a	_	
88-13	13988-13994	larger	_	
88-14	13995-14000	alpha	_	
88-15	14001-14010	indicates	_	
88-16	14011-14012	a	_	
88-17	14013-14020	greater	_	
88-18	14021-14027	number	_	
88-19	14028-14030	of	_	
88-20	14031-14035	high	_	
88-21	14036-14047	correlation	_	
88-22	14048-14059	connections	_	
88-23	14059-14060	.	_	

#Text=Finally, this process is repeated for all voxels in the gray matter resulting in a parametric image of the alpha parameter for each participant.
89-1	14061-14068	Finally	_	
89-2	14068-14069	,	_	
89-3	14070-14074	this	_	
89-4	14075-14082	process	_	
89-5	14083-14085	is	_	
89-6	14086-14094	repeated	_	
89-7	14095-14098	for	_	
89-8	14099-14102	all	_	
89-9	14103-14109	voxels	_	
89-10	14110-14112	in	_	
89-11	14113-14116	the	_	
89-12	14117-14121	gray	_	
89-13	14122-14128	matter	_	
89-14	14129-14138	resulting	_	
89-15	14139-14141	in	_	
89-16	14142-14143	a	_	
89-17	14144-14154	parametric	_	
89-18	14155-14160	image	_	
89-19	14161-14163	of	_	
89-20	14164-14167	the	_	
89-21	14168-14173	alpha	_	
89-22	14174-14183	parameter	_	
89-23	14184-14187	for	_	
89-24	14188-14192	each	_	
89-25	14193-14204	participant	_	
89-26	14204-14205	.	_	

#Text=Additionally, each ICD map was normalized by subtracting the mean across all voxels and dividing by the standard deviation across all voxels.
90-1	14206-14218	Additionally	_	
90-2	14218-14219	,	_	
90-3	14220-14224	each	_	
90-4	14225-14228	ICD	_	
90-5	14229-14232	map	_	
90-6	14233-14236	was	_	
90-7	14237-14247	normalized	_	
90-8	14248-14250	by	_	
90-9	14251-14262	subtracting	_	
90-10	14263-14266	the	_	
90-11	14267-14271	mean	_	
90-12	14272-14278	across	_	
90-13	14279-14282	all	_	
90-14	14283-14289	voxels	_	
90-15	14290-14293	and	_	
90-16	14294-14302	dividing	_	
90-17	14303-14305	by	_	
90-18	14306-14309	the	_	
90-19	14310-14318	standard	_	
90-20	14319-14328	deviation	_	
90-21	14329-14335	across	_	
90-22	14336-14339	all	_	
90-23	14340-14346	voxels	_	
90-24	14346-14347	.	_	

#Text=This z-score-like normalization does not change the underlying topography of connectivity pattern but allows for each map to be comparably scaled across participants.
91-1	14348-14352	This	_	
91-2	14353-14365	z-score-like	_	
91-3	14366-14379	normalization	_	
91-4	14380-14384	does	_	
91-5	14385-14388	not	_	
91-6	14389-14395	change	_	
91-7	14396-14399	the	_	
91-8	14400-14410	underlying	_	
91-9	14411-14421	topography	_	
91-10	14422-14424	of	_	
91-11	14425-14437	connectivity	_	
91-12	14438-14445	pattern	_	
91-13	14446-14449	but	_	
91-14	14450-14456	allows	_	
91-15	14457-14460	for	_	
91-16	14461-14465	each	_	
91-17	14466-14469	map	_	
91-18	14470-14472	to	_	
91-19	14473-14475	be	_	
91-20	14476-14486	comparably	_	
91-21	14487-14493	scaled	_	
91-22	14494-14500	across	_	
91-23	14501-14513	participants	_	
91-24	14513-14514	.	_	

#Text=Statistical analysis
#Text=ICD connectivity maps were warped into common space (see Supplemental material) and analyzed using voxel-wise random effects general linear modeling with group modeled as a between subject factor, cue conditions modeled as within subject factors, and subjects as random factors using 3dLME.
92-1	14515-14526	Statistical	_	
92-2	14527-14535	analysis	_	
92-3	14536-14539	ICD	_	
92-4	14540-14552	connectivity	_	
92-5	14553-14557	maps	_	
92-6	14558-14562	were	_	
92-7	14563-14569	warped	_	
92-8	14570-14574	into	_	
92-9	14575-14581	common	_	
92-10	14582-14587	space	_	
92-11	14588-14589	(	_	
92-12	14589-14592	see	_	
92-13	14593-14605	Supplemental	_	
92-14	14606-14614	material	_	
92-15	14614-14615	)	_	
92-16	14616-14619	and	_	
92-17	14620-14628	analyzed	_	
92-18	14629-14634	using	_	
92-19	14635-14645	voxel-wise	_	
92-20	14646-14652	random	_	
92-21	14653-14660	effects	_	
92-22	14661-14668	general	_	
92-23	14669-14675	linear	_	
92-24	14676-14684	modeling	_	
92-25	14685-14689	with	_	
92-26	14690-14695	group	_	
92-27	14696-14703	modeled	_	
92-28	14704-14706	as	_	
92-29	14707-14708	a	_	
92-30	14709-14716	between	_	
92-31	14717-14724	subject	_	
92-32	14725-14731	factor	_	
92-33	14731-14732	,	_	
92-34	14733-14736	cue	_	
92-35	14737-14747	conditions	_	
92-36	14748-14755	modeled	_	
92-37	14756-14758	as	_	
92-38	14759-14765	within	_	
92-39	14766-14773	subject	_	
92-40	14774-14781	factors	_	
92-41	14781-14782	,	_	
92-42	14783-14786	and	_	
92-43	14787-14795	subjects	_	
92-44	14796-14798	as	_	
92-45	14799-14805	random	_	
92-46	14806-14813	factors	_	
92-47	14814-14819	using	_	
92-48	14820-14825	3dLME	_	
92-49	14825-14826	.	_	

#Text=Imaging results are shown at a cluster-level threshold of p < 0.05 family-wise error (FWE) correction as determined by AFNI's 3dClustSim program (version 16.0.09) using a cluster forming threshold of p = 0.001, 10,000 iterations, a grey matter mask, and a smoothness estimated using 3dFWHMx with the –ACF option.
93-1	14827-14834	Imaging	_	
93-2	14835-14842	results	_	
93-3	14843-14846	are	_	
93-4	14847-14852	shown	_	
93-5	14853-14855	at	_	
93-6	14856-14857	a	_	
93-7	14858-14871	cluster-level	_	
93-8	14872-14881	threshold	_	
93-9	14882-14884	of	_	
93-10	14885-14886	p	_	
93-11	14886-14887	 	_	
93-12	14887-14888	<	_	
93-13	14888-14889	 	_	
93-14	14889-14893	0.05	_	
93-15	14894-14905	family-wise	_	
93-16	14906-14911	error	_	
93-17	14912-14913	(	_	
93-18	14913-14916	FWE	_	
93-19	14916-14917	)	_	
93-20	14918-14928	correction	_	
93-21	14929-14931	as	_	
93-22	14932-14942	determined	_	
93-23	14943-14945	by	_	
93-24	14946-14952	AFNI's	_	
93-25	14953-14963	3dClustSim	_	
93-26	14964-14971	program	_	
93-27	14972-14973	(	_	
93-28	14973-14980	version	_	
93-29	14981-14988	16.0.09	_	
93-30	14988-14989	)	_	
93-31	14990-14995	using	_	
93-32	14996-14997	a	_	
93-33	14998-15005	cluster	_	
93-34	15006-15013	forming	_	
93-35	15014-15023	threshold	_	
93-36	15024-15026	of	_	
93-37	15027-15028	p	_	
93-38	15028-15029	 	_	
93-39	15029-15030	=	_	
93-40	15030-15031	 	_	
93-41	15031-15036	0.001	_	
93-42	15036-15037	,	_	
93-43	15038-15044	10,000	_	
93-44	15045-15055	iterations	_	
93-45	15055-15056	,	_	
93-46	15057-15058	a	_	
93-47	15059-15063	grey	_	
93-48	15064-15070	matter	_	
93-49	15071-15075	mask	_	
93-50	15075-15076	,	_	
93-51	15077-15080	and	_	
93-52	15081-15082	a	_	
93-53	15083-15093	smoothness	_	
93-54	15094-15103	estimated	_	
93-55	15104-15109	using	_	
93-56	15110-15117	3dFWHMx	_	
93-57	15118-15122	with	_	
93-58	15123-15126	the	_	
93-59	15127-15128	–	_	
93-60	15128-15131	ACF	_	
93-61	15132-15138	option	_	
93-62	15138-15139	.	_	

#Text=Follow-up seed analyses were based on the ICD connectivity defined regions of interest.
94-1	15140-15149	Follow-up	_	
94-2	15150-15154	seed	_	
94-3	15155-15163	analyses	_	
94-4	15164-15168	were	_	
94-5	15169-15174	based	_	
94-6	15175-15177	on	_	
94-7	15178-15181	the	_	
94-8	15182-15185	ICD	_	
94-9	15186-15198	connectivity	_	
94-10	15199-15206	defined	_	
94-11	15207-15214	regions	_	
94-12	15215-15217	of	_	
94-13	15218-15226	interest	_	
94-14	15226-15227	.	_	

#Text=Anatomical locations were localized using the Yale Brodmann Atlas.
95-1	15228-15238	Anatomical	_	
95-2	15239-15248	locations	_	
95-3	15249-15253	were	_	
95-4	15254-15263	localized	_	
95-5	15264-15269	using	_	
95-6	15270-15273	the	_	
95-7	15274-15278	Yale	_	
95-8	15279-15287	Brodmann	_	
95-9	15288-15293	Atlas	_	
95-10	15293-15294	.	_	

#Text=Analysis of between group motion and methods used to minimize motion related confounds can be found in Supplemental material.
96-1	15295-15303	Analysis	_	
96-2	15304-15306	of	_	
96-3	15307-15314	between	_	
96-4	15315-15320	group	_	
96-5	15321-15327	motion	_	
96-6	15328-15331	and	_	
96-7	15332-15339	methods	_	
96-8	15340-15344	used	_	
96-9	15345-15347	to	_	
96-10	15348-15356	minimize	_	
96-11	15357-15363	motion	_	
96-12	15364-15371	related	_	
96-13	15372-15381	confounds	_	
96-14	15382-15385	can	_	
96-15	15386-15388	be	_	
96-16	15389-15394	found	_	
96-17	15395-15397	in	_	
96-18	15398-15410	Supplemental	_	
96-19	15411-15419	material	_	
96-20	15419-15420	.	_	

#Text=Analysis of non-imaging data was performed in R.
97-1	15421-15429	Analysis	_	
97-2	15430-15432	of	_	
97-3	15433-15444	non-imaging	_	
97-4	15445-15449	data	_	
97-5	15450-15453	was	_	
97-6	15454-15463	performed	_	
97-7	15464-15466	in	_	
97-8	15467-15468	R	_	
97-9	15468-15469	.	_	

#Text=Prospective time to relapse analysis
#Text=Relapse was assessed prospectively in the 90 days after completion of inpatient treatment.
98-1	15470-15481	Prospective	_	
98-2	15482-15486	time	_	
98-3	15487-15489	to	_	
98-4	15490-15497	relapse	_	
98-5	15498-15506	analysis	_	
98-6	15507-15514	Relapse	_	
98-7	15515-15518	was	_	
98-8	15519-15527	assessed	_	
98-9	15528-15541	prospectively	_	
98-10	15542-15544	in	_	
98-11	15545-15548	the	_	
98-12	15549-15551	90	_	
98-13	15551-15552	 	_	
98-14	15552-15556	days	_	
98-15	15557-15562	after	_	
98-16	15563-15573	completion	_	
98-17	15574-15576	of	_	
98-18	15577-15586	inpatient	_	
98-19	15587-15596	treatment	_	
98-20	15596-15597	.	_	

#Text=The first day of return to alcohol use during this 90-day follow-up period is considered as the target event and Cox proportional hazards regression, similar to a time-to-event survival analyses was conducted, as used in our previous studies.
99-1	15598-15601	The	_	
99-2	15602-15607	first	_	
99-3	15608-15611	day	_	
99-4	15612-15614	of	_	
99-5	15615-15621	return	_	
99-6	15622-15624	to	_	
99-7	15625-15632	alcohol	_	
99-8	15633-15636	use	_	
99-9	15637-15643	during	_	
99-10	15644-15648	this	_	
99-11	15649-15651	90	_	
99-12	15651-15652	-	_	
99-13	15652-15655	day	_	
99-14	15656-15665	follow-up	_	
99-15	15666-15672	period	_	
99-16	15673-15675	is	_	
99-17	15676-15686	considered	_	
99-18	15687-15689	as	_	
99-19	15690-15693	the	_	
99-20	15694-15700	target	_	
99-21	15701-15706	event	_	
99-22	15707-15710	and	_	
99-23	15711-15714	Cox	_	
99-24	15715-15727	proportional	_	
99-25	15728-15735	hazards	_	
99-26	15736-15746	regression	_	
99-27	15746-15747	,	_	
99-28	15748-15755	similar	_	
99-29	15756-15758	to	_	
99-30	15759-15760	a	_	
99-31	15761-15774	time-to-event	_	
99-32	15775-15783	survival	_	
99-33	15784-15792	analyses	_	
99-34	15793-15796	was	_	
99-35	15797-15806	conducted	_	
99-36	15806-15807	,	_	
99-37	15808-15810	as	_	
99-38	15811-15815	used	_	
99-39	15816-15818	in	_	
99-40	15819-15822	our	_	
99-41	15823-15831	previous	_	
99-42	15832-15839	studies	_	
99-43	15839-15840	.	_	

#Text=Cox proportional hazard regression was performed to investigate whether connectivity regions showing cue differences in AUD patients predicted the time to first alcohol relapse.
100-1	15841-15844	Cox	_	
100-2	15845-15857	proportional	_	
100-3	15858-15864	hazard	_	
100-4	15865-15875	regression	_	
100-5	15876-15879	was	_	
100-6	15880-15889	performed	_	
100-7	15890-15892	to	_	
100-8	15893-15904	investigate	_	
100-9	15905-15912	whether	_	
100-10	15913-15925	connectivity	_	
100-11	15926-15933	regions	_	
100-12	15934-15941	showing	_	
100-13	15942-15945	cue	_	
100-14	15946-15957	differences	_	
100-15	15958-15960	in	_	
100-16	15961-15964	AUD	_	
100-17	15965-15973	patients	_	
100-18	15974-15983	predicted	_	
100-19	15984-15987	the	_	
100-20	15988-15992	time	_	
100-21	15993-15995	to	_	
100-22	15996-16001	first	_	
100-23	16002-16009	alcohol	_	
100-24	16010-16017	relapse	_	
100-25	16017-16018	.	_	

#Text=Average ICD values of clusters identified in the whole-brain connectivity analysis were extracted and entered as independent variables.
101-1	16019-16026	Average	_	
101-2	16027-16030	ICD	_	
101-3	16031-16037	values	_	
101-4	16038-16040	of	_	
101-5	16041-16049	clusters	_	
101-6	16050-16060	identified	_	
101-7	16061-16063	in	_	
101-8	16064-16067	the	_	
101-9	16068-16079	whole-brain	_	
101-10	16080-16092	connectivity	_	
101-11	16093-16101	analysis	_	
101-12	16102-16106	were	_	
101-13	16107-16116	extracted	_	
101-14	16117-16120	and	_	
101-15	16121-16128	entered	_	
101-16	16129-16131	as	_	
101-17	16132-16143	independent	_	
101-18	16144-16153	variables	_	
101-19	16153-16154	.	_	

#Text=Preliminary analyses indicated that years of nicotine smoking and years of alcohol use were significantly correlated (p < 0.05) with time to relapse such that a greater number of years of smoking or alcohol use were associated with quicker relapse.
102-1	16155-16166	Preliminary	_	
102-2	16167-16175	analyses	_	
102-3	16176-16185	indicated	_	
102-4	16186-16190	that	_	
102-5	16191-16196	years	_	
102-6	16197-16199	of	_	
102-7	16200-16208	nicotine	_	
102-8	16209-16216	smoking	_	
102-9	16217-16220	and	_	
102-10	16221-16226	years	_	
102-11	16227-16229	of	_	
102-12	16230-16237	alcohol	_	
102-13	16238-16241	use	_	
102-14	16242-16246	were	_	
102-15	16247-16260	significantly	_	
102-16	16261-16271	correlated	_	
102-17	16272-16273	(	_	
102-18	16273-16274	p	_	
102-19	16274-16275	 	_	
102-20	16275-16276	<	_	
102-21	16276-16277	 	_	
102-22	16277-16281	0.05	_	
102-23	16281-16282	)	_	
102-24	16283-16287	with	_	
102-25	16288-16292	time	_	
102-26	16293-16295	to	_	
102-27	16296-16303	relapse	_	
102-28	16304-16308	such	_	
102-29	16309-16313	that	_	
102-30	16314-16315	a	_	
102-31	16316-16323	greater	_	
102-32	16324-16330	number	_	
102-33	16331-16333	of	_	
102-34	16334-16339	years	_	
102-35	16340-16342	of	_	
102-36	16343-16350	smoking	_	
102-37	16351-16353	or	_	
102-38	16354-16361	alcohol	_	
102-39	16362-16365	use	_	
102-40	16366-16370	were	_	
102-41	16371-16381	associated	_	
102-42	16382-16386	with	_	
102-43	16387-16394	quicker	_	
102-44	16395-16402	relapse	_	
102-45	16402-16403	.	_	

#Text=Thus, these were included as independent variables to evaluate their specific and independent effects.
103-1	16404-16408	Thus	_	
103-2	16408-16409	,	_	
103-3	16410-16415	these	_	
103-4	16416-16420	were	_	
103-5	16421-16429	included	_	
103-6	16430-16432	as	_	
103-7	16433-16444	independent	_	
103-8	16445-16454	variables	_	
103-9	16455-16457	to	_	
103-10	16458-16466	evaluate	_	
103-11	16467-16472	their	_	
103-12	16473-16481	specific	_	
103-13	16482-16485	and	_	
103-14	16486-16497	independent	_	
103-15	16498-16505	effects	_	
103-16	16505-16506	.	_	

#Text=Results
#Text=Study 1: relapse risk and connectivity in alcohol dependent patients
#Text=Relapse rates
#Text=Of the 45 AUD patients, 44 were successfully followed-up to determine relapse day.
104-1	16507-16514	Results	_	
104-2	16515-16520	Study	_	
104-3	16521-16522	1	_	
104-4	16522-16523	:	_	
104-5	16524-16531	relapse	_	
104-6	16532-16536	risk	_	
104-7	16537-16540	and	_	
104-8	16541-16553	connectivity	_	
104-9	16554-16556	in	_	
104-10	16557-16564	alcohol	_	
104-11	16565-16574	dependent	_	
104-12	16575-16583	patients	_	
104-13	16584-16591	Relapse	_	
104-14	16592-16597	rates	_	
104-15	16598-16600	Of	_	
104-16	16601-16604	the	_	
104-17	16605-16607	45	_	
104-18	16608-16611	AUD	_	
104-19	16612-16620	patients	_	
104-20	16620-16621	,	_	
104-21	16622-16624	44	_	
104-22	16625-16629	were	_	
104-23	16630-16642	successfully	_	
104-24	16643-16654	followed-up	_	
104-25	16655-16657	to	_	
104-26	16658-16667	determine	_	
104-27	16668-16675	relapse	_	
104-28	16676-16679	day	_	
104-29	16679-16680	.	_	

#Text=Relapse rates were 29.5% (13 of 44) at day 14, 45.5% (20 of 44) on day 30 and 70.5% (31 of 44) on day 90.
105-1	16681-16688	Relapse	_	
105-2	16689-16694	rates	_	
105-3	16695-16699	were	_	
105-4	16700-16705	29.5%	_	
105-5	16706-16707	(	_	
105-6	16707-16709	13	_	
105-7	16710-16712	of	_	
105-8	16713-16715	44	_	
105-9	16715-16716	)	_	
105-10	16717-16719	at	_	
105-11	16720-16723	day	_	
105-12	16724-16726	14	_	
105-13	16726-16727	,	_	
105-14	16728-16733	45.5%	_	
105-15	16734-16735	(	_	
105-16	16735-16737	20	_	
105-17	16738-16740	of	_	
105-18	16741-16743	44	_	
105-19	16743-16744	)	_	
105-20	16745-16747	on	_	
105-21	16748-16751	day	_	
105-22	16752-16754	30	_	
105-23	16755-16758	and	_	
105-24	16759-16764	70.5%	_	
105-25	16765-16766	(	_	
105-26	16766-16768	31	_	
105-27	16769-16771	of	_	
105-28	16772-16774	44	_	
105-29	16774-16775	)	_	
105-30	16776-16778	on	_	
105-31	16779-16782	day	_	
105-32	16783-16785	90	_	
105-33	16785-16786	.	_	

#Text=All 45 AUD patients were included in our analyses.
106-1	16787-16790	All	_	
106-2	16791-16793	45	_	
106-3	16794-16797	AUD	_	
106-4	16798-16806	patients	_	
106-5	16807-16811	were	_	
106-6	16812-16820	included	_	
106-7	16821-16823	in	_	
106-8	16824-16827	our	_	
106-9	16828-16836	analyses	_	
106-10	16836-16837	.	_	

#Text=ICD connectivity of AUD patients
#Text=With-in group differences in ICD connectivity were examined in all 45 AUD patients in Study 1 under the 3 different cue conditions.
107-1	16838-16841	ICD	_	
107-2	16842-16854	connectivity	_	
107-3	16855-16857	of	_	
107-4	16858-16861	AUD	_	
107-5	16862-16870	patients	_	
107-6	16871-16878	With-in	_	
107-7	16879-16884	group	_	
107-8	16885-16896	differences	_	
107-9	16897-16899	in	_	
107-10	16900-16903	ICD	_	
107-11	16904-16916	connectivity	_	
107-12	16917-16921	were	_	
107-13	16922-16930	examined	_	
107-14	16931-16933	in	_	
107-15	16934-16937	all	_	
107-16	16938-16940	45	_	
107-17	16941-16944	AUD	_	
107-18	16945-16953	patients	_	
107-19	16954-16956	in	_	
107-20	16957-16962	Study	_	
107-21	16963-16964	1	_	
107-22	16965-16970	under	_	
107-23	16971-16974	the	_	
107-24	16975-16976	3	_	
107-25	16977-16986	different	_	
107-26	16987-16990	cue	_	
107-27	16991-17001	conditions	_	
107-28	17001-17002	.	_	

#Text=Connectivity results indicated that AUD patients displayed significantly (p < 0.05 corrected) reduced cingulate cortex connectivity to whole brain for alcohol and stress cue trials compared to neutral cue trials (Fig. 1, Table S2).
108-1	17003-17015	Connectivity	_	
108-2	17016-17023	results	_	
108-3	17024-17033	indicated	_	
108-4	17034-17038	that	_	
108-5	17039-17042	AUD	_	
108-6	17043-17051	patients	_	
108-7	17052-17061	displayed	_	
108-8	17062-17075	significantly	_	
108-9	17076-17077	(	_	
108-10	17077-17078	p	_	
108-11	17078-17079	 	_	
108-12	17079-17080	<	_	
108-13	17080-17081	 	_	
108-14	17081-17085	0.05	_	
108-15	17086-17095	corrected	_	
108-16	17095-17096	)	_	
108-17	17097-17104	reduced	_	
108-18	17105-17114	cingulate	_	
108-19	17115-17121	cortex	_	
108-20	17122-17134	connectivity	_	
108-21	17135-17137	to	_	
108-22	17138-17143	whole	_	
108-23	17144-17149	brain	_	
108-24	17150-17153	for	_	
108-25	17154-17161	alcohol	_	
108-26	17162-17165	and	_	
108-27	17166-17172	stress	_	
108-28	17173-17176	cue	_	
108-29	17177-17183	trials	_	
108-30	17184-17192	compared	_	
108-31	17193-17195	to	_	
108-32	17196-17203	neutral	_	
108-33	17204-17207	cue	_	
108-34	17208-17214	trials	_	
108-35	17215-17216	(	_	
108-36	17216-17219	Fig	_	
108-37	17219-17220	.	_	
108-38	17221-17222	1	_	
108-39	17222-17223	,	_	
108-40	17224-17229	Table	_	
108-41	17230-17232	S2	_	
108-42	17232-17233	)	_	
108-43	17233-17234	.	_	

#Text=These regions included the anterior, mid, and posterior cingulate cortex.
109-1	17235-17240	These	_	
109-2	17241-17248	regions	_	
109-3	17249-17257	included	_	
109-4	17258-17261	the	_	
109-5	17262-17270	anterior	_	
109-6	17270-17271	,	_	
109-7	17272-17275	mid	_	
109-8	17275-17276	,	_	
109-9	17277-17280	and	_	
109-10	17281-17290	posterior	_	
109-11	17291-17300	cingulate	_	
109-12	17301-17307	cortex	_	
109-13	17307-17308	.	_	

#Text=Three ROIs (ACC, MCC, and PCC) were defined on the reference brain based our ICD main effects of condition from Fig. 1.
110-1	17309-17314	Three	_	
110-2	17315-17319	ROIs	_	
110-3	17320-17321	(	_	
110-4	17321-17324	ACC	_	
110-5	17324-17325	,	_	
110-6	17326-17329	MCC	_	
110-7	17329-17330	,	_	
110-8	17331-17334	and	_	
110-9	17335-17338	PCC	_	
110-10	17338-17339	)	_	
110-11	17340-17344	were	_	
110-12	17345-17352	defined	_	
110-13	17353-17355	on	_	
110-14	17356-17359	the	_	
110-15	17360-17369	reference	_	
110-16	17370-17375	brain	_	
110-17	17376-17381	based	_	
110-18	17382-17385	our	_	
110-19	17386-17389	ICD	_	
110-20	17390-17394	main	_	
110-21	17395-17402	effects	_	
110-22	17403-17405	of	_	
110-23	17406-17415	condition	_	
110-24	17416-17420	from	_	
110-25	17421-17424	Fig	_	
110-26	17424-17425	.	_	
110-27	17426-17427	1	_	
110-28	17427-17428	.	_	

#Text=Follow-up seed-to-whole brain connectivity analyses revealing connections from these regions to the whole brain are presented in Supplemental material and Fig.
111-1	17429-17438	Follow-up	_	
111-2	17439-17452	seed-to-whole	_	
111-3	17453-17458	brain	_	
111-4	17459-17471	connectivity	_	
111-5	17472-17480	analyses	_	
111-6	17481-17490	revealing	_	
111-7	17491-17502	connections	_	
111-8	17503-17507	from	_	
111-9	17508-17513	these	_	
111-10	17514-17521	regions	_	
111-11	17522-17524	to	_	
111-12	17525-17528	the	_	
111-13	17529-17534	whole	_	
111-14	17535-17540	brain	_	
111-15	17541-17544	are	_	
111-16	17545-17554	presented	_	
111-17	17555-17557	in	_	
111-18	17558-17570	Supplemental	_	
111-19	17571-17579	material	_	
111-20	17580-17583	and	_	
111-21	17584-17587	Fig	_	
111-22	17587-17588	.	_	

#Text=S1.
112-1	17589-17591	S1	_	
112-2	17591-17592	.	_	

#Text=Exploratory prospective time to relapse analysis
#Text=We examined the relationship between average ICD values of ACC, MCC, and PCC clusters for each cue condition, and subsequent time to relapse using Cox proportional hazard regression, after controlling for years of alcohol use and years of nicotine smoking.
113-1	17593-17604	Exploratory	_	
113-2	17605-17616	prospective	_	
113-3	17617-17621	time	_	
113-4	17622-17624	to	_	
113-5	17625-17632	relapse	_	
113-6	17633-17641	analysis	_	
113-7	17642-17644	We	_	
113-8	17645-17653	examined	_	
113-9	17654-17657	the	_	
113-10	17658-17670	relationship	_	
113-11	17671-17678	between	_	
113-12	17679-17686	average	_	
113-13	17687-17690	ICD	_	
113-14	17691-17697	values	_	
113-15	17698-17700	of	_	
113-16	17701-17704	ACC	_	
113-17	17704-17705	,	_	
113-18	17706-17709	MCC	_	
113-19	17709-17710	,	_	
113-20	17711-17714	and	_	
113-21	17715-17718	PCC	_	
113-22	17719-17727	clusters	_	
113-23	17728-17731	for	_	
113-24	17732-17736	each	_	
113-25	17737-17740	cue	_	
113-26	17741-17750	condition	_	
113-27	17750-17751	,	_	
113-28	17752-17755	and	_	
113-29	17756-17766	subsequent	_	
113-30	17767-17771	time	_	
113-31	17772-17774	to	_	
113-32	17775-17782	relapse	_	
113-33	17783-17788	using	_	
113-34	17789-17792	Cox	_	
113-35	17793-17805	proportional	_	
113-36	17806-17812	hazard	_	
113-37	17813-17823	regression	_	
113-38	17823-17824	,	_	
113-39	17825-17830	after	_	
113-40	17831-17842	controlling	_	
113-41	17843-17846	for	_	
113-42	17847-17852	years	_	
113-43	17853-17855	of	_	
113-44	17856-17863	alcohol	_	
113-45	17864-17867	use	_	
113-46	17868-17871	and	_	
113-47	17872-17877	years	_	
113-48	17878-17880	of	_	
113-49	17881-17889	nicotine	_	
113-50	17890-17897	smoking	_	
113-51	17897-17898	.	_	

#Text=For every unit increase of connectivity in the ACC (p = 0.03, Hazard Ratio (HR) = 5.4) or MCC (p = 0.05, HR = 4.5) during the neutral cues, AUD patients were approximately 5 times and 4 times more likely to relapse at the subsequent followup period, respectively (Table S3, Fig. 2).
114-1	17899-17902	For	_	
114-2	17903-17908	every	_	
114-3	17909-17913	unit	_	
114-4	17914-17922	increase	_	
114-5	17923-17925	of	_	
114-6	17926-17938	connectivity	_	
114-7	17939-17941	in	_	
114-8	17942-17945	the	_	
114-9	17946-17949	ACC	_	
114-10	17950-17951	(	_	
114-11	17951-17952	p	_	
114-12	17952-17953	 	_	
114-13	17953-17954	=	_	
114-14	17954-17955	 	_	
114-15	17955-17959	0.03	_	
114-16	17959-17960	,	_	
114-17	17961-17967	Hazard	_	
114-18	17968-17973	Ratio	_	
114-19	17974-17975	(	_	
114-20	17975-17977	HR	_	
114-21	17977-17978	)	_	
114-22	17978-17979	 	_	
114-23	17979-17980	=	_	
114-24	17980-17981	 	_	
114-25	17981-17984	5.4	_	
114-26	17984-17985	)	_	
114-27	17986-17988	or	_	
114-28	17989-17992	MCC	_	
114-29	17993-17994	(	_	
114-30	17994-17995	p	_	
114-31	17995-17996	 	_	
114-32	17996-17997	=	_	
114-33	17997-17998	 	_	
114-34	17998-18002	0.05	_	
114-35	18002-18003	,	_	
114-36	18004-18006	HR	_	
114-37	18006-18007	 	_	
114-38	18007-18008	=	_	
114-39	18008-18009	 	_	
114-40	18009-18012	4.5	_	
114-41	18012-18013	)	_	
114-42	18014-18020	during	_	
114-43	18021-18024	the	_	
114-44	18025-18032	neutral	_	
114-45	18033-18037	cues	_	
114-46	18037-18038	,	_	
114-47	18039-18042	AUD	_	
114-48	18043-18051	patients	_	
114-49	18052-18056	were	_	
114-50	18057-18070	approximately	_	
114-51	18071-18072	5	_	
114-52	18073-18078	times	_	
114-53	18079-18082	and	_	
114-54	18083-18084	4	_	
114-55	18085-18090	times	_	
114-56	18091-18095	more	_	
114-57	18096-18102	likely	_	
114-58	18103-18105	to	_	
114-59	18106-18113	relapse	_	
114-60	18114-18116	at	_	
114-61	18117-18120	the	_	
114-62	18121-18131	subsequent	_	
114-63	18132-18140	followup	_	
114-64	18141-18147	period	_	
114-65	18147-18148	,	_	
114-66	18149-18161	respectively	_	
114-67	18162-18163	(	_	
114-68	18163-18168	Table	_	
114-69	18169-18171	S3	_	
114-70	18171-18172	,	_	
114-71	18173-18176	Fig	_	
114-72	18176-18177	.	_	
114-73	18178-18179	2	_	
114-74	18179-18180	)	_	
114-75	18180-18181	.	_	

#Text=For every unit increase of the difference in PCC connectivity between alcohol cueing and stress cueing (p = 0.04, HR = 0.04), AUD patients were approximately 25 times less likely to relapse at the subsequent followup periods (Table S3, Fig. 2).
115-1	18182-18185	For	_	
115-2	18186-18191	every	_	
115-3	18192-18196	unit	_	
115-4	18197-18205	increase	_	
115-5	18206-18208	of	_	
115-6	18209-18212	the	_	
115-7	18213-18223	difference	_	
115-8	18224-18226	in	_	
115-9	18227-18230	PCC	_	
115-10	18231-18243	connectivity	_	
115-11	18244-18251	between	_	
115-12	18252-18259	alcohol	_	
115-13	18260-18266	cueing	_	
115-14	18267-18270	and	_	
115-15	18271-18277	stress	_	
115-16	18278-18284	cueing	_	
115-17	18285-18286	(	_	
115-18	18286-18287	p	_	
115-19	18287-18288	 	_	
115-20	18288-18289	=	_	
115-21	18289-18290	 	_	
115-22	18290-18294	0.04	_	
115-23	18294-18295	,	_	
115-24	18296-18298	HR	_	
115-25	18298-18299	 	_	
115-26	18299-18300	=	_	
115-27	18300-18301	 	_	
115-28	18301-18305	0.04	_	
115-29	18305-18306	)	_	
115-30	18306-18307	,	_	
115-31	18308-18311	AUD	_	
115-32	18312-18320	patients	_	
115-33	18321-18325	were	_	
115-34	18326-18339	approximately	_	
115-35	18340-18342	25	_	
115-36	18343-18348	times	_	
115-37	18349-18353	less	_	
115-38	18354-18360	likely	_	
115-39	18361-18363	to	_	
115-40	18364-18371	relapse	_	
115-41	18372-18374	at	_	
115-42	18375-18378	the	_	
115-43	18379-18389	subsequent	_	
115-44	18390-18398	followup	_	
115-45	18399-18406	periods	_	
115-46	18407-18408	(	_	
115-47	18408-18413	Table	_	
115-48	18414-18416	S3	_	
115-49	18416-18417	,	_	
115-50	18418-18421	Fig	_	
115-51	18421-18422	.	_	
115-52	18423-18424	2	_	
115-53	18424-18425	)	_	
115-54	18425-18426	.	_	

#Text=These exploratory results are left un-corrected for multiple comparisons in order to present preliminary findings to aid possible future studies.
116-1	18427-18432	These	_	
116-2	18433-18444	exploratory	_	
116-3	18445-18452	results	_	
116-4	18453-18456	are	_	
116-5	18457-18461	left	_	
116-6	18462-18474	un-corrected	_	
116-7	18475-18478	for	_	
116-8	18479-18487	multiple	_	
116-9	18488-18499	comparisons	_	
116-10	18500-18502	in	_	
116-11	18503-18508	order	_	
116-12	18509-18511	to	_	
116-13	18512-18519	present	_	
116-14	18520-18531	preliminary	_	
116-15	18532-18540	findings	_	
116-16	18541-18543	to	_	
116-17	18544-18547	aid	_	
116-18	18548-18556	possible	_	
116-19	18557-18563	future	_	
116-20	18564-18571	studies	_	
116-21	18571-18572	.	_	

#Text=Study 2: group differences between alcohol dependent patients and healthy control participants
#Text=In the second study, we compared a sub-group of 30 AUD patients with 30 matched HC participants (Table S1) to examine whether patterns of the cingulate cortex connectivity in AUD patients were different from those in HC participants.
117-1	18573-18578	Study	_	
117-2	18579-18580	2	_	
117-3	18580-18581	:	_	
117-4	18582-18587	group	_	
117-5	18588-18599	differences	_	
117-6	18600-18607	between	_	
117-7	18608-18615	alcohol	_	
117-8	18616-18625	dependent	_	
117-9	18626-18634	patients	_	
117-10	18635-18638	and	_	
117-11	18639-18646	healthy	_	
117-12	18647-18654	control	_	
117-13	18655-18667	participants	_	
117-14	18668-18670	In	_	
117-15	18671-18674	the	_	
117-16	18675-18681	second	_	
117-17	18682-18687	study	_	
117-18	18687-18688	,	_	
117-19	18689-18691	we	_	
117-20	18692-18700	compared	_	
117-21	18701-18702	a	_	
117-22	18703-18712	sub-group	_	
117-23	18713-18715	of	_	
117-24	18716-18718	30	_	
117-25	18719-18722	AUD	_	
117-26	18723-18731	patients	_	
117-27	18732-18736	with	_	
117-28	18737-18739	30	_	
117-29	18740-18747	matched	_	
117-30	18748-18750	HC	_	
117-31	18751-18763	participants	_	
117-32	18764-18765	(	_	
117-33	18765-18770	Table	_	
117-34	18771-18773	S1	_	
117-35	18773-18774	)	_	
117-36	18775-18777	to	_	
117-37	18778-18785	examine	_	
117-38	18786-18793	whether	_	
117-39	18794-18802	patterns	_	
117-40	18803-18805	of	_	
117-41	18806-18809	the	_	
117-42	18810-18819	cingulate	_	
117-43	18820-18826	cortex	_	
117-44	18827-18839	connectivity	_	
117-45	18840-18842	in	_	
117-46	18843-18846	AUD	_	
117-47	18847-18855	patients	_	
117-48	18856-18860	were	_	
117-49	18861-18870	different	_	
117-50	18871-18875	from	_	
117-51	18876-18881	those	_	
117-52	18882-18884	in	_	
117-53	18885-18887	HC	_	
117-54	18888-18900	participants	_	
117-55	18900-18901	.	_	

#Text=Smoking status was included as a covariate.
118-1	18902-18909	Smoking	_	
118-2	18910-18916	status	_	
118-3	18917-18920	was	_	
118-4	18921-18929	included	_	
118-5	18930-18932	as	_	
118-6	18933-18934	a	_	
118-7	18935-18944	covariate	_	
118-8	18944-18945	.	_	

#Text=Functional connectivity results revealed a significant (p < 0.05 corrected) cue by group interaction in the mid and posterior cingulate cortex (Table S4).
119-1	18946-18956	Functional	_	
119-2	18957-18969	connectivity	_	
119-3	18970-18977	results	_	
119-4	18978-18986	revealed	_	
119-5	18987-18988	a	_	
119-6	18989-19000	significant	_	
119-7	19001-19002	(	_	
119-8	19002-19003	p	_	
119-9	19003-19004	 	_	
119-10	19004-19005	<	_	
119-11	19005-19006	 	_	
119-12	19006-19010	0.05	_	
119-13	19011-19020	corrected	_	
119-14	19020-19021	)	_	
119-15	19022-19025	cue	_	
119-16	19026-19028	by	_	
119-17	19029-19034	group	_	
119-18	19035-19046	interaction	_	
119-19	19047-19049	in	_	
119-20	19050-19053	the	_	
119-21	19054-19057	mid	_	
119-22	19058-19061	and	_	
119-23	19062-19071	posterior	_	
119-24	19072-19081	cingulate	_	
119-25	19082-19088	cortex	_	
119-26	19089-19090	(	_	
119-27	19090-19095	Table	_	
119-28	19096-19098	S4	_	
119-29	19098-19099	)	_	
119-30	19099-19100	.	_	

#Text=As shown in Fig. 3, this effect was primarily driven by a reduction in cingulate connectivity during the alcohol and stress cue trials for the AUD patients compared to the HC participants and compared to the neutral cue.
120-1	19101-19103	As	_	
120-2	19104-19109	shown	_	
120-3	19110-19112	in	_	
120-4	19113-19116	Fig	_	
120-5	19116-19117	.	_	
120-6	19118-19119	3	_	
120-7	19119-19120	,	_	
120-8	19121-19125	this	_	
120-9	19126-19132	effect	_	
120-10	19133-19136	was	_	
120-11	19137-19146	primarily	_	
120-12	19147-19153	driven	_	
120-13	19154-19156	by	_	
120-14	19157-19158	a	_	
120-15	19159-19168	reduction	_	
120-16	19169-19171	in	_	
120-17	19172-19181	cingulate	_	
120-18	19182-19194	connectivity	_	
120-19	19195-19201	during	_	
120-20	19202-19205	the	_	
120-21	19206-19213	alcohol	_	
120-22	19214-19217	and	_	
120-23	19218-19224	stress	_	
120-24	19225-19228	cue	_	
120-25	19229-19235	trials	_	
120-26	19236-19239	for	_	
120-27	19240-19243	the	_	
120-28	19244-19247	AUD	_	
120-29	19248-19256	patients	_	
120-30	19257-19265	compared	_	
120-31	19266-19268	to	_	
120-32	19269-19272	the	_	
120-33	19273-19275	HC	_	
120-34	19276-19288	participants	_	
120-35	19289-19292	and	_	
120-36	19293-19301	compared	_	
120-37	19302-19304	to	_	
120-38	19305-19308	the	_	
120-39	19309-19316	neutral	_	
120-40	19317-19320	cue	_	
120-41	19320-19321	.	_	

#Text=Comparisons between all 45 AUD patients and 30 HC participants showed qualitatively similar results in the cingulate cortex (Fig.
121-1	19322-19333	Comparisons	_	
121-2	19334-19341	between	_	
121-3	19342-19345	all	_	
121-4	19346-19348	45	_	
121-5	19349-19352	AUD	_	
121-6	19353-19361	patients	_	
121-7	19362-19365	and	_	
121-8	19366-19368	30	_	
121-9	19369-19371	HC	_	
121-10	19372-19384	participants	_	
121-11	19385-19391	showed	_	
121-12	19392-19405	qualitatively	_	
121-13	19406-19413	similar	_	
121-14	19414-19421	results	_	
121-15	19422-19424	in	_	
121-16	19425-19428	the	_	
121-17	19429-19438	cingulate	_	
121-18	19439-19445	cortex	_	
121-19	19446-19447	(	_	
121-20	19447-19450	Fig	_	
121-21	19450-19451	.	_	

#Text=S2).
122-1	19452-19454	S2	_	
122-2	19454-19455	)	_	
122-3	19455-19456	.	_	

#Text=Discussion
#Text=In two studies, using a well-validated imagery paradigm and a novel voxel-wise connectivity method, we demonstrated differential connectivity responses to alcohol and stress cues in the cingulate cortex for AUD patients and their associations with early alcohol relapse, using a prospective clinical outcomes design.
123-1	19457-19467	Discussion	_	
123-2	19468-19470	In	_	
123-3	19471-19474	two	_	
123-4	19475-19482	studies	_	
123-5	19482-19483	,	_	
123-6	19484-19489	using	_	
123-7	19490-19491	a	_	
123-8	19492-19506	well-validated	_	
123-9	19507-19514	imagery	_	
123-10	19515-19523	paradigm	_	
123-11	19524-19527	and	_	
123-12	19528-19529	a	_	
123-13	19530-19535	novel	_	
123-14	19536-19546	voxel-wise	_	
123-15	19547-19559	connectivity	_	
123-16	19560-19566	method	_	
123-17	19566-19567	,	_	
123-18	19568-19570	we	_	
123-19	19571-19583	demonstrated	_	
123-20	19584-19596	differential	_	
123-21	19597-19609	connectivity	_	
123-22	19610-19619	responses	_	
123-23	19620-19622	to	_	
123-24	19623-19630	alcohol	_	
123-25	19631-19634	and	_	
123-26	19635-19641	stress	_	
123-27	19642-19646	cues	_	
123-28	19647-19649	in	_	
123-29	19650-19653	the	_	
123-30	19654-19663	cingulate	_	
123-31	19664-19670	cortex	_	
123-32	19671-19674	for	_	
123-33	19675-19678	AUD	_	
123-34	19679-19687	patients	_	
123-35	19688-19691	and	_	
123-36	19692-19697	their	_	
123-37	19698-19710	associations	_	
123-38	19711-19715	with	_	
123-39	19716-19721	early	_	
123-40	19722-19729	alcohol	_	
123-41	19730-19737	relapse	_	
123-42	19737-19738	,	_	
123-43	19739-19744	using	_	
123-44	19745-19746	a	_	
123-45	19747-19758	prospective	_	
123-46	19759-19767	clinical	_	
123-47	19768-19776	outcomes	_	
123-48	19777-19783	design	_	
123-49	19783-19784	.	_	

#Text=In the first study, 45 AUD patients exhibited a significant decrease in cingulate connectivity in responses to alcohol and stress cues compared to neutral cues.
124-1	19785-19787	In	_	
124-2	19788-19791	the	_	
124-3	19792-19797	first	_	
124-4	19798-19803	study	_	
124-5	19803-19804	,	_	
124-6	19805-19807	45	_	
124-7	19808-19811	AUD	_	
124-8	19812-19820	patients	_	
124-9	19821-19830	exhibited	_	
124-10	19831-19832	a	_	
124-11	19833-19844	significant	_	
124-12	19845-19853	decrease	_	
124-13	19854-19856	in	_	
124-14	19857-19866	cingulate	_	
124-15	19867-19879	connectivity	_	
124-16	19880-19882	in	_	
124-17	19883-19892	responses	_	
124-18	19893-19895	to	_	
124-19	19896-19903	alcohol	_	
124-20	19904-19907	and	_	
124-21	19908-19914	stress	_	
124-22	19915-19919	cues	_	
124-23	19920-19928	compared	_	
124-24	19929-19931	to	_	
124-25	19932-19939	neutral	_	
124-26	19940-19944	cues	_	
124-27	19944-19945	.	_	

#Text=Using relapse from a prospective 90-day follow-up period, and Cox proportional hazard regression, exploratory analyses suggests weaker connectivity in the ACC and MCC during neutral cue exposure were significantly associated with longer period of abstinence which translated to better recovery outcome.
125-1	19946-19951	Using	_	
125-2	19952-19959	relapse	_	
125-3	19960-19964	from	_	
125-4	19965-19966	a	_	
125-5	19967-19978	prospective	_	
125-6	19979-19981	90	_	
125-7	19981-19982	-	_	
125-8	19982-19985	day	_	
125-9	19986-19995	follow-up	_	
125-10	19996-20002	period	_	
125-11	20002-20003	,	_	
125-12	20004-20007	and	_	
125-13	20008-20011	Cox	_	
125-14	20012-20024	proportional	_	
125-15	20025-20031	hazard	_	
125-16	20032-20042	regression	_	
125-17	20042-20043	,	_	
125-18	20044-20055	exploratory	_	
125-19	20056-20064	analyses	_	
125-20	20065-20073	suggests	_	
125-21	20074-20080	weaker	_	
125-22	20081-20093	connectivity	_	
125-23	20094-20096	in	_	
125-24	20097-20100	the	_	
125-25	20101-20104	ACC	_	
125-26	20105-20108	and	_	
125-27	20109-20112	MCC	_	
125-28	20113-20119	during	_	
125-29	20120-20127	neutral	_	
125-30	20128-20131	cue	_	
125-31	20132-20140	exposure	_	
125-32	20141-20145	were	_	
125-33	20146-20159	significantly	_	
125-34	20160-20170	associated	_	
125-35	20171-20175	with	_	
125-36	20176-20182	longer	_	
125-37	20183-20189	period	_	
125-38	20190-20192	of	_	
125-39	20193-20203	abstinence	_	
125-40	20204-20209	which	_	
125-41	20210-20220	translated	_	
125-42	20221-20223	to	_	
125-43	20224-20230	better	_	
125-44	20231-20239	recovery	_	
125-45	20240-20247	outcome	_	
125-46	20247-20248	.	_	

#Text=Similarly, greater PCC connectivity during alcohol cues compared to stress cue conditions was associated significantly with longer time to relapse.
126-1	20249-20258	Similarly	_	
126-2	20258-20259	,	_	
126-3	20260-20267	greater	_	
126-4	20268-20271	PCC	_	
126-5	20272-20284	connectivity	_	
126-6	20285-20291	during	_	
126-7	20292-20299	alcohol	_	
126-8	20300-20304	cues	_	
126-9	20305-20313	compared	_	
126-10	20314-20316	to	_	
126-11	20317-20323	stress	_	
126-12	20324-20327	cue	_	
126-13	20328-20338	conditions	_	
126-14	20339-20342	was	_	
126-15	20343-20353	associated	_	
126-16	20354-20367	significantly	_	
126-17	20368-20372	with	_	
126-18	20373-20379	longer	_	
126-19	20380-20384	time	_	
126-20	20385-20387	to	_	
126-21	20388-20395	relapse	_	
126-22	20395-20396	.	_	

#Text=In the second study, group comparisons between a subset of the AUD patients and matched HC participants indicated that cingulate connectivity was significantly different between the groups.
127-1	20397-20399	In	_	
127-2	20400-20403	the	_	
127-3	20404-20410	second	_	
127-4	20411-20416	study	_	
127-5	20416-20417	,	_	
127-6	20418-20423	group	_	
127-7	20424-20435	comparisons	_	
127-8	20436-20443	between	_	
127-9	20444-20445	a	_	
127-10	20446-20452	subset	_	
127-11	20453-20455	of	_	
127-12	20456-20459	the	_	
127-13	20460-20463	AUD	_	
127-14	20464-20472	patients	_	
127-15	20473-20476	and	_	
127-16	20477-20484	matched	_	
127-17	20485-20487	HC	_	
127-18	20488-20500	participants	_	
127-19	20501-20510	indicated	_	
127-20	20511-20515	that	_	
127-21	20516-20525	cingulate	_	
127-22	20526-20538	connectivity	_	
127-23	20539-20542	was	_	
127-24	20543-20556	significantly	_	
127-25	20557-20566	different	_	
127-26	20567-20574	between	_	
127-27	20575-20578	the	_	
127-28	20579-20585	groups	_	
127-29	20585-20586	.	_	

#Text=Compared to HC participants, AUD patients showed reduced cingulate connectivity during the alcohol and stress cue trials and increased cingulate connectivity during the neutral cue trials.
128-1	20587-20595	Compared	_	
128-2	20596-20598	to	_	
128-3	20599-20601	HC	_	
128-4	20602-20614	participants	_	
128-5	20614-20615	,	_	
128-6	20616-20619	AUD	_	
128-7	20620-20628	patients	_	
128-8	20629-20635	showed	_	
128-9	20636-20643	reduced	_	
128-10	20644-20653	cingulate	_	
128-11	20654-20666	connectivity	_	
128-12	20667-20673	during	_	
128-13	20674-20677	the	_	
128-14	20678-20685	alcohol	_	
128-15	20686-20689	and	_	
128-16	20690-20696	stress	_	
128-17	20697-20700	cue	_	
128-18	20701-20707	trials	_	
128-19	20708-20711	and	_	
128-20	20712-20721	increased	_	
128-21	20722-20731	cingulate	_	
128-22	20732-20744	connectivity	_	
128-23	20745-20751	during	_	
128-24	20752-20755	the	_	
128-25	20756-20763	neutral	_	
128-26	20764-20767	cue	_	
128-27	20768-20774	trials	_	
128-28	20774-20775	.	_	

#Text=These group difference results are consistent with the Cox proportional hazard regression relapse findings in that AUD patients who were more similar to healthy controls in showing greater cingulate connectivity during alcohol cue trials or weakened connectivity during the neutral cue trials had more days of abstinence and better recovery period.
129-1	20776-20781	These	_	
129-2	20782-20787	group	_	
129-3	20788-20798	difference	_	
129-4	20799-20806	results	_	
129-5	20807-20810	are	_	
129-6	20811-20821	consistent	_	
129-7	20822-20826	with	_	
129-8	20827-20830	the	_	
129-9	20831-20834	Cox	_	
129-10	20835-20847	proportional	_	
129-11	20848-20854	hazard	_	
129-12	20855-20865	regression	_	
129-13	20866-20873	relapse	_	
129-14	20874-20882	findings	_	
129-15	20883-20885	in	_	
129-16	20886-20890	that	_	
129-17	20891-20894	AUD	_	
129-18	20895-20903	patients	_	
129-19	20904-20907	who	_	
129-20	20908-20912	were	_	
129-21	20913-20917	more	_	
129-22	20918-20925	similar	_	
129-23	20926-20928	to	_	
129-24	20929-20936	healthy	_	
129-25	20937-20945	controls	_	
129-26	20946-20948	in	_	
129-27	20949-20956	showing	_	
129-28	20957-20964	greater	_	
129-29	20965-20974	cingulate	_	
129-30	20975-20987	connectivity	_	
129-31	20988-20994	during	_	
129-32	20995-21002	alcohol	_	
129-33	21003-21006	cue	_	
129-34	21007-21013	trials	_	
129-35	21014-21016	or	_	
129-36	21017-21025	weakened	_	
129-37	21026-21038	connectivity	_	
129-38	21039-21045	during	_	
129-39	21046-21049	the	_	
129-40	21050-21057	neutral	_	
129-41	21058-21061	cue	_	
129-42	21062-21068	trials	_	
129-43	21069-21072	had	_	
129-44	21073-21077	more	_	
129-45	21078-21082	days	_	
129-46	21083-21085	of	_	
129-47	21086-21096	abstinence	_	
129-48	21097-21100	and	_	
129-49	21101-21107	better	_	
129-50	21108-21116	recovery	_	
129-51	21117-21123	period	_	
129-52	21123-21124	.	_	

#Text=Our results suggest that cingulate connectivity plays a significant role in the neural response to alcohol and stress cues and may contribute to subsequent relapse.
130-1	21125-21128	Our	_	
130-2	21129-21136	results	_	
130-3	21137-21144	suggest	_	
130-4	21145-21149	that	_	
130-5	21150-21159	cingulate	_	
130-6	21160-21172	connectivity	_	
130-7	21173-21178	plays	_	
130-8	21179-21180	a	_	
130-9	21181-21192	significant	_	
130-10	21193-21197	role	_	
130-11	21198-21200	in	_	
130-12	21201-21204	the	_	
130-13	21205-21211	neural	_	
130-14	21212-21220	response	_	
130-15	21221-21223	to	_	
130-16	21224-21231	alcohol	_	
130-17	21232-21235	and	_	
130-18	21236-21242	stress	_	
130-19	21243-21247	cues	_	
130-20	21248-21251	and	_	
130-21	21252-21255	may	_	
130-22	21256-21266	contribute	_	
130-23	21267-21269	to	_	
130-24	21270-21280	subsequent	_	
130-25	21281-21288	relapse	_	
130-26	21288-21289	.	_	

#Text=The cingulate cortex coordinates a vast number of behaviors through anatomical connections to many cortical and subcortical regions of the brain.
131-1	21290-21293	The	_	
131-2	21294-21303	cingulate	_	
131-3	21304-21310	cortex	_	
131-4	21311-21322	coordinates	_	
131-5	21323-21324	a	_	
131-6	21325-21329	vast	_	
131-7	21330-21336	number	_	
131-8	21337-21339	of	_	
131-9	21340-21349	behaviors	_	
131-10	21350-21357	through	_	
131-11	21358-21368	anatomical	_	
131-12	21369-21380	connections	_	
131-13	21381-21383	to	_	
131-14	21384-21388	many	_	
131-15	21389-21397	cortical	_	
131-16	21398-21401	and	_	
131-17	21402-21413	subcortical	_	
131-18	21414-21421	regions	_	
131-19	21422-21424	of	_	
131-20	21425-21428	the	_	
131-21	21429-21434	brain	_	
131-22	21434-21435	.	_	

#Text=These behaviors and connections are typically implicated in addiction and relapse.
132-1	21436-21441	These	_	
132-2	21442-21451	behaviors	_	
132-3	21452-21455	and	_	
132-4	21456-21467	connections	_	
132-5	21468-21471	are	_	
132-6	21472-21481	typically	_	
132-7	21482-21492	implicated	_	
132-8	21493-21495	in	_	
132-9	21496-21505	addiction	_	
132-10	21506-21509	and	_	
132-11	21510-21517	relapse	_	
132-12	21517-21518	.	_	

#Text=The vACC is anatomically connected to the OFC, nucleus accumbens, amygdala, hippocampus, and hypothalamus and is involved in affective and emotional processing.
133-1	21519-21522	The	_	
133-2	21523-21527	vACC	_	
133-3	21528-21530	is	_	
133-4	21531-21543	anatomically	_	
133-5	21544-21553	connected	_	
133-6	21554-21556	to	_	
133-7	21557-21560	the	_	
133-8	21561-21564	OFC	_	
133-9	21564-21565	,	_	
133-10	21566-21573	nucleus	_	
133-11	21574-21583	accumbens	_	
133-12	21583-21584	,	_	
133-13	21585-21593	amygdala	_	
133-14	21593-21594	,	_	
133-15	21595-21606	hippocampus	_	
133-16	21606-21607	,	_	
133-17	21608-21611	and	_	
133-18	21612-21624	hypothalamus	_	
133-19	21625-21628	and	_	
133-20	21629-21631	is	_	
133-21	21632-21640	involved	_	
133-22	21641-21643	in	_	
133-23	21644-21653	affective	_	
133-24	21654-21657	and	_	
133-25	21658-21667	emotional	_	
133-26	21668-21678	processing	_	
133-27	21678-21679	.	_	

#Text=The dACC is anatomically connected to the lateral prefrontal cortex, parietal cortex, and is involved in external attention, decision-making, and inhibition.
134-1	21680-21683	The	_	
134-2	21684-21688	dACC	_	
134-3	21689-21691	is	_	
134-4	21692-21704	anatomically	_	
134-5	21705-21714	connected	_	
134-6	21715-21717	to	_	
134-7	21718-21721	the	_	
134-8	21722-21729	lateral	_	
134-9	21730-21740	prefrontal	_	
134-10	21741-21747	cortex	_	
134-11	21747-21748	,	_	
134-12	21749-21757	parietal	_	
134-13	21758-21764	cortex	_	
134-14	21764-21765	,	_	
134-15	21766-21769	and	_	
134-16	21770-21772	is	_	
134-17	21773-21781	involved	_	
134-18	21782-21784	in	_	
134-19	21785-21793	external	_	
134-20	21794-21803	attention	_	
134-21	21803-21804	,	_	
134-22	21805-21820	decision-making	_	
134-23	21820-21821	,	_	
134-24	21822-21825	and	_	
134-25	21826-21836	inhibition	_	
134-26	21836-21837	.	_	

#Text=The PCC is anatomically connected to limbic structures (i.e. hippocampus and parahippocampus), lateral prefrontal cortex, and parietal cortex and is involved in internally directed attention.
135-1	21838-21841	The	_	
135-2	21842-21845	PCC	_	
135-3	21846-21848	is	_	
135-4	21849-21861	anatomically	_	
135-5	21862-21871	connected	_	
135-6	21872-21874	to	_	
135-7	21875-21881	limbic	_	
135-8	21882-21892	structures	_	
135-9	21893-21894	(	_	
135-10	21894-21897	i.e	_	
135-11	21897-21898	.	_	
135-12	21899-21910	hippocampus	_	
135-13	21911-21914	and	_	
135-14	21915-21930	parahippocampus	_	
135-15	21930-21931	)	_	
135-16	21931-21932	,	_	
135-17	21933-21940	lateral	_	
135-18	21941-21951	prefrontal	_	
135-19	21952-21958	cortex	_	
135-20	21958-21959	,	_	
135-21	21960-21963	and	_	
135-22	21964-21972	parietal	_	
135-23	21973-21979	cortex	_	
135-24	21980-21983	and	_	
135-25	21984-21986	is	_	
135-26	21987-21995	involved	_	
135-27	21996-21998	in	_	
135-28	21999-22009	internally	_	
135-29	22010-22018	directed	_	
135-30	22019-22028	attention	_	
135-31	22028-22029	.	_	

#Text=As alcohol and stress cues are known to engage these circuits and behaviors in AUD patients, it is notable that the cingulate cortex emerged as the key region from our analysis.
136-1	22030-22032	As	_	
136-2	22033-22040	alcohol	_	
136-3	22041-22044	and	_	
136-4	22045-22051	stress	_	
136-5	22052-22056	cues	_	
136-6	22057-22060	are	_	
136-7	22061-22066	known	_	
136-8	22067-22069	to	_	
136-9	22070-22076	engage	_	
136-10	22077-22082	these	_	
136-11	22083-22091	circuits	_	
136-12	22092-22095	and	_	
136-13	22096-22105	behaviors	_	
136-14	22106-22108	in	_	
136-15	22109-22112	AUD	_	
136-16	22113-22121	patients	_	
136-17	22121-22122	,	_	
136-18	22123-22125	it	_	
136-19	22126-22128	is	_	
136-20	22129-22136	notable	_	
136-21	22137-22141	that	_	
136-22	22142-22145	the	_	
136-23	22146-22155	cingulate	_	
136-24	22156-22162	cortex	_	
136-25	22163-22170	emerged	_	
136-26	22171-22173	as	_	
136-27	22174-22177	the	_	
136-28	22178-22181	key	_	
136-29	22182-22188	region	_	
136-30	22189-22193	from	_	
136-31	22194-22197	our	_	
136-32	22198-22206	analysis	_	
136-33	22206-22207	.	_	

#Text=The cingulate cortex contributes to a diverse set of large-scale functional networks.
137-1	22208-22211	The	_	
137-2	22212-22221	cingulate	_	
137-3	22222-22228	cortex	_	
137-4	22229-22240	contributes	_	
137-5	22241-22243	to	_	
137-6	22244-22245	a	_	
137-7	22246-22253	diverse	_	
137-8	22254-22257	set	_	
137-9	22258-22260	of	_	
137-10	22261-22272	large-scale	_	
137-11	22273-22283	functional	_	
137-12	22284-22292	networks	_	
137-13	22292-22293	.	_	

#Text=The PCC is a node in the DMN, the dACC is a node in the salience network, and middle portions of the cingulate are nodes in the central executive or frontoparietal network (FPN).
138-1	22294-22297	The	_	
138-2	22298-22301	PCC	_	
138-3	22302-22304	is	_	
138-4	22305-22306	a	_	
138-5	22307-22311	node	_	
138-6	22312-22314	in	_	
138-7	22315-22318	the	_	
138-8	22319-22322	DMN	_	
138-9	22322-22323	,	_	
138-10	22324-22327	the	_	
138-11	22328-22332	dACC	_	
138-12	22333-22335	is	_	
138-13	22336-22337	a	_	
138-14	22338-22342	node	_	
138-15	22343-22345	in	_	
138-16	22346-22349	the	_	
138-17	22350-22358	salience	_	
138-18	22359-22366	network	_	
138-19	22366-22367	,	_	
138-20	22368-22371	and	_	
138-21	22372-22378	middle	_	
138-22	22379-22387	portions	_	
138-23	22388-22390	of	_	
138-24	22391-22394	the	_	
138-25	22395-22404	cingulate	_	
138-26	22405-22408	are	_	
138-27	22409-22414	nodes	_	
138-28	22415-22417	in	_	
138-29	22418-22421	the	_	
138-30	22422-22429	central	_	
138-31	22430-22439	executive	_	
138-32	22440-22442	or	_	
138-33	22443-22457	frontoparietal	_	
138-34	22458-22465	network	_	
138-35	22466-22467	(	_	
138-36	22467-22470	FPN	_	
138-37	22470-22471	)	_	
138-38	22471-22472	.	_	

#Text=These three networks have been linked to the competition between internally and externally directed attention.
139-1	22473-22478	These	_	
139-2	22479-22484	three	_	
139-3	22485-22493	networks	_	
139-4	22494-22498	have	_	
139-5	22499-22503	been	_	
139-6	22504-22510	linked	_	
139-7	22511-22513	to	_	
139-8	22514-22517	the	_	
139-9	22518-22529	competition	_	
139-10	22530-22537	between	_	
139-11	22538-22548	internally	_	
139-12	22549-22552	and	_	
139-13	22553-22563	externally	_	
139-14	22564-22572	directed	_	
139-15	22573-22582	attention	_	
139-16	22582-22583	.	_	

#Text=The DMN attends to internal thoughts; whereas, the FPN attends to external stimuli.
140-1	22584-22587	The	_	
140-2	22588-22591	DMN	_	
140-3	22592-22599	attends	_	
140-4	22600-22602	to	_	
140-5	22603-22611	internal	_	
140-6	22612-22620	thoughts	_	
140-7	22620-22621	;	_	
140-8	22622-22629	whereas	_	
140-9	22629-22630	,	_	
140-10	22631-22634	the	_	
140-11	22635-22638	FPN	_	
140-12	22639-22646	attends	_	
140-13	22647-22649	to	_	
140-14	22650-22658	external	_	
140-15	22659-22666	stimuli	_	
140-16	22666-22667	.	_	

#Text=The salience network acts as a switch between the two.
141-1	22668-22671	The	_	
141-2	22672-22680	salience	_	
141-3	22681-22688	network	_	
141-4	22689-22693	acts	_	
141-5	22694-22696	as	_	
141-6	22697-22698	a	_	
141-7	22699-22705	switch	_	
141-8	22706-22713	between	_	
141-9	22714-22717	the	_	
141-10	22718-22721	two	_	
141-11	22721-22722	.	_	

#Text=The scripted cue trials used in this study are internally generated images of external cue contexts designed to provoke internally focused emotions such as anxiety and craving.
142-1	22723-22726	The	_	
142-2	22727-22735	scripted	_	
142-3	22736-22739	cue	_	
142-4	22740-22746	trials	_	
142-5	22747-22751	used	_	
142-6	22752-22754	in	_	
142-7	22755-22759	this	_	
142-8	22760-22765	study	_	
142-9	22766-22769	are	_	
142-10	22770-22780	internally	_	
142-11	22781-22790	generated	_	
142-12	22791-22797	images	_	
142-13	22798-22800	of	_	
142-14	22801-22809	external	_	
142-15	22810-22813	cue	_	
142-16	22814-22822	contexts	_	
142-17	22823-22831	designed	_	
142-18	22832-22834	to	_	
142-19	22835-22842	provoke	_	
142-20	22843-22853	internally	_	
142-21	22854-22861	focused	_	
142-22	22862-22870	emotions	_	
142-23	22871-22875	such	_	
142-24	22876-22878	as	_	
142-25	22879-22886	anxiety	_	
142-26	22887-22890	and	_	
142-27	22891-22898	craving	_	
142-28	22898-22899	.	_	

#Text=Our results may reflect alterations in the dynamics of internal and external attention associated with alcohol addiction just as emerging research on nicotine dependence has shown.
143-1	22900-22903	Our	_	
143-2	22904-22911	results	_	
143-3	22912-22915	may	_	
143-4	22916-22923	reflect	_	
143-5	22924-22935	alterations	_	
143-6	22936-22938	in	_	
143-7	22939-22942	the	_	
143-8	22943-22951	dynamics	_	
143-9	22952-22954	of	_	
143-10	22955-22963	internal	_	
143-11	22964-22967	and	_	
143-12	22968-22976	external	_	
143-13	22977-22986	attention	_	
143-14	22987-22997	associated	_	
143-15	22998-23002	with	_	
143-16	23003-23010	alcohol	_	
143-17	23011-23020	addiction	_	
143-18	23021-23025	just	_	
143-19	23026-23028	as	_	
143-20	23029-23037	emerging	_	
143-21	23038-23046	research	_	
143-22	23047-23049	on	_	
143-23	23050-23058	nicotine	_	
143-24	23059-23069	dependence	_	
143-25	23070-23073	has	_	
143-26	23074-23079	shown	_	
143-27	23079-23080	.	_	

#Text=Consistent with our results, maladaptations of functional response to alcohol and stress cues in the ACC are commonly implicated in alcohol dependence and are correlated with relapse.
144-1	23081-23091	Consistent	_	
144-2	23092-23096	with	_	
144-3	23097-23100	our	_	
144-4	23101-23108	results	_	
144-5	23108-23109	,	_	
144-6	23110-23124	maladaptations	_	
144-7	23125-23127	of	_	
144-8	23128-23138	functional	_	
144-9	23139-23147	response	_	
144-10	23148-23150	to	_	
144-11	23151-23158	alcohol	_	
144-12	23159-23162	and	_	
144-13	23163-23169	stress	_	
144-14	23170-23174	cues	_	
144-15	23175-23177	in	_	
144-16	23178-23181	the	_	
144-17	23182-23185	ACC	_	
144-18	23186-23189	are	_	
144-19	23190-23198	commonly	_	
144-20	23199-23209	implicated	_	
144-21	23210-23212	in	_	
144-22	23213-23220	alcohol	_	
144-23	23221-23231	dependence	_	
144-24	23232-23235	and	_	
144-25	23236-23239	are	_	
144-26	23240-23250	correlated	_	
144-27	23251-23255	with	_	
144-28	23256-23263	relapse	_	
144-29	23263-23264	.	_	

#Text=Functional alterations in the ACC are consistent across other addiction subtypes with analogous findings in stimulant, nicotine and cocaine dependent patients.
145-1	23265-23275	Functional	_	
145-2	23276-23287	alterations	_	
145-3	23288-23290	in	_	
145-4	23291-23294	the	_	
145-5	23295-23298	ACC	_	
145-6	23299-23302	are	_	
145-7	23303-23313	consistent	_	
145-8	23314-23320	across	_	
145-9	23321-23326	other	_	
145-10	23327-23336	addiction	_	
145-11	23337-23345	subtypes	_	
145-12	23346-23350	with	_	
145-13	23351-23360	analogous	_	
145-14	23361-23369	findings	_	
145-15	23370-23372	in	_	
145-16	23373-23382	stimulant	_	
145-17	23382-23383	,	_	
145-18	23384-23392	nicotine	_	
145-19	23393-23396	and	_	
145-20	23397-23404	cocaine	_	
145-21	23405-23414	dependent	_	
145-22	23415-23423	patients	_	
145-23	23423-23424	.	_	

#Text=In addition to functional changes, genetic variants in the ACC circuitry and morphological features of the ACC can increase relapse risk.
146-1	23425-23427	In	_	
146-2	23428-23436	addition	_	
146-3	23437-23439	to	_	
146-4	23440-23450	functional	_	
146-5	23451-23458	changes	_	
146-6	23458-23459	,	_	
146-7	23460-23467	genetic	_	
146-8	23468-23476	variants	_	
146-9	23477-23479	in	_	
146-10	23480-23483	the	_	
146-11	23484-23487	ACC	_	
146-12	23488-23497	circuitry	_	
146-13	23498-23501	and	_	
146-14	23502-23515	morphological	_	
146-15	23516-23524	features	_	
146-16	23525-23527	of	_	
146-17	23528-23531	the	_	
146-18	23532-23535	ACC	_	
146-19	23536-23539	can	_	
146-20	23540-23548	increase	_	
146-21	23549-23556	relapse	_	
146-22	23557-23561	risk	_	
146-23	23561-23562	.	_	

#Text=Therefore, the observed connectivity difference in the ACC for AUD patients may represent maladaptations of functional connections from the ACC to external and internal attention circuitry described above.
147-1	23563-23572	Therefore	_	
147-2	23572-23573	,	_	
147-3	23574-23577	the	_	
147-4	23578-23586	observed	_	
147-5	23587-23599	connectivity	_	
147-6	23600-23610	difference	_	
147-7	23611-23613	in	_	
147-8	23614-23617	the	_	
147-9	23618-23621	ACC	_	
147-10	23622-23625	for	_	
147-11	23626-23629	AUD	_	
147-12	23630-23638	patients	_	
147-13	23639-23642	may	_	
147-14	23643-23652	represent	_	
147-15	23653-23667	maladaptations	_	
147-16	23668-23670	of	_	
147-17	23671-23681	functional	_	
147-18	23682-23693	connections	_	
147-19	23694-23698	from	_	
147-20	23699-23702	the	_	
147-21	23703-23706	ACC	_	
147-22	23707-23709	to	_	
147-23	23710-23718	external	_	
147-24	23719-23722	and	_	
147-25	23723-23731	internal	_	
147-26	23732-23741	attention	_	
147-27	23742-23751	circuitry	_	
147-28	23752-23761	described	_	
147-29	23762-23767	above	_	
147-30	23767-23768	.	_	

#Text=While the ACC is a well-studied region in addiction circuitry, emerging evidence suggests that the PCC also plays a role in addiction and relapse.
148-1	23769-23774	While	_	
148-2	23775-23778	the	_	
148-3	23779-23782	ACC	_	
148-4	23783-23785	is	_	
148-5	23786-23787	a	_	
148-6	23788-23800	well-studied	_	
148-7	23801-23807	region	_	
148-8	23808-23810	in	_	
148-9	23811-23820	addiction	_	
148-10	23821-23830	circuitry	_	
148-11	23830-23831	,	_	
148-12	23832-23840	emerging	_	
148-13	23841-23849	evidence	_	
148-14	23850-23858	suggests	_	
148-15	23859-23863	that	_	
148-16	23864-23867	the	_	
148-17	23868-23871	PCC	_	
148-18	23872-23876	also	_	
148-19	23877-23882	plays	_	
148-20	23883-23884	a	_	
148-21	23885-23889	role	_	
148-22	23890-23892	in	_	
148-23	23893-23902	addiction	_	
148-24	23903-23906	and	_	
148-25	23907-23914	relapse	_	
148-26	23914-23915	.	_	

#Text=In task-based studies, PCC activity has been shown to differ in response to drug cues and has been linked with relapse in cocaine addicts and tobacco users.
149-1	23916-23918	In	_	
149-2	23919-23929	task-based	_	
149-3	23930-23937	studies	_	
149-4	23937-23938	,	_	
149-5	23939-23942	PCC	_	
149-6	23943-23951	activity	_	
149-7	23952-23955	has	_	
149-8	23956-23960	been	_	
149-9	23961-23966	shown	_	
149-10	23967-23969	to	_	
149-11	23970-23976	differ	_	
149-12	23977-23979	in	_	
149-13	23980-23988	response	_	
149-14	23989-23991	to	_	
149-15	23992-23996	drug	_	
149-16	23997-24001	cues	_	
149-17	24002-24005	and	_	
149-18	24006-24009	has	_	
149-19	24010-24014	been	_	
149-20	24015-24021	linked	_	
149-21	24022-24026	with	_	
149-22	24027-24034	relapse	_	
149-23	24035-24037	in	_	
149-24	24038-24045	cocaine	_	
149-25	24046-24053	addicts	_	
149-26	24054-24057	and	_	
149-27	24058-24065	tobacco	_	
149-28	24066-24071	users	_	
149-29	24071-24072	.	_	

#Text=Connectivity studies of AUD patients compared to controls have also shown altered PCC connectivity.
150-1	24073-24085	Connectivity	_	
150-2	24086-24093	studies	_	
150-3	24094-24096	of	_	
150-4	24097-24100	AUD	_	
150-5	24101-24109	patients	_	
150-6	24110-24118	compared	_	
150-7	24119-24121	to	_	
150-8	24122-24130	controls	_	
150-9	24131-24135	have	_	
150-10	24136-24140	also	_	
150-11	24141-24146	shown	_	
150-12	24147-24154	altered	_	
150-13	24155-24158	PCC	_	
150-14	24159-24171	connectivity	_	
150-15	24171-24172	.	_	

#Text=Together, these results provide further evidence that alterations in the PCC are a core component in addiction and relapse.
151-1	24173-24181	Together	_	
151-2	24181-24182	,	_	
151-3	24183-24188	these	_	
151-4	24189-24196	results	_	
151-5	24197-24204	provide	_	
151-6	24205-24212	further	_	
151-7	24213-24221	evidence	_	
151-8	24222-24226	that	_	
151-9	24227-24238	alterations	_	
151-10	24239-24241	in	_	
151-11	24242-24245	the	_	
151-12	24246-24249	PCC	_	
151-13	24250-24253	are	_	
151-14	24254-24255	a	_	
151-15	24256-24260	core	_	
151-16	24261-24270	component	_	
151-17	24271-24273	in	_	
151-18	24274-24283	addiction	_	
151-19	24284-24287	and	_	
151-20	24288-24295	relapse	_	
151-21	24295-24296	.	_	

#Text=The PCC plays a crucial role in adjusting behaviors in reward contingencies such as the presentation of alcohol cues.
152-1	24297-24300	The	_	
152-2	24301-24304	PCC	_	
152-3	24305-24310	plays	_	
152-4	24311-24312	a	_	
152-5	24313-24320	crucial	_	
152-6	24321-24325	role	_	
152-7	24326-24328	in	_	
152-8	24329-24338	adjusting	_	
152-9	24339-24348	behaviors	_	
152-10	24349-24351	in	_	
152-11	24352-24358	reward	_	
152-12	24359-24372	contingencies	_	
152-13	24373-24377	such	_	
152-14	24378-24380	as	_	
152-15	24381-24384	the	_	
152-16	24385-24397	presentation	_	
152-17	24398-24400	of	_	
152-18	24401-24408	alcohol	_	
152-19	24409-24413	cues	_	
152-20	24413-24414	.	_	

#Text=In our study, only the contrasts involving alcohol cues predicted subsequent relapse, whereby smaller differences in PCC connectivity between the alcohol condition and the stress conditions indicated greater risk of relapse (Fig. 3).
153-1	24415-24417	In	_	
153-2	24418-24421	our	_	
153-3	24422-24427	study	_	
153-4	24427-24428	,	_	
153-5	24429-24433	only	_	
153-6	24434-24437	the	_	
153-7	24438-24447	contrasts	_	
153-8	24448-24457	involving	_	
153-9	24458-24465	alcohol	_	
153-10	24466-24470	cues	_	
153-11	24471-24480	predicted	_	
153-12	24481-24491	subsequent	_	
153-13	24492-24499	relapse	_	
153-14	24499-24500	,	_	
153-15	24501-24508	whereby	_	
153-16	24509-24516	smaller	_	
153-17	24517-24528	differences	_	
153-18	24529-24531	in	_	
153-19	24532-24535	PCC	_	
153-20	24536-24548	connectivity	_	
153-21	24549-24556	between	_	
153-22	24557-24560	the	_	
153-23	24561-24568	alcohol	_	
153-24	24569-24578	condition	_	
153-25	24579-24582	and	_	
153-26	24583-24586	the	_	
153-27	24587-24593	stress	_	
153-28	24594-24604	conditions	_	
153-29	24605-24614	indicated	_	
153-30	24615-24622	greater	_	
153-31	24623-24627	risk	_	
153-32	24628-24630	of	_	
153-33	24631-24638	relapse	_	
153-34	24639-24640	(	_	
153-35	24640-24643	Fig	_	
153-36	24643-24644	.	_	
153-37	24645-24646	3	_	
153-38	24646-24647	)	_	
153-39	24647-24648	.	_	

#Text=The PCC connectivity was also reduced in the alcohol compared to neutral condition (Fig. 1) in the AUD subjects.
154-1	24649-24652	The	_	
154-2	24653-24656	PCC	_	
154-3	24657-24669	connectivity	_	
154-4	24670-24673	was	_	
154-5	24674-24678	also	_	
154-6	24679-24686	reduced	_	
154-7	24687-24689	in	_	
154-8	24690-24693	the	_	
154-9	24694-24701	alcohol	_	
154-10	24702-24710	compared	_	
154-11	24711-24713	to	_	
154-12	24714-24721	neutral	_	
154-13	24722-24731	condition	_	
154-14	24732-24733	(	_	
154-15	24733-24736	Fig	_	
154-16	24736-24737	.	_	
154-17	24738-24739	1	_	
154-18	24739-24740	)	_	
154-19	24741-24743	in	_	
154-20	24744-24747	the	_	
154-21	24748-24751	AUD	_	
154-22	24752-24760	subjects	_	
154-23	24760-24761	.	_	

#Text=This result may indicate an impaired ability to make flexible PCC connections in response to different emotional stimuli and difficulties with adjusting alcohol-related behaviors (e.g., craving, urge to drink) in AUD individuals, thereby increasing risk of relapse.
155-1	24762-24766	This	_	
155-2	24767-24773	result	_	
155-3	24774-24777	may	_	
155-4	24778-24786	indicate	_	
155-5	24787-24789	an	_	
155-6	24790-24798	impaired	_	
155-7	24799-24806	ability	_	
155-8	24807-24809	to	_	
155-9	24810-24814	make	_	
155-10	24815-24823	flexible	_	
155-11	24824-24827	PCC	_	
155-12	24828-24839	connections	_	
155-13	24840-24842	in	_	
155-14	24843-24851	response	_	
155-15	24852-24854	to	_	
155-16	24855-24864	different	_	
155-17	24865-24874	emotional	_	
155-18	24875-24882	stimuli	_	
155-19	24883-24886	and	_	
155-20	24887-24899	difficulties	_	
155-21	24900-24904	with	_	
155-22	24905-24914	adjusting	_	
155-23	24915-24930	alcohol-related	_	
155-24	24931-24940	behaviors	_	
155-25	24941-24942	(	_	
155-26	24942-24945	e.g	_	
155-27	24945-24946	.	_	
155-28	24946-24947	,	_	
155-29	24948-24955	craving	_	
155-30	24955-24956	,	_	
155-31	24957-24961	urge	_	
155-32	24962-24964	to	_	
155-33	24965-24970	drink	_	
155-34	24970-24971	)	_	
155-35	24972-24974	in	_	
155-36	24975-24978	AUD	_	
155-37	24979-24990	individuals	_	
155-38	24990-24991	,	_	
155-39	24992-24999	thereby	_	
155-40	25000-25010	increasing	_	
155-41	25011-25015	risk	_	
155-42	25016-25018	of	_	
155-43	25019-25026	relapse	_	
155-44	25026-25027	.	_	

#Text=In particular, AUD patients appear to have altered cingulate connectivity to the alcohol and stress cue.
156-1	25028-25030	In	_	
156-2	25031-25041	particular	_	
156-3	25041-25042	,	_	
156-4	25043-25046	AUD	_	
156-5	25047-25055	patients	_	
156-6	25056-25062	appear	_	
156-7	25063-25065	to	_	
156-8	25066-25070	have	_	
156-9	25071-25078	altered	_	
156-10	25079-25088	cingulate	_	
156-11	25089-25101	connectivity	_	
156-12	25102-25104	to	_	
156-13	25105-25108	the	_	
156-14	25109-25116	alcohol	_	
156-15	25117-25120	and	_	
156-16	25121-25127	stress	_	
156-17	25128-25131	cue	_	
156-18	25131-25132	.	_	

#Text=Our group contrast results from the second study show that AUD patients respond to alcohol and stress cues in a different manner than HC participants, but connectivity patterns are similar to HC participants for neutral cue conditions.
157-1	25133-25136	Our	_	
157-2	25137-25142	group	_	
157-3	25143-25151	contrast	_	
157-4	25152-25159	results	_	
157-5	25160-25164	from	_	
157-6	25165-25168	the	_	
157-7	25169-25175	second	_	
157-8	25176-25181	study	_	
157-9	25182-25186	show	_	
157-10	25187-25191	that	_	
157-11	25192-25195	AUD	_	
157-12	25196-25204	patients	_	
157-13	25205-25212	respond	_	
157-14	25213-25215	to	_	
157-15	25216-25223	alcohol	_	
157-16	25224-25227	and	_	
157-17	25228-25234	stress	_	
157-18	25235-25239	cues	_	
157-19	25240-25242	in	_	
157-20	25243-25244	a	_	
157-21	25245-25254	different	_	
157-22	25255-25261	manner	_	
157-23	25262-25266	than	_	
157-24	25267-25269	HC	_	
157-25	25270-25282	participants	_	
157-26	25282-25283	,	_	
157-27	25284-25287	but	_	
157-28	25288-25300	connectivity	_	
157-29	25301-25309	patterns	_	
157-30	25310-25313	are	_	
157-31	25314-25321	similar	_	
157-32	25322-25324	to	_	
157-33	25325-25327	HC	_	
157-34	25328-25340	participants	_	
157-35	25341-25344	for	_	
157-36	25345-25352	neutral	_	
157-37	25353-25356	cue	_	
157-38	25357-25367	conditions	_	
157-39	25367-25368	.	_	

#Text=Alcohol cues elicit reward responses in the brain.
158-1	25369-25376	Alcohol	_	
158-2	25377-25381	cues	_	
158-3	25382-25388	elicit	_	
158-4	25389-25395	reward	_	
158-5	25396-25405	responses	_	
158-6	25406-25408	in	_	
158-7	25409-25412	the	_	
158-8	25413-25418	brain	_	
158-9	25418-25419	.	_	

#Text=Studies have reported alcohol-related neuroadaptive changes in the brain circuits of alcohol dependent individuals, such that continued alcohol abuse increases incentive salience toward alcohol stimuli by altering the neural connectivity in reward and salience circuits.
159-1	25420-25427	Studies	_	
159-2	25428-25432	have	_	
159-3	25433-25441	reported	_	
159-4	25442-25457	alcohol-related	_	
159-5	25458-25471	neuroadaptive	_	
159-6	25472-25479	changes	_	
159-7	25480-25482	in	_	
159-8	25483-25486	the	_	
159-9	25487-25492	brain	_	
159-10	25493-25501	circuits	_	
159-11	25502-25504	of	_	
159-12	25505-25512	alcohol	_	
159-13	25513-25522	dependent	_	
159-14	25523-25534	individuals	_	
159-15	25534-25535	,	_	
159-16	25536-25540	such	_	
159-17	25541-25545	that	_	
159-18	25546-25555	continued	_	
159-19	25556-25563	alcohol	_	
159-20	25564-25569	abuse	_	
159-21	25570-25579	increases	_	
159-22	25580-25589	incentive	_	
159-23	25590-25598	salience	_	
159-24	25599-25605	toward	_	
159-25	25606-25613	alcohol	_	
159-26	25614-25621	stimuli	_	
159-27	25622-25624	by	_	
159-28	25625-25633	altering	_	
159-29	25634-25637	the	_	
159-30	25638-25644	neural	_	
159-31	25645-25657	connectivity	_	
159-32	25658-25660	in	_	
159-33	25661-25667	reward	_	
159-34	25668-25671	and	_	
159-35	25672-25680	salience	_	
159-36	25681-25689	circuits	_	
159-37	25689-25690	.	_	

#Text=Together, our findings of reduced cingulate connectivity specific to alcohol cue in AUD patients suggest that prolonged alcohol consumption in AUD individuals may sensitize and alter cingulate connectivity in response to alcohol cues, probably resulting from their incentive salience to alcohol-associated stimuli.
160-1	25691-25699	Together	_	
160-2	25699-25700	,	_	
160-3	25701-25704	our	_	
160-4	25705-25713	findings	_	
160-5	25714-25716	of	_	
160-6	25717-25724	reduced	_	
160-7	25725-25734	cingulate	_	
160-8	25735-25747	connectivity	_	
160-9	25748-25756	specific	_	
160-10	25757-25759	to	_	
160-11	25760-25767	alcohol	_	
160-12	25768-25771	cue	_	
160-13	25772-25774	in	_	
160-14	25775-25778	AUD	_	
160-15	25779-25787	patients	_	
160-16	25788-25795	suggest	_	
160-17	25796-25800	that	_	
160-18	25801-25810	prolonged	_	
160-19	25811-25818	alcohol	_	
160-20	25819-25830	consumption	_	
160-21	25831-25833	in	_	
160-22	25834-25837	AUD	_	
160-23	25838-25849	individuals	_	
160-24	25850-25853	may	_	
160-25	25854-25863	sensitize	_	
160-26	25864-25867	and	_	
160-27	25868-25873	alter	_	
160-28	25874-25883	cingulate	_	
160-29	25884-25896	connectivity	_	
160-30	25897-25899	in	_	
160-31	25900-25908	response	_	
160-32	25909-25911	to	_	
160-33	25912-25919	alcohol	_	
160-34	25920-25924	cues	_	
160-35	25924-25925	,	_	
160-36	25926-25934	probably	_	
160-37	25935-25944	resulting	_	
160-38	25945-25949	from	_	
160-39	25950-25955	their	_	
160-40	25956-25965	incentive	_	
160-41	25966-25974	salience	_	
160-42	25975-25977	to	_	
160-43	25978-25996	alcohol-associated	_	
160-44	25997-26004	stimuli	_	
160-45	26004-26005	.	_	

#Text=Further, our findings suggest that AUD patients with cingulate connectivity most similar to HC participants appear to have the most favorable relapse outcomes, emphasizing the crucial role of intact cingulate connectivity in maintaining alcohol abstinence.
161-1	26006-26013	Further	_	
161-2	26013-26014	,	_	
161-3	26015-26018	our	_	
161-4	26019-26027	findings	_	
161-5	26028-26035	suggest	_	
161-6	26036-26040	that	_	
161-7	26041-26044	AUD	_	
161-8	26045-26053	patients	_	
161-9	26054-26058	with	_	
161-10	26059-26068	cingulate	_	
161-11	26069-26081	connectivity	_	
161-12	26082-26086	most	_	
161-13	26087-26094	similar	_	
161-14	26095-26097	to	_	
161-15	26098-26100	HC	_	
161-16	26101-26113	participants	_	
161-17	26114-26120	appear	_	
161-18	26121-26123	to	_	
161-19	26124-26128	have	_	
161-20	26129-26132	the	_	
161-21	26133-26137	most	_	
161-22	26138-26147	favorable	_	
161-23	26148-26155	relapse	_	
161-24	26156-26164	outcomes	_	
161-25	26164-26165	,	_	
161-26	26166-26177	emphasizing	_	
161-27	26178-26181	the	_	
161-28	26182-26189	crucial	_	
161-29	26190-26194	role	_	
161-30	26195-26197	of	_	
161-31	26198-26204	intact	_	
161-32	26205-26214	cingulate	_	
161-33	26215-26227	connectivity	_	
161-34	26228-26230	in	_	
161-35	26231-26242	maintaining	_	
161-36	26243-26250	alcohol	_	
161-37	26251-26261	abstinence	_	
161-38	26261-26262	.	_	

#Text=Taken together, the current study using the ICD analysis sheds new light on the understanding of alcoholism by providing neural connectivity evidence that may underlie brain activity patterns using conventional task-based fMRI method.
162-1	26263-26268	Taken	_	
162-2	26269-26277	together	_	
162-3	26277-26278	,	_	
162-4	26279-26282	the	_	
162-5	26283-26290	current	_	
162-6	26291-26296	study	_	
162-7	26297-26302	using	_	
162-8	26303-26306	the	_	
162-9	26307-26310	ICD	_	
162-10	26311-26319	analysis	_	
162-11	26320-26325	sheds	_	
162-12	26326-26329	new	_	
162-13	26330-26335	light	_	
162-14	26336-26338	on	_	
162-15	26339-26342	the	_	
162-16	26343-26356	understanding	_	
162-17	26357-26359	of	_	
162-18	26360-26370	alcoholism	_	
162-19	26371-26373	by	_	
162-20	26374-26383	providing	_	
162-21	26384-26390	neural	_	
162-22	26391-26403	connectivity	_	
162-23	26404-26412	evidence	_	
162-24	26413-26417	that	_	
162-25	26418-26421	may	_	
162-26	26422-26430	underlie	_	
162-27	26431-26436	brain	_	
162-28	26437-26445	activity	_	
162-29	26446-26454	patterns	_	
162-30	26455-26460	using	_	
162-31	26461-26473	conventional	_	
162-32	26474-26484	task-based	_	
162-33	26485-26489	fMRI	_	
162-34	26490-26496	method	_	
162-35	26496-26497	.	_	

#Text=We report that that altered cingulate connectivity significantly contribute to alcohol-related pathology that is also significant for clinical outcomes of early relapse risk.
163-1	26498-26500	We	_	
163-2	26501-26507	report	_	
163-3	26508-26512	that	_	
163-4	26513-26517	that	_	
163-5	26518-26525	altered	_	
163-6	26526-26535	cingulate	_	
163-7	26536-26548	connectivity	_	
163-8	26549-26562	significantly	_	
163-9	26563-26573	contribute	_	
163-10	26574-26576	to	_	
163-11	26577-26592	alcohol-related	_	
163-12	26593-26602	pathology	_	
163-13	26603-26607	that	_	
163-14	26608-26610	is	_	
163-15	26611-26615	also	_	
163-16	26616-26627	significant	_	
163-17	26628-26631	for	_	
163-18	26632-26640	clinical	_	
163-19	26641-26649	outcomes	_	
163-20	26650-26652	of	_	
163-21	26653-26658	early	_	
163-22	26659-26666	relapse	_	
163-23	26667-26671	risk	_	
163-24	26671-26672	.	_	

#Text=Our prior task-based study identified hyperactivity in the vmPFC and parietal cortex (including the precuneus) during neutral states as key predictors of early relapse.
164-1	26673-26676	Our	_	
164-2	26677-26682	prior	_	
164-3	26683-26693	task-based	_	
164-4	26694-26699	study	_	
164-5	26700-26710	identified	_	
164-6	26711-26724	hyperactivity	_	
164-7	26725-26727	in	_	
164-8	26728-26731	the	_	
164-9	26732-26737	vmPFC	_	
164-10	26738-26741	and	_	
164-11	26742-26750	parietal	_	
164-12	26751-26757	cortex	_	
164-13	26758-26759	(	_	
164-14	26759-26768	including	_	
164-15	26769-26772	the	_	
164-16	26773-26782	precuneus	_	
164-17	26782-26783	)	_	
164-18	26784-26790	during	_	
164-19	26791-26798	neutral	_	
164-20	26799-26805	states	_	
164-21	26806-26808	as	_	
164-22	26809-26812	key	_	
164-23	26813-26823	predictors	_	
164-24	26824-26826	of	_	
164-25	26827-26832	early	_	
164-26	26833-26840	relapse	_	
164-27	26840-26841	.	_	

#Text=The vmPFC and parietal lobes are anatomically interconnected with the cingulate cortex with the former more connected with the ACC and the latter with the PCC.
165-1	26842-26845	The	_	
165-2	26846-26851	vmPFC	_	
165-3	26852-26855	and	_	
165-4	26856-26864	parietal	_	
165-5	26865-26870	lobes	_	
165-6	26871-26874	are	_	
165-7	26875-26887	anatomically	_	
165-8	26888-26902	interconnected	_	
165-9	26903-26907	with	_	
165-10	26908-26911	the	_	
165-11	26912-26921	cingulate	_	
165-12	26922-26928	cortex	_	
165-13	26929-26933	with	_	
165-14	26934-26937	the	_	
165-15	26938-26944	former	_	
165-16	26945-26949	more	_	
165-17	26950-26959	connected	_	
165-18	26960-26964	with	_	
165-19	26965-26968	the	_	
165-20	26969-26972	ACC	_	
165-21	26973-26976	and	_	
165-22	26977-26980	the	_	
165-23	26981-26987	latter	_	
165-24	26988-26992	with	_	
165-25	26993-26996	the	_	
165-26	26997-27000	PCC	_	
165-27	27000-27001	.	_	

#Text=Excessive connectivity during neutral states in the cingulate cortex may result in increased information transfer and processing, which may lead to hyper-reactivity in these regions.
166-1	27002-27011	Excessive	_	
166-2	27012-27024	connectivity	_	
166-3	27025-27031	during	_	
166-4	27032-27039	neutral	_	
166-5	27040-27046	states	_	
166-6	27047-27049	in	_	
166-7	27050-27053	the	_	
166-8	27054-27063	cingulate	_	
166-9	27064-27070	cortex	_	
166-10	27071-27074	may	_	
166-11	27075-27081	result	_	
166-12	27082-27084	in	_	
166-13	27085-27094	increased	_	
166-14	27095-27106	information	_	
166-15	27107-27115	transfer	_	
166-16	27116-27119	and	_	
166-17	27120-27130	processing	_	
166-18	27130-27131	,	_	
166-19	27132-27137	which	_	
166-20	27138-27141	may	_	
166-21	27142-27146	lead	_	
166-22	27147-27149	to	_	
166-23	27150-27166	hyper-reactivity	_	
166-24	27167-27169	in	_	
166-25	27170-27175	these	_	
166-26	27176-27183	regions	_	
166-27	27183-27184	.	_	

#Text=These results suggest that alcoholism may be characterized by abnormal activity in the medial PFC and precuneus, with underlying altered cingulate connectivity that bridges between these regions.
167-1	27185-27190	These	_	
167-2	27191-27198	results	_	
167-3	27199-27206	suggest	_	
167-4	27207-27211	that	_	
167-5	27212-27222	alcoholism	_	
167-6	27223-27226	may	_	
167-7	27227-27229	be	_	
167-8	27230-27243	characterized	_	
167-9	27244-27246	by	_	
167-10	27247-27255	abnormal	_	
167-11	27256-27264	activity	_	
167-12	27265-27267	in	_	
167-13	27268-27271	the	_	
167-14	27272-27278	medial	_	
167-15	27279-27282	PFC	_	
167-16	27283-27286	and	_	
167-17	27287-27296	precuneus	_	
167-18	27296-27297	,	_	
167-19	27298-27302	with	_	
167-20	27303-27313	underlying	_	
167-21	27314-27321	altered	_	
167-22	27322-27331	cingulate	_	
167-23	27332-27344	connectivity	_	
167-24	27345-27349	that	_	
167-25	27350-27357	bridges	_	
167-26	27358-27365	between	_	
167-27	27366-27371	these	_	
167-28	27372-27379	regions	_	
167-29	27379-27380	.	_	

#Text=Our finding highlights the importance of using ICD in understanding more comprehensive picture of alcohol pathology.
168-1	27381-27384	Our	_	
168-2	27385-27392	finding	_	
168-3	27393-27403	highlights	_	
168-4	27404-27407	the	_	
168-5	27408-27418	importance	_	
168-6	27419-27421	of	_	
168-7	27422-27427	using	_	
168-8	27428-27431	ICD	_	
168-9	27432-27434	in	_	
168-10	27435-27448	understanding	_	
168-11	27449-27453	more	_	
168-12	27454-27467	comprehensive	_	
168-13	27468-27475	picture	_	
168-14	27476-27478	of	_	
168-15	27479-27486	alcohol	_	
168-16	27487-27496	pathology	_	
168-17	27496-27497	.	_	

#Text=This study has several strengths including well-matched groups, successful prospective follow-up of AUD patients 90 days post-discharge from treatment, a well-validated individualized imagery task, and a novel, voxel-wise data-driven connectivity method.
169-1	27498-27502	This	_	
169-2	27503-27508	study	_	
169-3	27509-27512	has	_	
169-4	27513-27520	several	_	
169-5	27521-27530	strengths	_	
169-6	27531-27540	including	_	
169-7	27541-27553	well-matched	_	
169-8	27554-27560	groups	_	
169-9	27560-27561	,	_	
169-10	27562-27572	successful	_	
169-11	27573-27584	prospective	_	
169-12	27585-27594	follow-up	_	
169-13	27595-27597	of	_	
169-14	27598-27601	AUD	_	
169-15	27602-27610	patients	_	
169-16	27611-27613	90	_	
169-17	27613-27614	 	_	
169-18	27614-27618	days	_	
169-19	27619-27633	post-discharge	_	
169-20	27634-27638	from	_	
169-21	27639-27648	treatment	_	
169-22	27648-27649	,	_	
169-23	27650-27651	a	_	
169-24	27652-27666	well-validated	_	
169-25	27667-27681	individualized	_	
169-26	27682-27689	imagery	_	
169-27	27690-27694	task	_	
169-28	27694-27695	,	_	
169-29	27696-27699	and	_	
169-30	27700-27701	a	_	
169-31	27702-27707	novel	_	
169-32	27707-27708	,	_	
169-33	27709-27719	voxel-wise	_	
169-34	27720-27731	data-driven	_	
169-35	27732-27744	connectivity	_	
169-36	27745-27751	method	_	
169-37	27751-27752	.	_	

#Text=This study also has several limitations including a largely male population, the lack of pre-treatment connectivity data, and the lack of resting-state fMRI data.
170-1	27753-27757	This	_	
170-2	27758-27763	study	_	
170-3	27764-27768	also	_	
170-4	27769-27772	has	_	
170-5	27773-27780	several	_	
170-6	27781-27792	limitations	_	
170-7	27793-27802	including	_	
170-8	27803-27804	a	_	
170-9	27805-27812	largely	_	
170-10	27813-27817	male	_	
170-11	27818-27828	population	_	
170-12	27828-27829	,	_	
170-13	27830-27833	the	_	
170-14	27834-27838	lack	_	
170-15	27839-27841	of	_	
170-16	27842-27855	pre-treatment	_	
170-17	27856-27868	connectivity	_	
170-18	27869-27873	data	_	
170-19	27873-27874	,	_	
170-20	27875-27878	and	_	
170-21	27879-27882	the	_	
170-22	27883-27887	lack	_	
170-23	27888-27890	of	_	
170-24	27891-27904	resting-state	_	
170-25	27905-27909	fMRI	_	
170-26	27910-27914	data	_	
170-27	27914-27915	.	_	

#Text=Sex differences in connectivity and cue reactivity exist in healthy individuals, and, thus, may mask subtle changes in AUD connectivity.
171-1	27916-27919	Sex	_	
171-2	27920-27931	differences	_	
171-3	27932-27934	in	_	
171-4	27935-27947	connectivity	_	
171-5	27948-27951	and	_	
171-6	27952-27955	cue	_	
171-7	27956-27966	reactivity	_	
171-8	27967-27972	exist	_	
171-9	27973-27975	in	_	
171-10	27976-27983	healthy	_	
171-11	27984-27995	individuals	_	
171-12	27995-27996	,	_	
171-13	27997-28000	and	_	
171-14	28000-28001	,	_	
171-15	28002-28006	thus	_	
171-16	28006-28007	,	_	
171-17	28008-28011	may	_	
171-18	28012-28016	mask	_	
171-19	28017-28023	subtle	_	
171-20	28024-28031	changes	_	
171-21	28032-28034	in	_	
171-22	28035-28038	AUD	_	
171-23	28039-28051	connectivity	_	
171-24	28051-28052	.	_	

#Text=Research suggests that nicotine use can alter network dynamics of the cingulate in possibly similar ways.
172-1	28053-28061	Research	_	
172-2	28062-28070	suggests	_	
172-3	28071-28075	that	_	
172-4	28076-28084	nicotine	_	
172-5	28085-28088	use	_	
172-6	28089-28092	can	_	
172-7	28093-28098	alter	_	
172-8	28099-28106	network	_	
172-9	28107-28115	dynamics	_	
172-10	28116-28118	of	_	
172-11	28119-28122	the	_	
172-12	28123-28132	cingulate	_	
172-13	28133-28135	in	_	
172-14	28136-28144	possibly	_	
172-15	28145-28152	similar	_	
172-16	28153-28157	ways	_	
172-17	28157-28158	.	_	

#Text=Given the extensive comorbidity between alcohol and nicotine addiction found in general and clinical populations as well as in current study, it may be difficult to fully disentangle effects of alcohol dependency from effects of nicotine usage.
173-1	28159-28164	Given	_	
173-2	28165-28168	the	_	
173-3	28169-28178	extensive	_	
173-4	28179-28190	comorbidity	_	
173-5	28191-28198	between	_	
173-6	28199-28206	alcohol	_	
173-7	28207-28210	and	_	
173-8	28211-28219	nicotine	_	
173-9	28220-28229	addiction	_	
173-10	28230-28235	found	_	
173-11	28236-28238	in	_	
173-12	28239-28246	general	_	
173-13	28247-28250	and	_	
173-14	28251-28259	clinical	_	
173-15	28260-28271	populations	_	
173-16	28272-28274	as	_	
173-17	28275-28279	well	_	
173-18	28280-28282	as	_	
173-19	28283-28285	in	_	
173-20	28286-28293	current	_	
173-21	28294-28299	study	_	
173-22	28299-28300	,	_	
173-23	28301-28303	it	_	
173-24	28304-28307	may	_	
173-25	28308-28310	be	_	
173-26	28311-28320	difficult	_	
173-27	28321-28323	to	_	
173-28	28324-28329	fully	_	
173-29	28330-28341	disentangle	_	
173-30	28342-28349	effects	_	
173-31	28350-28352	of	_	
173-32	28353-28360	alcohol	_	
173-33	28361-28371	dependency	_	
173-34	28372-28376	from	_	
173-35	28377-28384	effects	_	
173-36	28385-28387	of	_	
173-37	28388-28396	nicotine	_	
173-38	28397-28402	usage	_	
173-39	28402-28403	.	_	

#Text=However, it should be noted that the current study included smoking status as a covariate, and within the AUD group, cingulate connectivity predicted early relapse, suggesting a significant contribution of chronic alcohol abuse over and above nicotine effects with important clinical implication for alcohol addiction pathology.
174-1	28404-28411	However	_	
174-2	28411-28412	,	_	
174-3	28413-28415	it	_	
174-4	28416-28422	should	_	
174-5	28423-28425	be	_	
174-6	28426-28431	noted	_	
174-7	28432-28436	that	_	
174-8	28437-28440	the	_	
174-9	28441-28448	current	_	
174-10	28449-28454	study	_	
174-11	28455-28463	included	_	
174-12	28464-28471	smoking	_	
174-13	28472-28478	status	_	
174-14	28479-28481	as	_	
174-15	28482-28483	a	_	
174-16	28484-28493	covariate	_	
174-17	28493-28494	,	_	
174-18	28495-28498	and	_	
174-19	28499-28505	within	_	
174-20	28506-28509	the	_	
174-21	28510-28513	AUD	_	
174-22	28514-28519	group	_	
174-23	28519-28520	,	_	
174-24	28521-28530	cingulate	_	
174-25	28531-28543	connectivity	_	
174-26	28544-28553	predicted	_	
174-27	28554-28559	early	_	
174-28	28560-28567	relapse	_	
174-29	28567-28568	,	_	
174-30	28569-28579	suggesting	_	
174-31	28580-28581	a	_	
174-32	28582-28593	significant	_	
174-33	28594-28606	contribution	_	
174-34	28607-28609	of	_	
174-35	28610-28617	chronic	_	
174-36	28618-28625	alcohol	_	
174-37	28626-28631	abuse	_	
174-38	28632-28636	over	_	
174-39	28637-28640	and	_	
174-40	28641-28646	above	_	
174-41	28647-28655	nicotine	_	
174-42	28656-28663	effects	_	
174-43	28664-28668	with	_	
174-44	28669-28678	important	_	
174-45	28679-28687	clinical	_	
174-46	28688-28699	implication	_	
174-47	28700-28703	for	_	
174-48	28704-28711	alcohol	_	
174-49	28712-28721	addiction	_	
174-50	28722-28731	pathology	_	
174-51	28731-28732	.	_	

#Text=Comparisons of pre- and post-treatment data with paired connectivity methods could improve connectivity's predictive power of relapse and the assessment of treatment efficacy.
175-1	28733-28744	Comparisons	_	
175-2	28745-28747	of	_	
175-3	28748-28751	pre	_	
175-4	28751-28752	-	_	
175-5	28753-28756	and	_	
175-6	28757-28771	post-treatment	_	
175-7	28772-28776	data	_	
175-8	28777-28781	with	_	
175-9	28782-28788	paired	_	
175-10	28789-28801	connectivity	_	
175-11	28802-28809	methods	_	
175-12	28810-28815	could	_	
175-13	28816-28823	improve	_	
175-14	28824-28838	connectivity's	_	
175-15	28839-28849	predictive	_	
175-16	28850-28855	power	_	
175-17	28856-28858	of	_	
175-18	28859-28866	relapse	_	
175-19	28867-28870	and	_	
175-20	28871-28874	the	_	
175-21	28875-28885	assessment	_	
175-22	28886-28888	of	_	
175-23	28889-28898	treatment	_	
175-24	28899-28907	efficacy	_	
175-25	28907-28908	.	_	

#Text=Unlike standard block or event-related imagery paradigms, our imagery paradigm included two 2.5-min blocks of continuous imagery data providing a sufficient amount of data for robust data-driven connectivity analyses.
176-1	28909-28915	Unlike	_	
176-2	28916-28924	standard	_	
176-3	28925-28930	block	_	
176-4	28931-28933	or	_	
176-5	28934-28947	event-related	_	
176-6	28948-28955	imagery	_	
176-7	28956-28965	paradigms	_	
176-8	28965-28966	,	_	
176-9	28967-28970	our	_	
176-10	28971-28978	imagery	_	
176-11	28979-28987	paradigm	_	
176-12	28988-28996	included	_	
176-13	28997-29000	two	_	
176-14	29001-29004	2.5	_	
176-15	29004-29005	-	_	
176-16	29005-29008	min	_	
176-17	29009-29015	blocks	_	
176-18	29016-29018	of	_	
176-19	29019-29029	continuous	_	
176-20	29030-29037	imagery	_	
176-21	29038-29042	data	_	
176-22	29043-29052	providing	_	
176-23	29053-29054	a	_	
176-24	29055-29065	sufficient	_	
176-25	29066-29072	amount	_	
176-26	29073-29075	of	_	
176-27	29076-29080	data	_	
176-28	29081-29084	for	_	
176-29	29085-29091	robust	_	
176-30	29092-29103	data-driven	_	
176-31	29104-29116	connectivity	_	
176-32	29117-29125	analyses	_	
176-33	29125-29126	.	_	

#Text=While this approach could be a strength allowing for the exploration of the neurobiology of relapse due to alcohol and stress cues, task-based fMRI studies can be limited in a clinical setting.
177-1	29127-29132	While	_	
177-2	29133-29137	this	_	
177-3	29138-29146	approach	_	
177-4	29147-29152	could	_	
177-5	29153-29155	be	_	
177-6	29156-29157	a	_	
177-7	29158-29166	strength	_	
177-8	29167-29175	allowing	_	
177-9	29176-29179	for	_	
177-10	29180-29183	the	_	
177-11	29184-29195	exploration	_	
177-12	29196-29198	of	_	
177-13	29199-29202	the	_	
177-14	29203-29215	neurobiology	_	
177-15	29216-29218	of	_	
177-16	29219-29226	relapse	_	
177-17	29227-29230	due	_	
177-18	29231-29233	to	_	
177-19	29234-29241	alcohol	_	
177-20	29242-29245	and	_	
177-21	29246-29252	stress	_	
177-22	29253-29257	cues	_	
177-23	29257-29258	,	_	
177-24	29259-29269	task-based	_	
177-25	29270-29274	fMRI	_	
177-26	29275-29282	studies	_	
177-27	29283-29286	can	_	
177-28	29287-29289	be	_	
177-29	29290-29297	limited	_	
177-30	29298-29300	in	_	
177-31	29301-29302	a	_	
177-32	29303-29311	clinical	_	
177-33	29312-29319	setting	_	
177-34	29319-29320	.	_	

#Text=Future studies should additionally examine resting-state connectivity to more comprehensively understand the clinical profile of alcohol addiction.
178-1	29321-29327	Future	_	
178-2	29328-29335	studies	_	
178-3	29336-29342	should	_	
178-4	29343-29355	additionally	_	
178-5	29356-29363	examine	_	
178-6	29364-29377	resting-state	_	
178-7	29378-29390	connectivity	_	
178-8	29391-29393	to	_	
178-9	29394-29398	more	_	
178-10	29399-29414	comprehensively	_	
178-11	29415-29425	understand	_	
178-12	29426-29429	the	_	
178-13	29430-29438	clinical	_	
178-14	29439-29446	profile	_	
178-15	29447-29449	of	_	
178-16	29450-29457	alcohol	_	
178-17	29458-29467	addiction	_	
178-18	29467-29468	.	_	

#Text=Conclusions
#Text=Functional connectivity of the cingulate cortex was identified as a key factor in the neurobiological response to alcohol and stress cues in AUD patients and a marker of later relapse.
179-1	29469-29480	Conclusions	_	
179-2	29481-29491	Functional	_	
179-3	29492-29504	connectivity	_	
179-4	29505-29507	of	_	
179-5	29508-29511	the	_	
179-6	29512-29521	cingulate	_	
179-7	29522-29528	cortex	_	
179-8	29529-29532	was	_	
179-9	29533-29543	identified	_	
179-10	29544-29546	as	_	
179-11	29547-29548	a	_	
179-12	29549-29552	key	_	
179-13	29553-29559	factor	_	
179-14	29560-29562	in	_	
179-15	29563-29566	the	_	
179-16	29567-29582	neurobiological	_	
179-17	29583-29591	response	_	
179-18	29592-29594	to	_	
179-19	29595-29602	alcohol	_	
179-20	29603-29606	and	_	
179-21	29607-29613	stress	_	
179-22	29614-29618	cues	_	
179-23	29619-29621	in	_	
179-24	29622-29625	AUD	_	
179-25	29626-29634	patients	_	
179-26	29635-29638	and	_	
179-27	29639-29640	a	_	
179-28	29641-29647	marker	_	
179-29	29648-29650	of	_	
179-30	29651-29656	later	_	
179-31	29657-29664	relapse	_	
179-32	29664-29665	.	_	

#Text=Alterations in the connectivity of the cingulate and future relapse predictions were revealed naturally from this data-driven analysis without the need for a priori seed or network definitions.
180-1	29666-29677	Alterations	_	
180-2	29678-29680	in	_	
180-3	29681-29684	the	_	
180-4	29685-29697	connectivity	_	
180-5	29698-29700	of	_	
180-6	29701-29704	the	_	
180-7	29705-29714	cingulate	_	
180-8	29715-29718	and	_	
180-9	29719-29725	future	_	
180-10	29726-29733	relapse	_	
180-11	29734-29745	predictions	_	
180-12	29746-29750	were	_	
180-13	29751-29759	revealed	_	
180-14	29760-29769	naturally	_	
180-15	29770-29774	from	_	
180-16	29775-29779	this	_	
180-17	29780-29791	data-driven	_	
180-18	29792-29800	analysis	_	
180-19	29801-29808	without	_	
180-20	29809-29812	the	_	
180-21	29813-29817	need	_	
180-22	29818-29821	for	_	
180-23	29822-29823	a	_	
180-24	29824-29830	priori	_	
180-25	29831-29835	seed	_	
180-26	29836-29838	or	_	
180-27	29839-29846	network	_	
180-28	29847-29858	definitions	_	
180-29	29858-29859	.	_	

#Text=Our results point to a potentially promising future of voxel-wise connectivity as a marker of relapse and for improving our understanding of this important disorder.
181-1	29860-29863	Our	_	
181-2	29864-29871	results	_	
181-3	29872-29877	point	_	
181-4	29878-29880	to	_	
181-5	29881-29882	a	_	
181-6	29883-29894	potentially	_	
181-7	29895-29904	promising	_	
181-8	29905-29911	future	_	
181-9	29912-29914	of	_	
181-10	29915-29925	voxel-wise	_	
181-11	29926-29938	connectivity	_	
181-12	29939-29941	as	_	
181-13	29942-29943	a	_	
181-14	29944-29950	marker	_	
181-15	29951-29953	of	_	
181-16	29954-29961	relapse	_	
181-17	29962-29965	and	_	
181-18	29966-29969	for	_	
181-19	29970-29979	improving	_	
181-20	29980-29983	our	_	
181-21	29984-29997	understanding	_	
181-22	29998-30000	of	_	
181-23	30001-30005	this	_	
181-24	30006-30015	important	_	
181-25	30016-30024	disorder	_	
181-26	30024-30025	.	_	

#Text=Disclosures
#Text=The authors report that they have no financial conflicts of interest with respect to this manuscript.
182-1	30026-30037	Disclosures	_	
182-2	30038-30041	The	_	
182-3	30042-30049	authors	_	
182-4	30050-30056	report	_	
182-5	30057-30061	that	_	
182-6	30062-30066	they	_	
182-7	30067-30071	have	_	
182-8	30072-30074	no	_	
182-9	30075-30084	financial	_	
182-10	30085-30094	conflicts	_	
182-11	30095-30097	of	_	
182-12	30098-30106	interest	_	
182-13	30107-30111	with	_	
182-14	30112-30119	respect	_	
182-15	30120-30122	to	_	
182-16	30123-30127	this	_	
182-17	30128-30138	manuscript	_	
182-18	30138-30139	.	_	

#Text=References
#Text=Effect of brain structure, brain function, and brain connectivity on relapse in alcohol-dependent patients
#Text=What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?
183-1	30140-30150	References	_	
183-2	30151-30157	Effect	_	
183-3	30158-30160	of	_	
183-4	30161-30166	brain	_	
183-5	30167-30176	structure	_	
183-6	30176-30177	,	_	
183-7	30178-30183	brain	_	
183-8	30184-30192	function	_	
183-9	30192-30193	,	_	
183-10	30194-30197	and	_	
183-11	30198-30203	brain	_	
183-12	30204-30216	connectivity	_	
183-13	30217-30219	on	_	
183-14	30220-30227	relapse	_	
183-15	30228-30230	in	_	
183-16	30231-30248	alcohol-dependent	_	
183-17	30249-30257	patients	_	
183-18	30258-30262	What	_	
183-19	30263-30265	is	_	
183-20	30266-30269	the	_	
183-21	30270-30274	role	_	
183-22	30275-30277	of	_	
183-23	30278-30286	dopamine	_	
183-24	30287-30289	in	_	
183-25	30290-30296	reward	_	
183-26	30296-30297	:	_	
183-27	30298-30305	hedonic	_	
183-28	30306-30312	impact	_	
183-29	30312-30313	,	_	
183-30	30314-30320	reward	_	
183-31	30321-30329	learning	_	
183-32	30329-30330	,	_	
183-33	30331-30333	or	_	
183-34	30334-30343	incentive	_	
183-35	30344-30352	salience	_	
183-36	30352-30353	?	_	

#Text=Connectivity-Based Parcellation of Human Cingulate Cortex and Its Relation to Functional Specialization
#Text=Chronic alcohol neuroadaptation and stress contribute to susceptibility for alcohol craving and relapse
#Text=Cognitive and emotional influences in anterior cingulate cortex
#Text=Resting-state synchrony during early alcohol abstinence can predict subsequent relapse
#Text=Resting-state synchrony in short-term versus long-term abstinent alcoholics
#Text=Changes in resting functional connectivity during abstinence in stimulant use disorder: a preliminary comparison of relapsers and abstainers
#Text=Disruption of functional connectivity of the default-mode network in alcoholism
#Text=The neural basis of drug stimulus processing and craving: an activation likelihood estimation meta-analysis
#Text=Volumetric differences in the anterior cingulate cortex prospectively predict alcohol-related problems in adolescence
#Text=Linear mixed-effects modeling approach to FMRI group analysis
#Text=Identifying neurobiological phenotypes associated with alcohol use disorder severity
#Text=Nicotine replacement in abstinent smokers improves cognitive withdrawal symptoms with modulation of resting brain network dynamics
#Text=Potential use and challenges of functional connectivity mapping in intractable epilepsy
#Text=Neural substrates of smoking cue reactivity: a meta-analysis of fMRI studies
#Text=Exposure to the taste of alcohol elicits activation of the mesocorticolimbic neurocircuitry
#Text=Differential brain response to alcohol cue distractors across stages of alcohol dependence
#Text=Cue-induced cocaine craving: neuroanatomical specificity for drug users and drug stimuli
#Text=Functional connectivity during exposure to favorite-food, stress, and neutral-relaxing imagery differs between smokers and nonsmokers
#Text=Why we like to drink: a functional magnetic resonance imaging study of the rewarding and anxiolytic effects of alcohol
#Text=Cue-induced activation of the striatum and medial prefrontal cortex is associated with subsequent relapse in abstinent alcoholics
#Text=The reward circuit: linking primate anatomy and human imaging
#Text=A genetically modulated, intrinsic cingulate circuit supports human nicotine addiction
#Text=Factors modulating neural reactivity to drug cues in addiction: a survey of human neuroimaging studies
#Text=Unified framework for development, deployment and robust testing of neuroimaging algorithms
#Text=Cue-induced brain activity changes and relapse in cocaine-dependent patients
#Text=The role of the posterior cingulate cortex in cognition and disease
#Text=Behavioral and neurological foundations for the moral and legal implications of intoxication, addictive behaviors and disinhibition
#Text=Large-scale brain network coupling predicts acute nicotine abstinence effects on craving and cognitive function
#Text=Working memory-related neural activity predicts future smoking relapse
#Text=Abnormal brain default-mode network functional connectivity in drug addicts
#Text=Binge alcohol consumption in emerging adults: anterior cingulate cortical “thinness” is associated with alcohol use patterns
#Text=Individual differences in imagery and the psychophysiology of emotion
#Text=A preliminary investigation of Stroop-related intrinsic connectivity in cocaine dependence: associations with treatment outcomes
#Text=The resting brain of alcoholics
#Text=Posterior cingulate cortex: adapting behavior to a changing world
#Text=Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders
#Text=The incentive sensitization theory of addiction: some current issues
#Text=The intrinsic connectivity distribution: a novel contrast measure reflecting voxel level functional connectivity
#Text=The impact of image smoothness on intrinsic functional connectivity and head motion confounds
#Text=Coupled intrinsic connectivity distribution analysis: a method for exploratory connectivity analysis of paired FMRI data
#Text=Sex differences in normal age trajectories of functional brain networks
#Text=Subcortical correlates of craving in recently abstinent alcoholic patients
#Text=Dissociable intrinsic connectivity networks for salience processing and executive control
#Text=Sex differences in neural responses to stress and alcohol context cues
#Text=Disrupted ventromedial prefrontal function, alcohol craving, and subsequent relapse risk
#Text=Modeling stress and drug craving in the laboratory: implications for addiction treatment development
#Text=Effects of adrenal sensitivity, stress- and cue-induced craving, and anxiety on subsequent alcohol relapse and treatment outcomes
#Text=The future of FMRI connectivity
#Text=The reliability of the alcohol timeline follow back when administered by telephone and by computer
#Text=Resting state functional connectivity in addiction: lessons learned and a road ahead
#Text=Salience processing and insular cortical function and dysfunction
#Text=
#Text=The organization of the human cerebral cortex estimated by intrinsic functional connectivity
#Text=Supplementary data
#Text=Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.nicl.2016.10.019.
184-1	30354-30372	Connectivity-Based	_	
184-2	30373-30385	Parcellation	_	
184-3	30386-30388	of	_	
184-4	30389-30394	Human	_	
184-5	30395-30404	Cingulate	_	
184-6	30405-30411	Cortex	_	
184-7	30412-30415	and	_	
184-8	30416-30419	Its	_	
184-9	30420-30428	Relation	_	
184-10	30429-30431	to	_	
184-11	30432-30442	Functional	_	
184-12	30443-30457	Specialization	_	
184-13	30458-30465	Chronic	_	
184-14	30466-30473	alcohol	_	
184-15	30474-30489	neuroadaptation	_	
184-16	30490-30493	and	_	
184-17	30494-30500	stress	_	
184-18	30501-30511	contribute	_	
184-19	30512-30514	to	_	
184-20	30515-30529	susceptibility	_	
184-21	30530-30533	for	_	
184-22	30534-30541	alcohol	_	
184-23	30542-30549	craving	_	
184-24	30550-30553	and	_	
184-25	30554-30561	relapse	_	
184-26	30562-30571	Cognitive	_	
184-27	30572-30575	and	_	
184-28	30576-30585	emotional	_	
184-29	30586-30596	influences	_	
184-30	30597-30599	in	_	
184-31	30600-30608	anterior	_	
184-32	30609-30618	cingulate	_	
184-33	30619-30625	cortex	_	
184-34	30626-30639	Resting-state	_	
184-35	30640-30649	synchrony	_	
184-36	30650-30656	during	_	
184-37	30657-30662	early	_	
184-38	30663-30670	alcohol	_	
184-39	30671-30681	abstinence	_	
184-40	30682-30685	can	_	
184-41	30686-30693	predict	_	
184-42	30694-30704	subsequent	_	
184-43	30705-30712	relapse	_	
184-44	30713-30726	Resting-state	_	
184-45	30727-30736	synchrony	_	
184-46	30737-30739	in	_	
184-47	30740-30750	short-term	_	
184-48	30751-30757	versus	_	
184-49	30758-30767	long-term	_	
184-50	30768-30777	abstinent	_	
184-51	30778-30788	alcoholics	_	
184-52	30789-30796	Changes	_	
184-53	30797-30799	in	_	
184-54	30800-30807	resting	_	
184-55	30808-30818	functional	_	
184-56	30819-30831	connectivity	_	
184-57	30832-30838	during	_	
184-58	30839-30849	abstinence	_	
184-59	30850-30852	in	_	
184-60	30853-30862	stimulant	_	
184-61	30863-30866	use	_	
184-62	30867-30875	disorder	_	
184-63	30875-30876	:	_	
184-64	30877-30878	a	_	
184-65	30879-30890	preliminary	_	
184-66	30891-30901	comparison	_	
184-67	30902-30904	of	_	
184-68	30905-30914	relapsers	_	
184-69	30915-30918	and	_	
184-70	30919-30929	abstainers	_	
184-71	30930-30940	Disruption	_	
184-72	30941-30943	of	_	
184-73	30944-30954	functional	_	
184-74	30955-30967	connectivity	_	
184-75	30968-30970	of	_	
184-76	30971-30974	the	_	
184-77	30975-30987	default-mode	_	
184-78	30988-30995	network	_	
184-79	30996-30998	in	_	
184-80	30999-31009	alcoholism	_	
184-81	31010-31013	The	_	
184-82	31014-31020	neural	_	
184-83	31021-31026	basis	_	
184-84	31027-31029	of	_	
184-85	31030-31034	drug	_	
184-86	31035-31043	stimulus	_	
184-87	31044-31054	processing	_	
184-88	31055-31058	and	_	
184-89	31059-31066	craving	_	
184-90	31066-31067	:	_	
184-91	31068-31070	an	_	
184-92	31071-31081	activation	_	
184-93	31082-31092	likelihood	_	
184-94	31093-31103	estimation	_	
184-95	31104-31117	meta-analysis	_	
184-96	31118-31128	Volumetric	_	
184-97	31129-31140	differences	_	
184-98	31141-31143	in	_	
184-99	31144-31147	the	_	
184-100	31148-31156	anterior	_	
184-101	31157-31166	cingulate	_	
184-102	31167-31173	cortex	_	
184-103	31174-31187	prospectively	_	
184-104	31188-31195	predict	_	
184-105	31196-31211	alcohol-related	_	
184-106	31212-31220	problems	_	
184-107	31221-31223	in	_	
184-108	31224-31235	adolescence	_	
184-109	31236-31242	Linear	_	
184-110	31243-31256	mixed-effects	_	
184-111	31257-31265	modeling	_	
184-112	31266-31274	approach	_	
184-113	31275-31277	to	_	
184-114	31278-31282	FMRI	_	
184-115	31283-31288	group	_	
184-116	31289-31297	analysis	_	
184-117	31298-31309	Identifying	_	
184-118	31310-31325	neurobiological	_	
184-119	31326-31336	phenotypes	_	
184-120	31337-31347	associated	_	
184-121	31348-31352	with	_	
184-122	31353-31360	alcohol	_	
184-123	31361-31364	use	_	
184-124	31365-31373	disorder	_	
184-125	31374-31382	severity	_	
184-126	31383-31391	Nicotine	_	
184-127	31392-31403	replacement	_	
184-128	31404-31406	in	_	
184-129	31407-31416	abstinent	_	
184-130	31417-31424	smokers	_	
184-131	31425-31433	improves	_	
184-132	31434-31443	cognitive	_	
184-133	31444-31454	withdrawal	_	
184-134	31455-31463	symptoms	_	
184-135	31464-31468	with	_	
184-136	31469-31479	modulation	_	
184-137	31480-31482	of	_	
184-138	31483-31490	resting	_	
184-139	31491-31496	brain	_	
184-140	31497-31504	network	_	
184-141	31505-31513	dynamics	_	
184-142	31514-31523	Potential	_	
184-143	31524-31527	use	_	
184-144	31528-31531	and	_	
184-145	31532-31542	challenges	_	
184-146	31543-31545	of	_	
184-147	31546-31556	functional	_	
184-148	31557-31569	connectivity	_	
184-149	31570-31577	mapping	_	
184-150	31578-31580	in	_	
184-151	31581-31592	intractable	_	
184-152	31593-31601	epilepsy	_	
184-153	31602-31608	Neural	_	
184-154	31609-31619	substrates	_	
184-155	31620-31622	of	_	
184-156	31623-31630	smoking	_	
184-157	31631-31634	cue	_	
184-158	31635-31645	reactivity	_	
184-159	31645-31646	:	_	
184-160	31647-31648	a	_	
184-161	31649-31662	meta-analysis	_	
184-162	31663-31665	of	_	
184-163	31666-31670	fMRI	_	
184-164	31671-31678	studies	_	
184-165	31679-31687	Exposure	_	
184-166	31688-31690	to	_	
184-167	31691-31694	the	_	
184-168	31695-31700	taste	_	
184-169	31701-31703	of	_	
184-170	31704-31711	alcohol	_	
184-171	31712-31719	elicits	_	
184-172	31720-31730	activation	_	
184-173	31731-31733	of	_	
184-174	31734-31737	the	_	
184-175	31738-31755	mesocorticolimbic	_	
184-176	31756-31770	neurocircuitry	_	
184-177	31771-31783	Differential	_	
184-178	31784-31789	brain	_	
184-179	31790-31798	response	_	
184-180	31799-31801	to	_	
184-181	31802-31809	alcohol	_	
184-182	31810-31813	cue	_	
184-183	31814-31825	distractors	_	
184-184	31826-31832	across	_	
184-185	31833-31839	stages	_	
184-186	31840-31842	of	_	
184-187	31843-31850	alcohol	_	
184-188	31851-31861	dependence	_	
184-189	31862-31873	Cue-induced	_	
184-190	31874-31881	cocaine	_	
184-191	31882-31889	craving	_	
184-192	31889-31890	:	_	
184-193	31891-31906	neuroanatomical	_	
184-194	31907-31918	specificity	_	
184-195	31919-31922	for	_	
184-196	31923-31927	drug	_	
184-197	31928-31933	users	_	
184-198	31934-31937	and	_	
184-199	31938-31942	drug	_	
184-200	31943-31950	stimuli	_	
184-201	31951-31961	Functional	_	
184-202	31962-31974	connectivity	_	
184-203	31975-31981	during	_	
184-204	31982-31990	exposure	_	
184-205	31991-31993	to	_	
184-206	31994-32007	favorite-food	_	
184-207	32007-32008	,	_	
184-208	32009-32015	stress	_	
184-209	32015-32016	,	_	
184-210	32017-32020	and	_	
184-211	32021-32037	neutral-relaxing	_	
184-212	32038-32045	imagery	_	
184-213	32046-32053	differs	_	
184-214	32054-32061	between	_	
184-215	32062-32069	smokers	_	
184-216	32070-32073	and	_	
184-217	32074-32084	nonsmokers	_	
184-218	32085-32088	Why	_	
184-219	32089-32091	we	_	
184-220	32092-32096	like	_	
184-221	32097-32099	to	_	
184-222	32100-32105	drink	_	
184-223	32105-32106	:	_	
184-224	32107-32108	a	_	
184-225	32109-32119	functional	_	
184-226	32120-32128	magnetic	_	
184-227	32129-32138	resonance	_	
184-228	32139-32146	imaging	_	
184-229	32147-32152	study	_	
184-230	32153-32155	of	_	
184-231	32156-32159	the	_	
184-232	32160-32169	rewarding	_	
184-233	32170-32173	and	_	
184-234	32174-32184	anxiolytic	_	
184-235	32185-32192	effects	_	
184-236	32193-32195	of	_	
184-237	32196-32203	alcohol	_	
184-238	32204-32215	Cue-induced	_	
184-239	32216-32226	activation	_	
184-240	32227-32229	of	_	
184-241	32230-32233	the	_	
184-242	32234-32242	striatum	_	
184-243	32243-32246	and	_	
184-244	32247-32253	medial	_	
184-245	32254-32264	prefrontal	_	
184-246	32265-32271	cortex	_	
184-247	32272-32274	is	_	
184-248	32275-32285	associated	_	
184-249	32286-32290	with	_	
184-250	32291-32301	subsequent	_	
184-251	32302-32309	relapse	_	
184-252	32310-32312	in	_	
184-253	32313-32322	abstinent	_	
184-254	32323-32333	alcoholics	_	
184-255	32334-32337	The	_	
184-256	32338-32344	reward	_	
184-257	32345-32352	circuit	_	
184-258	32352-32353	:	_	
184-259	32354-32361	linking	_	
184-260	32362-32369	primate	_	
184-261	32370-32377	anatomy	_	
184-262	32378-32381	and	_	
184-263	32382-32387	human	_	
184-264	32388-32395	imaging	_	
184-265	32396-32397	A	_	
184-266	32398-32409	genetically	_	
184-267	32410-32419	modulated	_	
184-268	32419-32420	,	_	
184-269	32421-32430	intrinsic	_	
184-270	32431-32440	cingulate	_	
184-271	32441-32448	circuit	_	
184-272	32449-32457	supports	_	
184-273	32458-32463	human	_	
184-274	32464-32472	nicotine	_	
184-275	32473-32482	addiction	_	
184-276	32483-32490	Factors	_	
184-277	32491-32501	modulating	_	
184-278	32502-32508	neural	_	
184-279	32509-32519	reactivity	_	
184-280	32520-32522	to	_	
184-281	32523-32527	drug	_	
184-282	32528-32532	cues	_	
184-283	32533-32535	in	_	
184-284	32536-32545	addiction	_	
184-285	32545-32546	:	_	
184-286	32547-32548	a	_	
184-287	32549-32555	survey	_	
184-288	32556-32558	of	_	
184-289	32559-32564	human	_	
184-290	32565-32577	neuroimaging	_	
184-291	32578-32585	studies	_	
184-292	32586-32593	Unified	_	
184-293	32594-32603	framework	_	
184-294	32604-32607	for	_	
184-295	32608-32619	development	_	
184-296	32619-32620	,	_	
184-297	32621-32631	deployment	_	
184-298	32632-32635	and	_	
184-299	32636-32642	robust	_	
184-300	32643-32650	testing	_	
184-301	32651-32653	of	_	
184-302	32654-32666	neuroimaging	_	
184-303	32667-32677	algorithms	_	
184-304	32678-32689	Cue-induced	_	
184-305	32690-32695	brain	_	
184-306	32696-32704	activity	_	
184-307	32705-32712	changes	_	
184-308	32713-32716	and	_	
184-309	32717-32724	relapse	_	
184-310	32725-32727	in	_	
184-311	32728-32745	cocaine-dependent	_	
184-312	32746-32754	patients	_	
184-313	32755-32758	The	_	
184-314	32759-32763	role	_	
184-315	32764-32766	of	_	
184-316	32767-32770	the	_	
184-317	32771-32780	posterior	_	
184-318	32781-32790	cingulate	_	
184-319	32791-32797	cortex	_	
184-320	32798-32800	in	_	
184-321	32801-32810	cognition	_	
184-322	32811-32814	and	_	
184-323	32815-32822	disease	_	
184-324	32823-32833	Behavioral	_	
184-325	32834-32837	and	_	
184-326	32838-32850	neurological	_	
184-327	32851-32862	foundations	_	
184-328	32863-32866	for	_	
184-329	32867-32870	the	_	
184-330	32871-32876	moral	_	
184-331	32877-32880	and	_	
184-332	32881-32886	legal	_	
184-333	32887-32899	implications	_	
184-334	32900-32902	of	_	
184-335	32903-32915	intoxication	_	
184-336	32915-32916	,	_	
184-337	32917-32926	addictive	_	
184-338	32927-32936	behaviors	_	
184-339	32937-32940	and	_	
184-340	32941-32954	disinhibition	_	
184-341	32955-32966	Large-scale	_	
184-342	32967-32972	brain	_	
184-343	32973-32980	network	_	
184-344	32981-32989	coupling	_	
184-345	32990-32998	predicts	_	
184-346	32999-33004	acute	_	
184-347	33005-33013	nicotine	_	
184-348	33014-33024	abstinence	_	
184-349	33025-33032	effects	_	
184-350	33033-33035	on	_	
184-351	33036-33043	craving	_	
184-352	33044-33047	and	_	
184-353	33048-33057	cognitive	_	
184-354	33058-33066	function	_	
184-355	33067-33074	Working	_	
184-356	33075-33089	memory-related	_	
184-357	33090-33096	neural	_	
184-358	33097-33105	activity	_	
184-359	33106-33114	predicts	_	
184-360	33115-33121	future	_	
184-361	33122-33129	smoking	_	
184-362	33130-33137	relapse	_	
184-363	33138-33146	Abnormal	_	
184-364	33147-33152	brain	_	
184-365	33153-33165	default-mode	_	
184-366	33166-33173	network	_	
184-367	33174-33184	functional	_	
184-368	33185-33197	connectivity	_	
184-369	33198-33200	in	_	
184-370	33201-33205	drug	_	
184-371	33206-33213	addicts	_	
184-372	33214-33219	Binge	_	
184-373	33220-33227	alcohol	_	
184-374	33228-33239	consumption	_	
184-375	33240-33242	in	_	
184-376	33243-33251	emerging	_	
184-377	33252-33258	adults	_	
184-378	33258-33259	:	_	
184-379	33260-33268	anterior	_	
184-380	33269-33278	cingulate	_	
184-381	33279-33287	cortical	_	
184-382	33288-33289	“	_	
184-383	33289-33297	thinness	_	
184-384	33297-33298	”	_	
184-385	33299-33301	is	_	
184-386	33302-33312	associated	_	
184-387	33313-33317	with	_	
184-388	33318-33325	alcohol	_	
184-389	33326-33329	use	_	
184-390	33330-33338	patterns	_	
184-391	33339-33349	Individual	_	
184-392	33350-33361	differences	_	
184-393	33362-33364	in	_	
184-394	33365-33372	imagery	_	
184-395	33373-33376	and	_	
184-396	33377-33380	the	_	
184-397	33381-33397	psychophysiology	_	
184-398	33398-33400	of	_	
184-399	33401-33408	emotion	_	
184-400	33409-33410	A	_	
184-401	33411-33422	preliminary	_	
184-402	33423-33436	investigation	_	
184-403	33437-33439	of	_	
184-404	33440-33454	Stroop-related	_	
184-405	33455-33464	intrinsic	_	
184-406	33465-33477	connectivity	_	
184-407	33478-33480	in	_	
184-408	33481-33488	cocaine	_	
184-409	33489-33499	dependence	_	
184-410	33499-33500	:	_	
184-411	33501-33513	associations	_	
184-412	33514-33518	with	_	
184-413	33519-33528	treatment	_	
184-414	33529-33537	outcomes	_	
184-415	33538-33541	The	_	
184-416	33542-33549	resting	_	
184-417	33550-33555	brain	_	
184-418	33556-33558	of	_	
184-419	33559-33569	alcoholics	_	
184-420	33570-33579	Posterior	_	
184-421	33580-33589	cingulate	_	
184-422	33590-33596	cortex	_	
184-423	33596-33597	:	_	
184-424	33598-33606	adapting	_	
184-425	33607-33615	behavior	_	
184-426	33616-33618	to	_	
184-427	33619-33620	a	_	
184-428	33621-33629	changing	_	
184-429	33630-33635	world	_	
184-430	33636-33642	Global	_	
184-431	33643-33649	burden	_	
184-432	33650-33652	of	_	
184-433	33653-33660	disease	_	
184-434	33661-33664	and	_	
184-435	33665-33671	injury	_	
184-436	33672-33675	and	_	
184-437	33676-33684	economic	_	
184-438	33685-33689	cost	_	
184-439	33690-33702	attributable	_	
184-440	33703-33705	to	_	
184-441	33706-33713	alcohol	_	
184-442	33714-33717	use	_	
184-443	33718-33721	and	_	
184-444	33722-33733	alcohol-use	_	
184-445	33734-33743	disorders	_	
184-446	33744-33747	The	_	
184-447	33748-33757	incentive	_	
184-448	33758-33771	sensitization	_	
184-449	33772-33778	theory	_	
184-450	33779-33781	of	_	
184-451	33782-33791	addiction	_	
184-452	33791-33792	:	_	
184-453	33793-33797	some	_	
184-454	33798-33805	current	_	
184-455	33806-33812	issues	_	
184-456	33813-33816	The	_	
184-457	33817-33826	intrinsic	_	
184-458	33827-33839	connectivity	_	
184-459	33840-33852	distribution	_	
184-460	33852-33853	:	_	
184-461	33854-33855	a	_	
184-462	33856-33861	novel	_	
184-463	33862-33870	contrast	_	
184-464	33871-33878	measure	_	
184-465	33879-33889	reflecting	_	
184-466	33890-33895	voxel	_	
184-467	33896-33901	level	_	
184-468	33902-33912	functional	_	
184-469	33913-33925	connectivity	_	
184-470	33926-33929	The	_	
184-471	33930-33936	impact	_	
184-472	33937-33939	of	_	
184-473	33940-33945	image	_	
184-474	33946-33956	smoothness	_	
184-475	33957-33959	on	_	
184-476	33960-33969	intrinsic	_	
184-477	33970-33980	functional	_	
184-478	33981-33993	connectivity	_	
184-479	33994-33997	and	_	
184-480	33998-34002	head	_	
184-481	34003-34009	motion	_	
184-482	34010-34019	confounds	_	
184-483	34020-34027	Coupled	_	
184-484	34028-34037	intrinsic	_	
184-485	34038-34050	connectivity	_	
184-486	34051-34063	distribution	_	
184-487	34064-34072	analysis	_	
184-488	34072-34073	:	_	
184-489	34074-34075	a	_	
184-490	34076-34082	method	_	
184-491	34083-34086	for	_	
184-492	34087-34098	exploratory	_	
184-493	34099-34111	connectivity	_	
184-494	34112-34120	analysis	_	
184-495	34121-34123	of	_	
184-496	34124-34130	paired	_	
184-497	34131-34135	FMRI	_	
184-498	34136-34140	data	_	
184-499	34141-34144	Sex	_	
184-500	34145-34156	differences	_	
184-501	34157-34159	in	_	
184-502	34160-34166	normal	_	
184-503	34167-34170	age	_	
184-504	34171-34183	trajectories	_	
184-505	34184-34186	of	_	
184-506	34187-34197	functional	_	
184-507	34198-34203	brain	_	
184-508	34204-34212	networks	_	
184-509	34213-34224	Subcortical	_	
184-510	34225-34235	correlates	_	
184-511	34236-34238	of	_	
184-512	34239-34246	craving	_	
184-513	34247-34249	in	_	
184-514	34250-34258	recently	_	
184-515	34259-34268	abstinent	_	
184-516	34269-34278	alcoholic	_	
184-517	34279-34287	patients	_	
184-518	34288-34299	Dissociable	_	
184-519	34300-34309	intrinsic	_	
184-520	34310-34322	connectivity	_	
184-521	34323-34331	networks	_	
184-522	34332-34335	for	_	
184-523	34336-34344	salience	_	
184-524	34345-34355	processing	_	
184-525	34356-34359	and	_	
184-526	34360-34369	executive	_	
184-527	34370-34377	control	_	
184-528	34378-34381	Sex	_	
184-529	34382-34393	differences	_	
184-530	34394-34396	in	_	
184-531	34397-34403	neural	_	
184-532	34404-34413	responses	_	
184-533	34414-34416	to	_	
184-534	34417-34423	stress	_	
184-535	34424-34427	and	_	
184-536	34428-34435	alcohol	_	
184-537	34436-34443	context	_	
184-538	34444-34448	cues	_	
184-539	34449-34458	Disrupted	_	
184-540	34459-34471	ventromedial	_	
184-541	34472-34482	prefrontal	_	
184-542	34483-34491	function	_	
184-543	34491-34492	,	_	
184-544	34493-34500	alcohol	_	
184-545	34501-34508	craving	_	
184-546	34508-34509	,	_	
184-547	34510-34513	and	_	
184-548	34514-34524	subsequent	_	
184-549	34525-34532	relapse	_	
184-550	34533-34537	risk	_	
184-551	34538-34546	Modeling	_	
184-552	34547-34553	stress	_	
184-553	34554-34557	and	_	
184-554	34558-34562	drug	_	
184-555	34563-34570	craving	_	
184-556	34571-34573	in	_	
184-557	34574-34577	the	_	
184-558	34578-34588	laboratory	_	
184-559	34588-34589	:	_	
184-560	34590-34602	implications	_	
184-561	34603-34606	for	_	
184-562	34607-34616	addiction	_	
184-563	34617-34626	treatment	_	
184-564	34627-34638	development	_	
184-565	34639-34646	Effects	_	
184-566	34647-34649	of	_	
184-567	34650-34657	adrenal	_	
184-568	34658-34669	sensitivity	_	
184-569	34669-34670	,	_	
184-570	34671-34677	stress	_	
184-571	34677-34678	-	_	
184-572	34679-34682	and	_	
184-573	34683-34694	cue-induced	_	
184-574	34695-34702	craving	_	
184-575	34702-34703	,	_	
184-576	34704-34707	and	_	
184-577	34708-34715	anxiety	_	
184-578	34716-34718	on	_	
184-579	34719-34729	subsequent	_	
184-580	34730-34737	alcohol	_	
184-581	34738-34745	relapse	_	
184-582	34746-34749	and	_	
184-583	34750-34759	treatment	_	
184-584	34760-34768	outcomes	_	
184-585	34769-34772	The	_	
184-586	34773-34779	future	_	
184-587	34780-34782	of	_	
184-588	34783-34787	FMRI	_	
184-589	34788-34800	connectivity	_	
184-590	34801-34804	The	_	
184-591	34805-34816	reliability	_	
184-592	34817-34819	of	_	
184-593	34820-34823	the	_	
184-594	34824-34831	alcohol	_	
184-595	34832-34840	timeline	_	
184-596	34841-34847	follow	_	
184-597	34848-34852	back	_	
184-598	34853-34857	when	_	
184-599	34858-34870	administered	_	
184-600	34871-34873	by	_	
184-601	34874-34883	telephone	_	
184-602	34884-34887	and	_	
184-603	34888-34890	by	_	
184-604	34891-34899	computer	_	
184-605	34900-34907	Resting	_	
184-606	34908-34913	state	_	
184-607	34914-34924	functional	_	
184-608	34925-34937	connectivity	_	
184-609	34938-34940	in	_	
184-610	34941-34950	addiction	_	
184-611	34950-34951	:	_	
184-612	34952-34959	lessons	_	
184-613	34960-34967	learned	_	
184-614	34968-34971	and	_	
184-615	34972-34973	a	_	
184-616	34974-34978	road	_	
184-617	34979-34984	ahead	_	
184-618	34985-34993	Salience	_	
184-619	34994-35004	processing	_	
184-620	35005-35008	and	_	
184-621	35009-35016	insular	_	
184-622	35017-35025	cortical	_	
184-623	35026-35034	function	_	
184-624	35035-35038	and	_	
184-625	35039-35050	dysfunction	_	
184-626	35052-35055	The	_	
184-627	35056-35068	organization	_	
184-628	35069-35071	of	_	
184-629	35072-35075	the	_	
184-630	35076-35081	human	_	
184-631	35082-35090	cerebral	_	
184-632	35091-35097	cortex	_	
184-633	35098-35107	estimated	_	
184-634	35108-35110	by	_	
184-635	35111-35120	intrinsic	_	
184-636	35121-35131	functional	_	
184-637	35132-35144	connectivity	_	
184-638	35145-35158	Supplementary	_	
184-639	35159-35163	data	_	
184-640	35164-35177	Supplementary	_	
184-641	35178-35182	data	_	
184-642	35183-35185	to	_	
184-643	35186-35190	this	_	
184-644	35191-35198	article	_	
184-645	35199-35202	can	_	
184-646	35203-35205	be	_	
184-647	35206-35211	found	_	
184-648	35212-35218	online	_	
184-649	35219-35221	at	_	
184-650	35222-35226	http	_	
184-651	35226-35227	:	_	
184-652	35227-35228	/	_	
184-653	35228-35229	/	_	
184-654	35229-35239	dx.doi.org	_	
184-655	35239-35240	/	_	
184-656	35240-35247	10.1016	_	
184-657	35247-35248	/	_	
184-658	35248-35254	j.nicl	_	
184-659	35254-35266	.2016.10.019	_	
184-660	35266-35267	.	_	

#Text=Main effects of cue condition in AUD patients.
185-1	35268-35272	Main	_	
185-2	35273-35280	effects	_	
185-3	35281-35283	of	_	
185-4	35284-35287	cue	_	
185-5	35288-35297	condition	_	
185-6	35298-35300	in	_	
185-7	35301-35304	AUD	_	
185-8	35305-35313	patients	_	
185-9	35313-35314	.	_	

#Text=Voxel-wise connectivity revealed a significant (p < 0.05 corrected) main effect of cue trials in the cingulate cortex as shown in A) sagittal slices.
186-1	35315-35325	Voxel-wise	_	
186-2	35326-35338	connectivity	_	
186-3	35339-35347	revealed	_	
186-4	35348-35349	a	_	
186-5	35350-35361	significant	_	
186-6	35362-35363	(	_	
186-7	35363-35364	p	_	
186-8	35364-35365	 	_	
186-9	35365-35366	<	_	
186-10	35366-35367	 	_	
186-11	35367-35371	0.05	_	
186-12	35372-35381	corrected	_	
186-13	35381-35382	)	_	
186-14	35383-35387	main	_	
186-15	35388-35394	effect	_	
186-16	35395-35397	of	_	
186-17	35398-35401	cue	_	
186-18	35402-35408	trials	_	
186-19	35409-35411	in	_	
186-20	35412-35415	the	_	
186-21	35416-35425	cingulate	_	
186-22	35426-35432	cortex	_	
186-23	35433-35435	as	_	
186-24	35436-35441	shown	_	
186-25	35442-35444	in	_	
186-26	35445-35446	A	_	
186-27	35446-35447	)	_	
186-28	35448-35456	sagittal	_	
186-29	35457-35463	slices	_	
186-30	35463-35464	.	_	

#Text=These effects were driven by reduced cingulate connectivity during the B) alcohol, and C) stress cue trials compared to the neutral cue trials.
187-1	35465-35470	These	_	
187-2	35471-35478	effects	_	
187-3	35479-35483	were	_	
187-4	35484-35490	driven	_	
187-5	35491-35493	by	_	
187-6	35494-35501	reduced	_	
187-7	35502-35511	cingulate	_	
187-8	35512-35524	connectivity	_	
187-9	35525-35531	during	_	
187-10	35532-35535	the	_	
187-11	35536-35537	B	_	
187-12	35537-35538	)	_	
187-13	35539-35546	alcohol	_	
187-14	35546-35547	,	_	
187-15	35548-35551	and	_	
187-16	35552-35553	C	_	
187-17	35553-35554	)	_	
187-18	35555-35561	stress	_	
187-19	35562-35565	cue	_	
187-20	35566-35572	trials	_	
187-21	35573-35581	compared	_	
187-22	35582-35584	to	_	
187-23	35585-35588	the	_	
187-24	35589-35596	neutral	_	
187-25	35597-35600	cue	_	
187-26	35601-35607	trials	_	
187-27	35607-35608	.	_	

#Text=Warm colors indicate regions of significant F statistics for main effects of task.
188-1	35609-35613	Warm	_	
188-2	35614-35620	colors	_	
188-3	35621-35629	indicate	_	
188-4	35630-35637	regions	_	
188-5	35638-35640	of	_	
188-6	35641-35652	significant	_	
188-7	35653-35654	F	_	
188-8	35655-35665	statistics	_	
188-9	35666-35669	for	_	
188-10	35670-35674	main	_	
188-11	35675-35682	effects	_	
188-12	35683-35685	of	_	
188-13	35686-35690	task	_	
188-14	35690-35691	.	_	

#Text=Cool colors indicate regions of significant decreases in tissue connectivity during alcohol and stress cues relative to neutral cue connectivity.
189-1	35692-35696	Cool	_	
189-2	35697-35703	colors	_	
189-3	35704-35712	indicate	_	
189-4	35713-35720	regions	_	
189-5	35721-35723	of	_	
189-6	35724-35735	significant	_	
189-7	35736-35745	decreases	_	
189-8	35746-35748	in	_	
189-9	35749-35755	tissue	_	
189-10	35756-35768	connectivity	_	
189-11	35769-35775	during	_	
189-12	35776-35783	alcohol	_	
189-13	35784-35787	and	_	
189-14	35788-35794	stress	_	
189-15	35795-35799	cues	_	
189-16	35800-35808	relative	_	
189-17	35809-35811	to	_	
189-18	35812-35819	neutral	_	
189-19	35820-35823	cue	_	
189-20	35824-35836	connectivity	_	
189-21	35836-35837	.	_	

#Text=Note that all figures are shown in radiological convention (subject left is image right).
190-1	35838-35842	Note	_	
190-2	35843-35847	that	_	
190-3	35848-35851	all	_	
190-4	35852-35859	figures	_	
190-5	35860-35863	are	_	
190-6	35864-35869	shown	_	
190-7	35870-35872	in	_	
190-8	35873-35885	radiological	_	
190-9	35886-35896	convention	_	
190-10	35897-35898	(	_	
190-11	35898-35905	subject	_	
190-12	35906-35910	left	_	
190-13	35911-35913	is	_	
190-14	35914-35919	image	_	
190-15	35920-35925	right	_	
190-16	35925-35926	)	_	
190-17	35926-35927	.	_	

#Text=Fig. 1
#Text=Estimated survival functions for connectivity predicting relapse.
191-1	35928-35931	Fig	_	
191-2	35931-35932	.	_	
191-3	35933-35934	1	_	
191-4	35935-35944	Estimated	_	
191-5	35945-35953	survival	_	
191-6	35954-35963	functions	_	
191-7	35964-35967	for	_	
191-8	35968-35980	connectivity	_	
191-9	35981-35991	predicting	_	
191-10	35992-35999	relapse	_	
191-11	35999-36000	.	_	

#Text=Estimated survival functions for time to relapse (with the number of years of alcohol use and nicotine smoking held constant) are shown for the mean ICD connectivity value and ± 1 and 2 standard deviation above/below the mean.
192-1	36001-36010	Estimated	_	
192-2	36011-36019	survival	_	
192-3	36020-36029	functions	_	
192-4	36030-36033	for	_	
192-5	36034-36038	time	_	
192-6	36039-36041	to	_	
192-7	36042-36049	relapse	_	
192-8	36050-36051	(	_	
192-9	36051-36055	with	_	
192-10	36056-36059	the	_	
192-11	36060-36066	number	_	
192-12	36067-36069	of	_	
192-13	36070-36075	years	_	
192-14	36076-36078	of	_	
192-15	36079-36086	alcohol	_	
192-16	36087-36090	use	_	
192-17	36091-36094	and	_	
192-18	36095-36103	nicotine	_	
192-19	36104-36111	smoking	_	
192-20	36112-36116	held	_	
192-21	36117-36125	constant	_	
192-22	36125-36126	)	_	
192-23	36127-36130	are	_	
192-24	36131-36136	shown	_	
192-25	36137-36140	for	_	
192-26	36141-36144	the	_	
192-27	36145-36149	mean	_	
192-28	36150-36153	ICD	_	
192-29	36154-36166	connectivity	_	
192-30	36167-36172	value	_	
192-31	36173-36176	and	_	
192-32	36176-36177	 	_	
192-33	36177-36178	±	_	
192-34	36178-36179	 	_	
192-35	36179-36180	1	_	
192-36	36181-36184	and	_	
192-37	36185-36186	2	_	
192-38	36187-36195	standard	_	
192-39	36196-36205	deviation	_	
192-40	36206-36211	above	_	
192-41	36211-36212	/	_	
192-42	36212-36217	below	_	
192-43	36218-36221	the	_	
192-44	36222-36226	mean	_	
192-45	36226-36227	.	_	

#Text=Weaker connectivity in the A) ACC and B) MCC during neutral cueing was significantly (p < 0.05) associated with longer time to relapse.
193-1	36228-36234	Weaker	_	
193-2	36235-36247	connectivity	_	
193-3	36248-36250	in	_	
193-4	36251-36254	the	_	
193-5	36255-36256	A	_	
193-6	36256-36257	)	_	
193-7	36258-36261	ACC	_	
193-8	36262-36265	and	_	
193-9	36266-36267	B	_	
193-10	36267-36268	)	_	
193-11	36269-36272	MCC	_	
193-12	36273-36279	during	_	
193-13	36280-36287	neutral	_	
193-14	36288-36294	cueing	_	
193-15	36295-36298	was	_	
193-16	36299-36312	significantly	_	
193-17	36313-36314	(	_	
193-18	36314-36315	p	_	
193-19	36315-36316	 	_	
193-20	36316-36317	<	_	
193-21	36317-36318	 	_	
193-22	36318-36322	0.05	_	
193-23	36322-36323	)	_	
193-24	36324-36334	associated	_	
193-25	36335-36339	with	_	
193-26	36340-36346	longer	_	
193-27	36347-36351	time	_	
193-28	36352-36354	to	_	
193-29	36355-36362	relapse	_	
193-30	36362-36363	.	_	

#Text=C) Greater connectivity in the PCC during alcohol cueing compared to stress cueing was significantly (p < 0.05) associated with longer time to relapse.
194-1	36364-36365	C	_	
194-2	36365-36366	)	_	
194-3	36367-36374	Greater	_	
194-4	36375-36387	connectivity	_	
194-5	36388-36390	in	_	
194-6	36391-36394	the	_	
194-7	36395-36398	PCC	_	
194-8	36399-36405	during	_	
194-9	36406-36413	alcohol	_	
194-10	36414-36420	cueing	_	
194-11	36421-36429	compared	_	
194-12	36430-36432	to	_	
194-13	36433-36439	stress	_	
194-14	36440-36446	cueing	_	
194-15	36447-36450	was	_	
194-16	36451-36464	significantly	_	
194-17	36465-36466	(	_	
194-18	36466-36467	p	_	
194-19	36467-36468	 	_	
194-20	36468-36469	<	_	
194-21	36469-36470	 	_	
194-22	36470-36474	0.05	_	
194-23	36474-36475	)	_	
194-24	36476-36486	associated	_	
194-25	36487-36491	with	_	
194-26	36492-36498	longer	_	
194-27	36499-36503	time	_	
194-28	36504-36506	to	_	
194-29	36507-36514	relapse	_	
194-30	36514-36515	.	_	

#Text=These figures of estimated survival functions show the x-axis up to day 60 because all patients who relapsed in the 90-day follow-up period relapsed with-in 60 days.
195-1	36516-36521	These	_	
195-2	36522-36529	figures	_	
195-3	36530-36532	of	_	
195-4	36533-36542	estimated	_	
195-5	36543-36551	survival	_	
195-6	36552-36561	functions	_	
195-7	36562-36566	show	_	
195-8	36567-36570	the	_	
195-9	36571-36577	x-axis	_	
195-10	36578-36580	up	_	
195-11	36581-36583	to	_	
195-12	36584-36587	day	_	
195-13	36588-36590	60	_	
195-14	36591-36598	because	_	
195-15	36599-36602	all	_	
195-16	36603-36611	patients	_	
195-17	36612-36615	who	_	
195-18	36616-36624	relapsed	_	
195-19	36625-36627	in	_	
195-20	36628-36631	the	_	
195-21	36632-36634	90	_	
195-22	36634-36635	-	_	
195-23	36635-36638	day	_	
195-24	36639-36648	follow-up	_	
195-25	36649-36655	period	_	
195-26	36656-36664	relapsed	_	
195-27	36665-36672	with-in	_	
195-28	36673-36675	60	_	
195-29	36675-36676	 	_	
195-30	36676-36680	days	_	
195-31	36680-36681	.	_	

#Text=Fig. 2
#Text=Comparison of AUD patients and HC participants.
196-1	36682-36685	Fig	_	
196-2	36685-36686	.	_	
196-3	36687-36688	2	_	
196-4	36689-36699	Comparison	_	
196-5	36700-36702	of	_	
196-6	36703-36706	AUD	_	
196-7	36707-36715	patients	_	
196-8	36716-36719	and	_	
196-9	36720-36722	HC	_	
196-10	36723-36735	participants	_	
196-11	36735-36736	.	_	

#Text=Voxel-wise connectivity comparisons of 30 AUD patients and 30 matched HC participants revealed a significant (p < 0.05 corrected) cue by group interaction.
197-1	36737-36747	Voxel-wise	_	
197-2	36748-36760	connectivity	_	
197-3	36761-36772	comparisons	_	
197-4	36773-36775	of	_	
197-5	36776-36778	30	_	
197-6	36779-36782	AUD	_	
197-7	36783-36791	patients	_	
197-8	36792-36795	and	_	
197-9	36796-36798	30	_	
197-10	36799-36806	matched	_	
197-11	36807-36809	HC	_	
197-12	36810-36822	participants	_	
197-13	36823-36831	revealed	_	
197-14	36832-36833	a	_	
197-15	36834-36845	significant	_	
197-16	36846-36847	(	_	
197-17	36847-36848	p	_	
197-18	36848-36849	 	_	
197-19	36849-36850	<	_	
197-20	36850-36851	 	_	
197-21	36851-36855	0.05	_	
197-22	36856-36865	corrected	_	
197-23	36865-36866	)	_	
197-24	36867-36870	cue	_	
197-25	36871-36873	by	_	
197-26	36874-36879	group	_	
197-27	36880-36891	interaction	_	
197-28	36891-36892	.	_	

#Text=A) The cue by group interaction was observed in mid and posterior cingulate cortex.
198-1	36893-36894	A	_	
198-2	36894-36895	)	_	
198-3	36896-36899	The	_	
198-4	36900-36903	cue	_	
198-5	36904-36906	by	_	
198-6	36907-36912	group	_	
198-7	36913-36924	interaction	_	
198-8	36925-36928	was	_	
198-9	36929-36937	observed	_	
198-10	36938-36940	in	_	
198-11	36941-36944	mid	_	
198-12	36945-36948	and	_	
198-13	36949-36958	posterior	_	
198-14	36959-36968	cingulate	_	
198-15	36969-36975	cortex	_	
198-16	36975-36976	.	_	

#Text=Warm colors indicate regions of significant F statistics for cue by group interactions.
199-1	36977-36981	Warm	_	
199-2	36982-36988	colors	_	
199-3	36989-36997	indicate	_	
199-4	36998-37005	regions	_	
199-5	37006-37008	of	_	
199-6	37009-37020	significant	_	
199-7	37021-37022	F	_	
199-8	37023-37033	statistics	_	
199-9	37034-37037	for	_	
199-10	37038-37041	cue	_	
199-11	37042-37044	by	_	
199-12	37045-37050	group	_	
199-13	37051-37063	interactions	_	
199-14	37063-37064	.	_	

#Text=B) Mean ICD connectivity and C) mean differences between cue conditions from the cingulate cortex regions showing a significant cue by group interaction were visualized in corresponding bar graphs.
200-1	37065-37066	B	_	
200-2	37066-37067	)	_	
200-3	37068-37072	Mean	_	
200-4	37073-37076	ICD	_	
200-5	37077-37089	connectivity	_	
200-6	37090-37093	and	_	
200-7	37094-37095	C	_	
200-8	37095-37096	)	_	
200-9	37097-37101	mean	_	
200-10	37102-37113	differences	_	
200-11	37114-37121	between	_	
200-12	37122-37125	cue	_	
200-13	37126-37136	conditions	_	
200-14	37137-37141	from	_	
200-15	37142-37145	the	_	
200-16	37146-37155	cingulate	_	
200-17	37156-37162	cortex	_	
200-18	37163-37170	regions	_	
200-19	37171-37178	showing	_	
200-20	37179-37180	a	_	
200-21	37181-37192	significant	_	
200-22	37193-37196	cue	_	
200-23	37197-37199	by	_	
200-24	37200-37205	group	_	
200-25	37206-37217	interaction	_	
200-26	37218-37222	were	_	
200-27	37223-37233	visualized	_	
200-28	37234-37236	in	_	
200-29	37237-37250	corresponding	_	
200-30	37251-37254	bar	_	
200-31	37255-37261	graphs	_	
200-32	37261-37262	.	_	

#Text=Pairwise comparisons of simple contrasts suggest that these main effects and interactions were primarily driven by differences in the alcohol and stress cue condition.
201-1	37263-37271	Pairwise	_	
201-2	37272-37283	comparisons	_	
201-3	37284-37286	of	_	
201-4	37287-37293	simple	_	
201-5	37294-37303	contrasts	_	
201-6	37304-37311	suggest	_	
201-7	37312-37316	that	_	
201-8	37317-37322	these	_	
201-9	37323-37327	main	_	
201-10	37328-37335	effects	_	
201-11	37336-37339	and	_	
201-12	37340-37352	interactions	_	
201-13	37353-37357	were	_	
201-14	37358-37367	primarily	_	
201-15	37368-37374	driven	_	
201-16	37375-37377	by	_	
201-17	37378-37389	differences	_	
201-18	37390-37392	in	_	
201-19	37393-37396	the	_	
201-20	37397-37404	alcohol	_	
201-21	37405-37408	and	_	
201-22	37409-37415	stress	_	
201-23	37416-37419	cue	_	
201-24	37420-37429	condition	_	
201-25	37429-37430	.	_	

#Text=Light grey denotes AUD patients and dark grey denotes HC participants.
202-1	37431-37436	Light	_	
202-2	37437-37441	grey	_	
202-3	37442-37449	denotes	_	
202-4	37450-37453	AUD	_	
202-5	37454-37462	patients	_	
202-6	37463-37466	and	_	
202-7	37467-37471	dark	_	
202-8	37472-37476	grey	_	
202-9	37477-37484	denotes	_	
202-10	37485-37487	HC	_	
202-11	37488-37500	participants	_	
202-12	37500-37501	.	_	

#Text=Fig. 3
203-1	37502-37505	Fig	_	
203-2	37505-37506	.	_	
203-3	37507-37508	3	_	
